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ABSTRACT 
Optimised pre-clinical models are required for TB drug development to better predict the 
pharmacokinetics of anti-TB drugs to shorten the time taken for novel drugs and combinations 
to be approved for clinical trial. 
Microdialysis can be used to measure unbound drug concentrations in awake freely moving 
animals in order to describe the pharmacokinetic behaviour of drugs in the organs as a 
continuous sampling technique. The aim of this PhD was to develop and optimise the 
microdialysis methodology  in the guinea pig model to better understand the pharmacokinetics 
of anti-TB drugs in the lung.  
Meticulous in vitro experiments were performed with each drug before progressing into in vivo 
experiments because the recovery (concentration of the drug in the tissue fluid related to that 
in the collected dialysate) of the drug was dependent upon a variety of experimental 
conditions. Mass spectrometry of the dialysate was used to determine the impact of flow rate,  
perfusion fluid, and the molecular weight cut-off and membrane length of probes on the 
recovery of rifampicin at physiologically relevant concentrations. Following identification of a 
correlation between rifampicin concentrations in lung and skeletal muscle and determination 
of probe efficiency, experiments were conducted to measure rifampicin in the sacrospinalis of 
guinea pigs using microdialysis.  This demonstrated feasibility to use microdialysis in the 
guinea pig to generate organ-specific pharmacokinetic data. The data were robust and 
reproducible especially when compared to those generated from blood sampling. Lung 
concentrations were estimated  from the sacrospinalis enabling calculation of AUC:MIC and 
Cmax:MIC ratios (PK/PD parameters associated with mycobacterial killing). Human-like 
values for these ratios were obtained in the lung but not in blood, indicating  the power of the 
microdialysis to more accurately measure the PK parameters of drugs in organs. These studies 
established the microdialysis methodology and demonstrated its potential in developing 
predictive pre-clinical models. 
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CHAPTER 1 
INTRODUCTION 
1.1 TUBERCULOSIS 
1.1.1 GLOBAL BURDEN OF TB DISEASE AND IMPACT OF INTERVENTIONS. 
Tuberculosis (TB), still, kills more people than any other infectious disease with 1.7 million 
deaths in 2017 alone1. It is the oldest infectious disease known to man and despite the 
causative agent, Mycobacterium tuberculosis, being identified by Robert Koch in 18822 and 
studied ever since, tuberculosis kills more people every three days than the whole of the West 
African Ebola outbreak in 2015. This continuing vast global burden can be attributed to a 
number of reasons including; the ability of the organism  to enter a latent state3, susceptibility 
to disease being strongly linked with social and economic inequalities4, the association with 
and exacerbation of TB disease in persons co-infected with other diseases, especially HIV5 and 
diabetes6, the ability of the bacterium to manipulate host immunity in order to ensure  
survival7, and to adapt to resist drug treatment leading to the emergence of drug-resistant 
strains8.  
Mycobacterium tuberculosis (M.tb), is a bacterium (Order: Actinomycetales, Genus: 
Mycobacteria) which is part of the Mycobacterium tuberculosis complex (MTBC). The MTBC 
also contains M. bovis, M. canetti, M. africanum, M. microti and M. marinum, all of which (except 
M. bovis) are adapted to a particular host species and share a common African ancestor which 
originated 35,000-15,000 years ago9. There are currently seven main circulating lineages of 
M.tb, classified using large sequence polymorphisms (LSPs) and single nucleotide 
polymorphisms (SNPs)10 . The lineages are associated with distinct geographical regions and 
each differs genotypically and phenotypically including differences in virulence and drug 
resistance11. The highest burden of TB disease is found in East and South East Asia (caused 
mainly by Lineages 1, 2 and 3) whereas Lineage 4 causes the majority of disease in Europe, 
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North Africa and the Americas. Lineages 5 and 6 are classified as M. africanum and these 
lineages are limited to West-African regions, where they are responsible for 50% of the TB 
disease burden12, and Lineage 7 is localised to Ethiopia and associated with immigrants from 
Ethiopia13. TB is, therefore, a heterogeneously distributed disease with certain regions of the 
world having higher disease burdens than others.  
It is evident why TB is referred to as the ‘Plague of Poverty14’ when eight low and middle 
income countries account for 60% of TB associated deaths; India, China, Indonesia, Nigeria, 
Pakistan, Bangladesh, The Phillipines and South Africa. South Africa is also the location of the 
world’s largest HIV epidemic15. 12% of all new active tuberculosis cases and 25% of all 
tuberculosis related deaths are due to HIV co-infection and active tuberculosis is the primary 
cause of hospitalisation in HIV infected adults and children1. There are numerous other pre-
disposing and precipitating factors that contribute to the global TB burden which are shown in 
Figure 1.1. 
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FIGURE 1.1: PRE-DISPOSING AND PRECIPITATING FACTORS THAT HAVE INCREASED THE GLOBAL TB BURDEN. This diagram was based on information found in ‘Risk 
Factors for Tuberculosis16’ and ‘The Ongoing Challenge of Latent Tuberculosis 17’. 
19 
 
The influence of socio-economic factors on TB is evidenced by the fact that between the late 
1940’s and 1980, the global burden of TB declined due to the combination of socio-economic 
growth and reform, declining poverty, improved living conditions, and increased hygiene but 
this period also saw the introduction of mass vaccination of the population with the BCG 
(Bacille Calmette Guerin) vaccine18. BCG has proven efficacy at preventing extra-pulmonary TB 
in children, although in adults the efficacy of BCG is variable dependent upon numerous factors 
including host, environmental and mycobacterial, yet still to this day it is the only licenced 
vaccine for TB19. 
The incidence of TB disease declined even further when the anti-tuberculosis drugs were 
introduced, with streptomycin co-administered with bed-rest as early as 1944 and the first 
drug regimen of streptomycin, para-amino salicylic acid (PAS) and isoniazid used in 195220. 
However, in the 1990s, catalysed by the global HIV outbreak in the 1980s, an increase of poor 
living conditions especially in the former USSR, and patient non-compliance with the lengthy 
and toxic anti-TB drug regimens, the global burden of TB again increased and TB was declared 
a global health emergency in 199121. This resurgence of disease burden highlights that in order 
to reduce the incidence of TB disease social, economic and environmental interventions need 
to be considered as well as medical interventions, such as drugs, diagnostics and vaccines.  
1.1.2 HOST-PATHOGEN FACTORS THAT INFLUENCE TREATMENT OF TB 
DISEASE 
Infection with M.tb is established  in the lung following inhalation of one or more droplet nuclei, 
each of which is estimated to  contain between 1-3 bacilli22. Once inhaled, the bacteria lodge in 
the alveoli where ingestion by alveolar macrophages occurs. Within macrophages, the bacteria 
deploy several mechanisms to resist intracellular killing including blocking of phagosome-
lysosome fusion23. In addition to resisting killing by macrophages, M.tb has an array of 
strategies for survival and adaptation to the host environment which involve manipulation of 
the innate and acquired immune system23. In the lungs, a consequence of the host-pathogen 
interaction is the development of granulomas which form following recruitment of 
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lymphocytes and monocytes to the initial site of infection7. These granulomas may resolve 
upon successful eradication of the bacteria or, as bacteria replicate and cause cell damage 
which stimulates further host responses, the granuloma matures to an organised aggregation 
of different cell types which form around a central core of bacteria and cell debris, collectively 
described as the caseum. The necrotic caseum can fuse with the airway structure to form a 
cavity, which also contains a large number of slow growing and non-replicating 
mycobacteria24. 
Whilst granulomas are a host defence mechanism to enclose the bacteria and restrict spread, 
M.tb is able to survive and persist within these structures and this environment can be a 
protective niche, for example from drugs which,  due to destruction of the vasculature, are 
unable to reach the bacteria25. It is known that genetically drug sensitive bacteria can be found 
persisting in granulomas throughout the treatment duration in different locations26. These 
lesions are also associated with different types of microenvironments such as oxygen tension, 
low pH and nutrient supply, which are known to affect drug efficacy27. Any or a combination of 
these host factors are responsible for the fact that drug treatment regimens are not always 
successful in complete eradication of M.tb from the host. The ability of M.tb to resist immune-
mediated killing and persist means that relapse of disease can occur following the end of 
treatment28. The aim of a therapeutic regimen is therefore not just to treat and resolve the 
symptoms and consequences of active disease but also to prevent relapse by killing persisting 
organisms29. 
The process by which M.tb resists host defences and initiates a progressive infection leading 
to active disease is thought to occur in only a small proportion of those infected, approximately 
5-10% with the remaining 90% becoming  latently infected17 with none of the clinical 
symptoms associated with active disease. It is estimated that 23% of the world’s population is 
latently infected with M.tb1. The precise mechanisms by which the bacteria are maintained in 
a quiescent state are not fully understood but it is clear that there is a spectrum of disease 
states in latently infected individuals30. People that have latent TB infection (LTBI), are at risk 
of developing active disease, especially if immunosuppressed through disease or malnutrition 
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or by being exposed to immunosuppressive therapies. Individuals with LTBI are therefore, in 
some instances, treated with a preventative antibiotic regimen. This regimen involves daily 
treatment with isoniazid for a period of 6-9 months31, with new regimens introduced that 
replaced isoniazid with rifampicin to shorten treatment duration and improve patient 
compliance32.  
Other host factors such as age (babies, children, adults and elderly) can influence the clinical 
manifestations of disease yet the approach taken to treatment is similar. Co-morbidities such 
as HIV/AIDS, not only alter the course or severity of disease but have an impact upon TB 
therapy due to drug-drug interactions.   Thus, there is huge complexity in TB disease which 
brings significant challenges in the design and implementation of drug treatment regimens.  
1.2 DRUG THERAPY FOR TUBERCULOSIS DISEASE 
Before the advent of drug therapy, the treatments for TB disease were best described by 
George Bernard Shaw as a ‘commercial system of quackery and poison’. Treatment could be 
bestowed by the touch of monarchs, artificial pneumothorax and operations intended to 
collapse the lung (i.e. thoracoplasty, plombage or phrenic crush) were conducted and often 
curative, but most famously used were the Sanatoriums. The Sanatoriums were known as 
‘waiting rooms of death’ and bed rest, for 18 months minimum, in the open air with the 
presence of air-purifying pine trees was the main treatment. The last Sanatorium (Cheshire 
Joint Sanatorium, Loggerheads, Staffordshire) was closed in 1969 when it was confirmed that 
open air treatments had no significance in relation to drug therapy 33.  
The first drug to be used to treat TB, streptomycin, was introduced in 1944 but it was quickly 
apparent that this drug alone was not sufficient to cure patients. A second drug with activity 
against TB, para-amino salicylic acid was identified around the same time and, when used in 
combination with streptomycin was more effective than streptomycin alone. This success in 
combination therapy initiated an era of TB drug discovery and clinical trials, during which 
several new drugs, and drug combinations were tested between 1952 and 1963, as illustrated 
in Figure 1.2.   Rifampicin was discovered in 1963 and the current four front-line anti-TB drugs, 
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isoniazid, pyrazinamide, rifampicin and ethambutol, were introduced  as a combination 
regimen in the 1980s (Figure 1.2). This regimen is still in use today, 40 years later and involves 
a combination of isoniazid and rifampicin for six months, with the first two months 
supplemented with pyrazinamide and ethambutol34.  The doses administered are based on 
pharmacokinetics, previous historical clinical trial efficacy data, toxicity, cost and availability 
of the drugs during the 1980s when the regimen was initially introduced35. Further details of 
the drugs in the front-line regimen is given in the following sections. Table 1.1 shows all the 
drugs that have been used over time including those used now. 
Anti-TB drugs for drug sensitive TB need to be taken daily for a six month period (as a 
minimum) and it is the duration, expense, availability of the drugs in the poorest countries and 
toxic side effects of the treatment that often leads to patient non-compliance. A key issue 
associated with patient non-compliance is the emergence of multi- and extensively- drug 
resistant TB (MDR and XDR-TB respectively)24. The introduction of novel diagnostic 
technologies such as Xpert MTB/RIF that can rapidly identify resistance to rifampicin and first-
line line probe assays (LPA) that detect both isoniazid and rifampicin resistance, not only 
ensure the patient is receiving the right treatment, but also aid in decreasing the growing 
resistance to these important front-line drugs35,36.  
Additionally, the front-line drugs are likely to be ineffective against 1 bacillus in a population 
of 108 (varies between 106 - 109 bacteria for different drugs) which could select for resistance 
in the persisting population37. Therefore, regimens that clear these persistent bacteria are 
instrumental in controlling resistance, and also may lead to shorter treatment durations 
improving patient compliance29. Strategies have been implemented to help with patient 
compliance, such as directly observed therapies (DOTS) and novel strategies such as 99DOTS 
which uses smart phones, both approaches have been implemented with success 38.  
MDR-TB which accounts for 3.5% of all new TB cases1, is resistant to treatment with isoniazid 
and rifampicin and must be treated with a second-line drug regimen. XDR-TB, which has been 
identified in 127 WHO member states, is defined as MDR-TB with resistance to at least one 
fluoroquinolone or second-line injectable agent (amikacin, capreomycin or kanamycin)1. The 
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minimum treatment period for MDR-TB is 20 months, adding to issues of poor compliance due 
to cost and toxicity. In 2018, the WHO released new guidance for treatment of drug-resistant 
(DR) TB categorising second line and novel drugs into three categories based on safety and 
efficacy. The drugs to be prioritised and used in combination for the treatment of DR-TB are 
levofloxacin or moxifloxacin, bedaquiline and linezolid39. Kanamycin and capreomycin are no 
longer recommended due to associations with treatment failure (relapse) and the fact that they 
are injectable agents39.  
As highlighted in Figure 1.2, after the discovery of rifampicin in 1963, there was a lull in anti-
TB drug discovery until the 1990s when rifapentine, rifabutin and the widely used 
fluroquinolones for MDR-TB were discovered, however no new drugs were discovered for the 
treatment of TB until pretonamid in 200040. Even with these discoveries, it takes a minimum 
of six years to get a novel TB drug to market, and at least 20 years for the introduction of a 
novel regimen41. Hence, over time drugs were re-purposed for use of the treatment of TB and 
throughout history, many drugs have been used. However due to the continued emergence of 
drug resistance and toxicity of the treatment regimens there remains  a need for new anti-TB 
drugs and regimens that are shorter, less expensive and less toxic.   
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FIGURE 1.2: TIMELINE OF ANTI-TUBERCULOSIS DRUGS SHOWING WHEN THEY WERE INITIALLY DISCOVERED. Diagram adapted from  Global TB Drug Development 
Pipeline40 and WHO Global TB Report 20181  
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Antibiotic 
Type of TB (DS, 
MDR, XDR) 
Antibiotic Class Target Treatment Uses/ Comments 
Amikacin 
Broad Spectrum 
Antibiotics/ MDR-
TB 
Aminoglycoside 
Injectable Agents 
 
 
Protein synthesis (via 30s ribosomal 
subunit)/ 
Bactericidal with bacteriostatic 
properties at low concentrations 
 
Downgraded to Group C medication for MDR-
TB 42. 
Capreomycin 
August 2018, no longer recommended for 
treatment of MDR-TB39. 
Gentamicin 
Use limited by serious adverse effects 
(ototoxicity and nephrotoxicity)43 however 
aerosolised gentamicin significantly reduced 
bacterial burden in mouse model 44.  
Kanamycin 
August 2018, no longer recommended for 
treatment of MDR-TB39. 
Streptomycin 
Not licenced for treatment of TB in UK as half 
of UK cases are resistant. 
Tobramycin Synergism with clarithromycin 45. 
 
Cycloserine 
MDR-TB 
Small molecule; analogue 
of amino acid D-alanine. Cell wall (peptidoglycan) synthesis 
 
Also used for treatment of Mycobacterium 
Avium complex46. 
Terizidone Pro-drug of cycloserine. 
Re-purposed drug. Treatment of urogenital 
TB 47. 
 
Enviomycin X 
Tuberactinomycin 
Injectable Agents 
Protein synthesis (via 30s and 70S 
ribosomal subunit) 
Bactericidal against M. avium complex 48.  
Viomycin XDR-TB 
Rarely used. Structural basis for capreomycin. 
 
 
Ethionamide 
MDR-TB 
Thioamide 
 
Cell wall (mycolic acid) synthesis 
(similar mechanism to isoniazid) 
although largely unknown/ 
Bacteriostatic 
Treatment of tuberculous meningitis and 
tuberculoma.   
Prothionamide 
 
Interchangeable with ethionamide as similar 
efficacy between the two, but prothionamide 
is better tolerated 49. 
TABLE 1.1: DRUGS THAT HAVE BEEN OR CURRENTLY ARE USED FOR THE TREATMENT OF TB.   
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Antibiotic 
Type of TB (DS, 
MDR, XDR) 
Antibiotic Class Target Treatment Uses/ Comments 
Ciprofloxacin 
Broad Spectrum 
Antibiotics/ 
MDR-TB 
Fluoroquinolone 
Cell division via DNA gyrase and 
topoisomerase 
Used for treatment of numerous bacterial 
infections. 
Gatifloxacin 
Withdrawn from market due to association with 
dysglycemia50. 
Levofloxacin 
Second choice fluoroquinolone 51. Less likely to be 
metabolically induced by rifamycins that 
moxifloxacin 52. 
Moxifloxacin 
First choice fluoroquinolone and has been 
incorporated into novel regimens 53.  
Ofloxacin 
Used when drug-susceptibility test results are not 
available before starting treatment 54. Associated 
resistance with inadequate dosing. 
Sparfloxacin High associated toxicity 55. 
 
Linezolid 
MDR and XDR-
TB 
Oxazolidinone 
 
Protein synthesis (via 50S) at early 
stage of translocation. 
 
Approved for use with bedaquiline and 
pretonamid (BPaL) by FDA for XDR/ non 
responsive MDR-TB56. 
Sutezolid 
Currently in Phase II Trials. Superior 
antimycobacterial activity than linezolid in vitro 
and in mouse 57; better safety profile than linezolid 
58. 
 
Rifabutin RR-TB 
Rifamycin 
 
DNA-dependant RNA polymerase 
suppressing RNA synthesis. 
 
Recommended for active TB if rifampicin 
intolerance. Less DDIs than rifampicin, can be 
taken with ART 59. 
Rifampicin 
DS-TB 
See Section 1.2.2 
Rifapentine 
Long acting derivative of rifampicin requiring once 
weekly administration. Currently in Phase III trials 
with/out Moxifloxacin to shorten treatment of DS-
TB to 4 months1. 
CONTINUATION OF TABLE 1.1: DRUGS THAT HAVE BEEN OR CURRENTLY ARE USED FOR THE TREATMENT OF TB.   
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Antibiotic 
Type of TB (DS, 
MDR, XDR) 
Antibiotic Class Target Treatment Uses/ Comments 
Delamanid 
MDR-TB Nitroimidazole 
Cell wall (mycolic acid) synthesis Phase III clinical trials60. Approved for use by EMA 
2014. 
Pretonamid 
Dual activity depending on growth 
rate; cell wall and NO respiratory 
effects 
Phase III clinical trials, incorporated into novel 
regimens and shows efficacy with bedaquiline and 
linezolid61. See Table 1.2 
 
Para-amino 
salicylic acid 
XDR-TB 
Antimycobacterial 
Folic acid synthesis. 
Use in front-line regimen discontinued due to 
discovery of INH &RIF. High associated toxicity 62.   
Ethambutol DS-TB Synthesis of cell wall components See Section 1.2.4 
 
Thioacetazone 
Isoniazid 
Resistant-TB 
Thiosemicarbazone 
Cell wall (mycolic acid) synthesis 
(similar mechanism to isoniazid) 
although largely unknown 
Rarely used as associated adverse reactions 
especially with HIV co-infection 63. 
Clofazimine MDR-TB Riminophenazine 
Cell division via binding to guanidine 
bases 
Currently in Phase III trials. Used for treatment of 
leprosy 64. Not licenced for treatment of TB in UK. 
Clarithromycin MDR-TB Macrolide 
Protein synthesis via 50S ribosomal 
subunit. 
Associated with drug interactions including 
rifabutin 65. Not licenced for treatment of TB in UK. 
Bedaquiline MDR-TB Diarylquinalone ATP synthase. 
Phase III clinical trials, incorporated into novel 
regimens. See Table 1.2. 
Isoniazid DS-TB Hydrazide Cell wall (mycolic acid) synthesis See Section 1.2.1 
Pyrazinamide DS-TB Pyrazinoic acid amide 
Membrane potential disruption and 
inhibition of trans-translation 
See Section 1.2.3 
 
Doxycycline X (R) Tetracycline 
Protein synthesis (via 30s ribosomal 
subunit) 
Not considered effective against TB until 2012 as 
shown to directly inhibit bacterial growth in guinea 
pigs 66. 
Fusidic acid X (R) Fusidane 
Protein synthesis via elongation 
factor 
Activity shown in vitro 67. 
 
CONTINUATION OF TABLE 1.1: DRUGS THAT HAVE BEEN OR CURRENTLY ARE USED FOR THE TREATMENT OF TB. X indicates not currently used against TB. (R) indicates repurposed.   
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1.2.1 ISONIAZID 
Isoniazid (isonicotinylhyradrazine) is an orally delivered mycobactericidal drug, introduced 
for human use in 1952. The action of INH is biphasic in humans, exerting bactericidal activity 
on rapidly growing mycobacteria, and bacteriostatic action on slow growing mycobacteria68. 
The precise mechanism of action of isoniazid is poorly understood69. It is known that INH is a 
prodrug which is activated to the active form of the drug via peroxidation by the catalase-
peroxidase enzyme KatG found in mycobacteria 70,71. Activation via oxidation of INH via KatG 
creates  carbon, oxygen and nitrogen free radicals which are central to the action of INH due to 
damage of a range of cellular components (lipids, proteins and nucleic acids72). This oxidation 
occurs in the presence of NADH which leads to the formation of an intra-cellular INH-NADH 
complex which binds and inhibits enoyl-acyl carrier protein reductase InhA73 . The cell wall 
structure of M.tb is comprised of a mycolic acid-arabinogalactan-peptidoglycan complex, this 
has minimal permeability which aids M.tb survival and is an additional barrier to drug 
treatment74.  The inhibition of InhA disrupts mycolic acid synthesis, a key component of the 
mycobacterial cell wall leading to death of the bacteria. The chemical structure of isoniazid is 
shown in Figure 1.4. 
Resistance to INH developed shortly after its introduction and involves mutations in a number 
of genes, however the main mutations that contribute to INH resistance are within the KatG 
gene or the inhA regulatory region69. Mutations in KatG confer high level isoniazid resistance, 
which means INH is ineffective against M.tb with this mutation. However, mutations in the inhA 
regulatory region cause low level resistance which indicates that administration of high dose 
INH may be effective75. Recently due to this resistance, moxifloxacin has been used in place of 
INH and this led to superior sterilising activity and hence shortened treatments regimens when 
compared to HRZ in BALB/C and C3HEB/Fej mice76, however moxifloxacin failed to clear 
persistent bacteria in the Cornell mouse model77. This was also true in humans as when this 
regimen was tested as part of the REMoX-TB trial, with the hope of reducing treatment 
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duration to four months, it did not show non-inferiority due to a higher relapse rate than 
current front-line regimen78.  
1.2.2 RIFAMPICIN 
Rifampicin, a semisynthetic derivative of the rifamycins, is part of the ansamycin family of 
antibiotics which have activity against gram positive bacteria (Chemical Structure; Figure 1.4). 
It has the most potent sterilising activity in the front-line anti-TB drug regimen and is the most 
effective against persistent  bacteria79. Hence, when rifampicin was incorporated into regimens 
in the 1970s and 1980s the treatment period decreased from 18 to 6-9 months. Rifampicin is 
effective against both growing and stationary phase bacilli80 and exerts its therapeutic effects 
by binding to the β-subunit of RNA polymerase via 4-methyl-1-piperazinaminyl, thereby 
inhibiting RNA transcription in-turn preventing protein synthesis in bacterial cells81. 
Resistance to rifampicin is associated with mutations in the rpoB gene which codes for the β-
subunit of RNA polymerase (the target of rifampicin)82. It is interesting to note that unlike 
isoniazid, rifampicin mono-resistance is rare, hence usually rifampicin resistance is a strong 
indicator of multi-drug resistance1.  
It is known that rifampicin was introduced at suboptimal doses due to cost, availability and 
proposed toxicity and this dose is still in use today35,83. However, humans can tolerate daily 
doses of 35mg/kg (as opposed to the currently used 10mg/kg) and this increased dose is 
known to increase bacterial elimination84. It is known that the maximum tolerated dose of 
rifampicin in humans is 40mg/kg and doses higher than this have led to the development of 
unconjugated hyperbilirubinemia (G. Davies, Personal communication). It has also been shown 
that BALB/C mice can tolerate up to 50mg/kg daily. This higher dose was associated with a 
shortened treatment duration of 6 weeks from the usual 14 weeks with no occurrence of 
relapse when trialled in the Cornell mouse model79. High dose rifampicin is currently in both 
Phase II and Phase III clinical trials for drug-sensitive TB.   
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1.2.3 PYRAZINAMIDE 
Pyrazinamide (Pyrazine-2-carboxamide, PZA) is used during the initial treatment phase with 
isoniazid and rifampicin for drug- sensitive tuberculosis treatment. It was primarily added to 
the regimen to reduce the rate of relapse 85 as well as enhancing the activity of rifampicin, 
thereby shortening treatment duration from 9 to 6 months. It is also part of the majority of 
regimens for multi-drug resistant TB due to its possible in vitro synergism with the newly 
developed drugs 86.  The structure of PZA is shown in Figure 1.4. The mechanism of action of 
PZA is poorly understood, however it is a prodrug known to be converted in an acidic 
environment to pyrazinoic acid via the pyrazinamidase enzyme 87.  A mechanism of PZA 
resistance is associated with defects in this enzyme due to mutations in the pncA regulatory 
gene88.  Pyrazinoic acid, which accumulates intracellularly appears to have no specific targets87 
but it diffuses out of the bacteria and is then protonated. The protonated form (HPOA) re-
enters the bacterium and accumulates and disrupts homeostasis89. PZA/ Pyrazinoic acid is 
known to be poorly active against multiplying bacteria and the proposed target is dormant or 
persistent bacilli 90.   
It is well known that PZA shows minimal activity in vitro and this is primarily related to pH, a 
key factor in determining the activity of PZA87. However, there are conflicting reports of its 
activity in vivo in animal studies. Ahmad et al state that pyrazinamide shows sterilising, dose-
dependent activity and synergism with rifampicin against chronic TB infection in guinea pigs 
as it does it humans 90, however this is in contrast to data generated by Dickinson91 and 
Steenken92. In mice, PZA had a dose dependant response for the first three weeks of treatment 
but did not confer any additional protection at later time points27. However, despite these 
conflicting data in animals, it is found in humans that PZA acts as a sterilising drug for the first 
two months of treatment93.  
1.2.4 ETHAMBUTOL 
Ethambutol (2S,2’S)-2,2’-(Ethane-1,2-diyldiimino)dibutan-1-o) is a synthetic compound 
(structure shown in Figure 1.4) discovered in 1961. It was introduced into the anti-TB drug 
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regimen to prevent the emergence of drug resistance as ethambutol was found to be active 
against isoniazid and streptomycin resistant strains of TB94. The mode of action is to inhibit 
arabinosyl transferase the enzyme responsible for  arabinogalactan and arabinomannan 
biosynthesis, which are two key components of the mycobacterium cell wall95. Ethambutol is 
efficacious against the majority of strains of the MTBC including M. bovis 96.  
1.2.5 NEW DRUG DEVELOPMENT AND CLINICAL TRIALS 
For 40 years, no novel drugs were introduced for the treatment of TB until bedaquiline (BDQ) 
was approved by FDA in 2013. The safety and efficacy of BDQ is still being evaluated in Phase 
III trials as part of the STREAM (Evaluation of Standardised Treatment Regimen of Anti-
tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) trial where bedaquiline 
was incorporated into a number of regimens with pre-existing and repurposed anti-TB drugs 
with the aim of shortening the treatment of MDR-TB97.  However, due to success in earlier trials, 
over 70 countries have already started using BDQ to improve treatment outcomes of those with 
MDR or XDR-TB1. BDQ is a relatively well tolerated drug and only 0.6% of patients had 
treatment discontinuation due to adverse events98. Other promising drugs both in Phase III 
trials as part of novel regimens for MDR-TB are delamanid and pretonamid. A novel 
combination regimen containing pretonamid, moxifloxacin and pyrazinamide demonstrated 
more effective sterilisation in the mouse model than the current front-line regimen 99.  Other 
novel drugs being investigated have different modes of action to the traditional drugs, such as 
the indazole sulfanomides100 and DprE1 inhibitors101. The TB drug development pipeline is 
shown in Table 1.2.  
The majority of on-going anti-TB drug trials focus on MDR and XDR-TB, such as Nix-TB, 
STREAM and MDR-END with the overarching aim of shortening the duration of drug treatment. 
Another aim of these trials is to identify regimens that are compatible with Anti-Retroviral 
Therapy such as the RAFA trial  in which an increased daily dose of rifampicin showed an 80% 
decrease in mortality associated with advanced HIV/TB co-infection compared with the 
standard daily dose of rifampicin102.  
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As highlighted in Figure 1.2, tuberculosis drug development is a slow process and contributing 
factors are the slow growth of the organism, the complicated spectrum of TB disease in 
humans, including latent infection (adding at least another two years to the length of the drug 
development pipeline) and a lack of well-validated models and tools for pre-clinical 
development, especially those that recapitulate the diverse heterogenous states of TB disease. 
Some of the issues which surround the evaluation of new drugs pre-clinically include a limited 
understanding of the pharmacokinetics of drugs and how these relate to anti-mycobacterial 
activity.  It is clear that to improve and eventually shorten the time taken for new drugs to be 
approved for use in the TB drug development pipeline there is a need for improved and better 
pre-clinical models to predict the pharmacokinetics of the anti-TB drugs both in vitro and in 
vivo.  
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Phase I Phase II Phase III 
Contezolid (MRX-1) 
Oxazolidinone 
Delpazolid (LCB01-0371) 
Oxazolidinone; LegoChem 
Biosciences 
Bedaquiline (TMC-207) 
GSK-3036656 
Oxaborole; GSK 
SQ109 
Small molecule drug; Sequella Inc 
& NIH 
Delamanid (OPC-67683) 
Macozinone (PBTZ169) 
Benzothiazinone; Nearmedic 
Plus 
Sutezolid (PNU-100480) 
Oxazolidinone 
Pretomanid (PA-824) 
OPC-167832 
Carbostyril; Otsuka 
Linezolid dose-ranging 
Oxazolidinone 
Clofazimine 
Riminophenazine 
TBA-7371 
Enzyme inhibitor (DprE1); TB 
Alliance 
High Dose Rifampicin for DS-TB 
PanACEA 
High Dose Rifampicin for 
treatment of DS-TB 
TBI-166 
Riminophenazine; TB Alliance 
with Institute of Materia 
Medica, Chinese Academy of 
Medical Sciences & Peking 
Union Medical College. 
Bedaquiline and Delaminind 
(Deliberate Trial) 
Rifapentine for treatment of 
DS-TB 
BTZ-043 
Benzothiazone; DprE1 
inhibitor; University of Munich 
 
Bedaquiline-Pretonamid-
Moxifloxicin-Pyrazinamide 
(BPaMZ) 
Bedaquiline – Pretomanid – 
Linezolid (NiX-TB trial) 
 Bedaquiline- Pretonamid- 
existing and re-purposed anti-TB 
drugs for MDR-TB (TB 
PRACTECAL Phase 2/3 trial) 
Bedaquiline – Pretomanid – 
Linezolid (ZeNix trial) – 
Linezolid optimization 
Delamanid-linezolid-levofloxacin-
pyrazinamide for quinolone 
sensitive MDR-TB (MDR-END 
trial) 
Bedaquiline with two 
optimised background 
regimens (oral, 9 months; 
with oral and injectables, 6 
months) (STREAM trial) 
Levofloxacin with optimised 
background regimen (OBR) for 
MDR-TB (OPTI-Q) 
 
Bedaquiline – Linezolid – 
Levofloxacin with OBR for 
MDR-TB (NExT trial) 
 Bedaquiline and delamanid 
with various existing 
regimens for MDR-TB and 
XDR-TB (endTB trial) 
Pretomanid – Moxifloxacin – 
Pyrazinamide regimen 
(STAND trial) 
Rifapentine – Moxifloxacin 
for treatment of DS-TB (TB 
Trial Consortium Study 
31/A5349) 
 
TABLE 1.2: THE GLOBAL CLINICAL DEVELOPMENT PIPELINE FOR NEW ANTI-TB DRUGS AND REGIMENS. 
Adapted from WHO Global TB report1 
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1.2.6 PREDICT TB CONSORTIUM 
A component of the studies required to address the aims of this PhD project were conducted 
within the PreDiCT TB consortium project funded by the EU Innovative Medicines Initiative 
(IMI) with in kind contributions from industry partners, predominantly GSK. The overall goal 
of PreDiCT TB was to develop and enhance an integrated set of pre-clinical in vitro and in vivo 
models that provide critical data for the purpose of identifying decision criteria for the 
progression of novel drugs and combinations to innovate early phase drug development and 
clinical trials.  This was achieved by evaluating a defined set of anti-TB drugs in a set of novel 
and enhanced pre-clinical experimental systems, that encompass the range of physiological 
states of M.tb, and relating these data to human clinical trial data via in silico modelling. The 
impact of the PreDiCT TB consortium has been a comprehensive analysis of pre-clinical and 
clinical databases which will ultimately inform the predictive value of pre-clinical tools 
accelerating the drug development pathway to the clinic. 
Eighteen in vivo models were used in the consortium; zebrafish, mouse models that span 
multiple aspects of TB disease, non-human primates and guinea pigs. The experiments that 
were conducted in guinea pigs are those that relate to this project. There were a number of  PK 
experiments conducted (in uninfected guinea pigs) to optimise the dose of drug administered 
with an aim to identify drug doses that reflect human exposures. Those PK experiments are 
described in Chapter 2 of this thesis and the results obtained were used as the basis for drug 
concentrations tested in the in vitro microdialysis work up studies (Chapter 3) and the in vivo 
microdialysis studies (Chapter 5).  
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1.3 PHARMACOKINETICS 
1.3.1. OVERVIEW OF PHARMACOKINETICS 
The time-dependant bactericidal activity of penicillin and the concentration-dependant 
bactericidal activity of streptomycin, originally described by Eagle in 1948, were the first 
indication that pharmacokinetics (PK) and pharmacodynamics (PD) were inextricably linked 
to drug efficacy 103. Three main PK/PD parameters are often calculated to predict drug efficacy:  
• The ratio of peak drug concentration relative to Minimal Inhibitory Concentration 
(Cmax: MIC  ratio) 
• Area under the concentration time curve relative to MIC (AUC:MIC) 
• Time during which the drug concentration exceeds MIC (T>MIC).  
The parameter associated with microbial killing by the four front-line anti-TB drugs is 
AUC:MIC, although rifampicin activity also is consistent with  a Cmax: MIC effect104. It is 
incredibly important to achieve MIC concentrations as sub-lethal treatment can cause bacterial 
resistance, but the MIC  is a pre-determined, single value that does not account for patient, drug 
or pathogen factors which can affect therapy. Therefore, to better understand the drug and its 
effect, PK, which is the quantitation over time of a drug in the body, is measured. PK analyses 
should incorporate the physiochemical properties of the drug, blood flow, permeabilities of 
membranes and tissues, plasma protein and tissue binding 105.  
There are four main components that contribute to the pharmacokinetic (PK) properties  of a 
drug: absorption, distribution, metabolism and elimination (ADME), as shown in Figure 1.3.  
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FIGURE 1.3: PHARMACOKINETICS. A basic schematic showing how absorption, distribution, 
metabolism and excretion/elimination (ADME) are interlinked to form the overarching 
pharmacokinetic profile of the drug.  
1.3.2 ABSORPTION 
Most pharmaceuticals, including the front-line anti-TB drugs (isoniazid, rifampicin, 
pyrazinamide and ethambutol) are taken orally; therefore following drug dissolution the sites 
of absorption are the gastrointestinal (GI) tract, the stomach and the small intestine. GI 
absorption of drugs involves the transport of the drug across the gut epithelium and the 
internal environment of the GI tract, especially the pH, is critical in determining the actual site 
of absorption. Other factors such as the physio-chemical properties of the drug affect 
absorption.  
The biopharmaceutics classification system classifies drugs based upon aqueous solubility 
(LogS) and the associated bioavailability of the drug, as absorption is directly linked to 
bioavailability. The classes I-IV indicate how the drug will be absorbed and the subsequent 
bioavailability following oral administration. Class I drugs are highly soluble and permeable 
indicating high bioavailability, Class II are highly soluble with low permeability (rifampicin106), 
Class III are highly soluble and poorly permeable (ethambutol107, isoniazid108, 
pyrazinamide109) and Class IV are relatively insoluble and impermeable indicating low 
bioavailability. However, rifampicin is a zwitterion meaning that solubility increases in both 
acid and basic solutions and this means that absorption can occur at a number of GI sites110. 
As shown by the structure in Figure 1.4, isoniazid is a relatively simple drug with low molecular 
weight (137.14g/mol). It is highly soluble with a LogS of -0.56. Rifampicin has a very complex 
structure (Figure 1.4). This complexity means that rifampicin has the highest Mw of all the 
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front-line anti-TB drugs (822.94g/mol) as well as being the least soluble (LogS -8.18). There 
are structural similarities between pyrazinamide and isoniazid as shown in Figure 1.4. The 
physiochemical properties between the two are similar and pyrazinamide has a Mw 
123.11g/mol and LogS of -0.65. In terms of physiochemical properties, ethambutol is similar 
to isoniazid and pyrazinamide (Figure 1.4), with a low Mw (204.31g/mol) and high solubility 
(LogS -0.46). 
As tuberculosis is primarily a pulmonary disease, the delivery of drugs via the lungs has been 
considered for the development of novel anti-TB compounds111,112. The route of administration 
will have a direct impact on the absorption of the drug and subsequently their distribution and 
excretion; however, regardless of route, all drugs will enter the systemic circulation. Entering 
the systemic circulation means there is potential for drug to be ‘lost’ via first pass metabolism 
in the liver which greatly affects lipid soluble drugs and it is known that rifampicin undergoes 
first pass metabolism113. First pass metabolism, although hard to distinguish from poor 
absorption, means that the bioavailability of the drug decreases. Other losses in the GI tract 
also need to be considered, for example, 6-8% of the total dose of rifampicin degrades in the 
stomach due to the pH106. Ethambutol has an unusual absorption pattern, potentially due to its 
binding and chelation with molecules in GI fluids or tissues 114.   
Following absorption, all drugs are distributed simultaneously to all tissues, including the 
organs of elimination, via the blood.  
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FIGURE 1.4: CHEMICAL STRUCTURES OF THE FRONT-LINE ANTI-TB DRUGS. Drawn in ChemBioDraw 
Version 12.  
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1.3.3 DISTRIBUTION 
Distribution is a measured in L/Kg and provides an indication  of the amount of drug which is 
distributed in the body in relation to the plasma concentration and is a critical determinant 
and predictor for drug activity 115. There are large differences in the distribution of drugs to 
tissues, which are caused by differences in the physiochemical properties of the drug 
(primarily lipophilicity (LogP) and ionisation), perfusion rate, permeability of the tissue 
membranes and differences in protein binding in various tissues and plasma in the body. 
Perfusion rate is particularly important in relation to the lungs due to high vascularisation. 
Moderate to highly basic and lipophilic drugs  are highly distributed to the lung and the rate of 
delivery is dependent upon blood flow. 
The most important factor in relation to distribution is protein binding in the blood and tissues 
because the efficacy of the drug relies upon the unbound pharmacologically active fraction. 
Small Mw drugs are highly bound to plasma proteins but not to tissue proteins and highly polar 
drugs tend not to bind to any proteins. Acidic drugs commonly bind to albumin (the most 
abundant plasma protein), basic drugs bind to α1-acid-glycoprotein (which is largely restricted 
to plasma) and neutral lipophilic compounds are associated with lipoproteins (found in tissue 
extra cellular water). Basic drugs have a greater volume of distribution than acidic drugs due 
to  higher tissue protein binding. Although binding is generally a reversible process, it can also 
affect the efficacy and toxicity of the drug, as well as modifying the time above MIC116. 
Rifampicin is the only front-line anti-TB drug which shows a relatively high level of plasma 
protein binding (92.2±1.1% (Humans))117; however it has been suggested that plasma protein 
binding is only problematic if it is over 95% as it is for the novel anti-TB drug bedaquiline 
(99.8±0.1% (Humans))116. Protein binding does differ between species and therefore it is 
imperative to know the degree of protein binding of the drug in the species being studied in 
order to fully describe the PK parameters, for example, in mice rifampicin is 97.1±0.2% plasma 
protein bound (PPB), in guinea pigs 69.5±2.3% PPB and in macaques 90.3±1.0% PPB117.  
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1.3.4 METABOLISM 
Metabolism, in general, renders compounds more polar and hydrophilic; however, there are 
exceptions to this. Metabolism can also activate prodrugs into the therapeutically active 
metabolite, as is the case with pyrazinamide (see Section 1.2). The majority of drug metabolism 
occurs in the liver and it can change the biological activity of the drug, by either decreasing the 
toxicity or increasing the chemical reactivity or toxicity. Most metabolic reactions, including 
those associated with the anti-TB drugs118–120, involve induction or inhibition of cytochrome 
P450s (CYP 450s) which are intracellular monooxygenase enzymes.  As with protein binding, 
it is important to understand species differences in relation to CYPs; rats and dogs primarily 
use CYP 2C enzymes for drug metabolism and humans primarily use CYP 3A. Non-human 
primates and guinea pigs have the highest total CYP 450s in the liver microsomes when 
compared to humans indicating that metabolism and clearance processes maybe faster in these 
species 121. 
Rifampicin is a known inducer of enzyme systems, especially the CYP 450 enzymes and this is 
due to a high affinity of the drug for the Pregnane X receptor (PxR). The PxR, activated by a 
number of structurally diverse xenobiotics and drugs, mediates the induction of CYP 3A genes 
122. Rifampicin is also known to induce P-glycoprotein (Pgp), a protein pump which uses ATP 
to transport large hydrophobic molecules across the plasma membrane, via induction of the 
multidrug resistant (mdr1 and mdr2) gene family123. It was shown that repeated 
administration of two different doses of rifampicin (15mg/kg and 50mg/kg), given twice daily 
for 7 days and 3 days respectively, induced mdr2 and subsequently Pgp expression in NHPs. 
Interestingly, the lower dose (administered for longer) was associated with higher expression 
of liver mdr2 and Pgp when compared to the control124.  An increase in Pgp expression may 
lead to increased biliary clearance of rifampicin and can therefore alter the PK profile of the 
drug potentially leading to drug resistance125. 
In addition to inducing its own metabolism (via CYP 3A4), rifampicin causes the induction of 
other co-administered drugs and is a potent metabolic inducer of many other drugs including 
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bedaquiline and anti-retroviral agents126. This can change the assumed pharmacokinetic 
profiles of these drugs primarily reducing the AUC plasma-concentration time curve and 
decreasing drug efficacy120. Rifapentine and rifabutin are not as potent metabolic inducers as 
rifampicin. 
The metabolism of isoniazid is unusual. It is a prodrug whose metabolism to acetylhydrazine 
is affected by genetic polymorphisms in humans. Isoniazid is metabolised in the liver via 
acetylation and the differences in metabolism and consequently elimination kinetics are due 
to polymorphisms of the N-acetyltransferase (NAT2) gene which can be predicted based upon 
ethnicity 127. Individuals taking isoniazid with a fast acetylator status will have a decreased 
plasma concentration of INH and have a decreased risk of toxicity128. Individuals with a slow 
acetylator status will have a higher plasma concentration of INH and will accumulate InhA and 
are subsequently more susceptible to hepatoxicity especially those co-administered 
pyrazinamide127,128.   Isoniazid can decrease the clearance of several drugs, including anti-
retroviral efavirenz, via inhibition of the CYP 450s (2A6) even though  this is not the primary 
route of isoniazid metabolism119. There are conflicting reports on the concomitant 
administration of rifampicin and isoniazid in regards to metabolism. There is evidence that 
isoniazid can decrease the bioavailability of rifampicin, however it has been shown that the 
induction effect of rifampicin on the CYPs far outweighs the inhibitory effects of isoniazid 129. 
1.3.5 ELIMINATION 
After the drug has been metabolised or bio-transformed into a more water soluble and 
therefore easily excretable compound, the drug can then be eliminated or cleared.  Elimination 
rates can vary widely for different drugs due to differences in organ perfusion, plasma protein 
binding, disease state and other patient specific factors such as age. For instance, the PK of 
ethambutol is directly influenced by age, with lower clearance and longer elimination half-life 
with increasing age 130. Isoniazid, pyrazinamide and ethambutol are all excreted via the kidney, 
whereas rifampicin is excreted via the biliary route because large polar molecules, or heavier 
protein bound molecules are more readily excreted via biliary excretion131. Rifampicin 
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clearance is a non-linear saturable process. Due to rifampicin’s ability to induce its own 
metabolism, repeated oral administration increases the clearance126. Elimination, often 
defined as renal or non-renal excretion, is the primary PK parameter that is commonly 
measured. Renal excretion can be measured via the amount of unchanged drug or hydrophilic 
metabolites in the urine.  
1.3.6 MODELLING OF PHARMACOKINETIC DATA 
Most of the PK parameters of drugs are gained in animal model species and the overarching 
aim of such studies is to relate these PK parameters to humans. This is done by mathematical 
modelling and allometry. Allometry can only be used to predict human-based parameters if the 
parameter is fully dependant on body weight such as heat production132.  Modelling is used to 
identify typical trends in PK data and to understand and quantify relationships between dose, 
concentration, therapeutic and adverse effects 133. The models can then be predictive of drug 
responses for drugs that exhibit similar properties to those modelled without conducting in 
vivo experiments. It is stated by Hatton, that modelling could be improved by use of a multitude 
of different animal species intended to reflect different physiological functions 134. There are 
different types of models that can be generated such as physiologically-based pharmacokinetic 
(PBPK) models that predict the PK of drugs using pre-clinical ADME data 135. These models are 
comprised of organ representative compartments connected by circulating blood flow and 
incorporate drug specific parameters to predict the drug PK in humans136 . There are also the 
conventional PK models which can be one, two or three compartment structures. 
Modelling of the Population PK (PopPK) parameters of the anti-TB drugs has been described 
using conventional compartmental models based on blood drug concentration data following 
a single dose. These data were from mice137. Rifampicin PK parameters in blood were fitted 
with  first order absorption and elimination in a one-compartment model. A one-compartment 
model was also used for isoniazid and showed dose dependant clearance. Both ethambutol and 
pyrazinamide required a two-compartment model and similarly to isoniazid, pyrazinamide 
showed dose dependant clearance. In humans, when the blood drug concentration data were 
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modelled a two-compartmental model was used for INH and ETH,  a one-compartment model 
for PZA130 and a one-compartment model for RIF138,139. The majority of models have been 
generated from PK data collected from the blood and it would be important to understand if 
organ PK data could be modelled in the same way (i.e. one-compartment model for RIF).  
1.4 MICRODIALYSIS 
1.4.1 METHODS FOR DETERMINING TISSUE PK 
The majority of known drug pharmacokinetics are based upon total drug concentrations 
measured using blood and urine because the site of drug action is rarely accessible. It is often 
assumed that plasma drug concentrations are similar to organ drug concentrations, however 
there are examples where this is not the case, especially for well perfused organs such as the 
lung140. There are very few methods that allow quantitation of drug directly in the tissue 
compartments; they are non-invasive molecular imaging techniques such as PET (Positron 
emission tomography) scanning and semi-invasive microdialysis.  
An advantage of microdialysis over the imaging techniques is the ability to directly measure 
the unbound pharmacologically active drug which is of key importance in pharmacokinetic 
studies. Microdialysis is also relatively inexpensive and requires less specialist equipment 
compared to the imaging techniques 141. Imaging techniques do however have high temporal 
and spatial resolution and, similar to microdialysis can measure drug concentrations at 
multiple sites simultaneously. Other methods have been used to determine tissue 
pharmacokinetics of antimicrobials such as the skin blister technique, bronchoalveolar lavage 
and tissue biopsy. However, these methods are mostly static and can generally only provide 
total drug concentrations at one or very few time points per animal and therefore numerous 
animals are needed to provide multiple time points. The advantages and disadvantages of the 
methodologies used to measure organ or tissue PK are highlighted in Table 1.3. 
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 Microdialysis PET Tissue Biopsy 
Matrix Sampled ECF Total Tissue Total Tissue 
Invasive? Semi-invasive No (Radioactive 
Exposure) 
Yes 
Measures UB 
Drug? 
Yes No (B and UB) No (UB, B, vascular 
concentrations) 
Continuous 
Monitoring? At 
multiple sites? 
Yes Yes No 
Expensive? No (when 
compared to 
PET) 
Yes (very 
technically 
complex; requires 
specialist centres) 
No 
Disadvantages Time 
consuming 
calibration 
Limited number of 
drugs that can be 
radio-labelled; 
inclusion of 
metabolite signal. 
Invasiveness and 
hybrid tissue 
concentration owing 
to mixture of different 
compartments. 
TABLE 1.3: COMPARISON BETWEEN MICRODIALYSIS, PET AND TISSUE BIOPSY. The key methods 
used to obtain pharmacokinetic data at the organ level. Adapted from Brunner and Langer 
2006.  
 
It is unlikely that there are any techniques superior to microdialysis for collecting only the 
unbound pharmacologically active and therefore clinically relevant portion of the drug.  
1.4.2 INTRODUCTION TO MICRODIALYSIS 
Microdialysis can be used to describe the pharmacokinetic behaviour of drugs in the organs 
rather than in circulation as a continuous monitoring and sampling technique. The concept of 
microdialysis was originally introduced by Professor Urban Ungerstedt (Karolinska Institute, 
Stockholm) in the early 1970’s as a novel technique for neurological studies whereby the 
concentrations of neurotransmitters could be measured directly in the extracellular fluid of the 
central nervous system and brain using dialysis tubing as an artificial blood capillary142. 
Initially the data gained were not quantitative which proved problematic for pharmacokinetic 
research. To overcome this, calibration techniques were developed, originally by Lönroth et al 
(1987) who developed the ‘no-net-flux’ method for endogenous glucose143. Microdialysis was 
first used in clinical pharmacokinetic studies in 1991 to study acetaminophen disposition in 
anaesthetised rats 144. 
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Microdialysis is now used for a wide range of pharmacokinetic studies, as well as being 
included in the FDAs Critical Path Initiative (2004) which focusses on the implementation of 
new technologies in the development of drugs.  
Microdialysis is a technique for sampling the chemistry of the interstitial fluid of tissues and 
organs. Hence microdialysis can be used to describe the pharmacokinetic behaviours of the 
drugs in organs, in live freely moving animals, as a continuous sampling technique. The 
continuous nature of the sampling is due to the fact microdialysis does not interfere with blood 
homeostasis, so the number of samples taken is not limited145. It can therefore have 
applications as a continuous real time monitoring technique, when coupled to online analysis, 
to measure analytes such as blood glucose.  
Microdialysis sampling has been conducted in virtually every organ of the body in a wide range 
of species as evidenced by over 10,000 publications of which 1,600 involve human applications 
of the technique. A literature search focussing on publications between 2014 and 2019 with 
microdialysis being the main technique employed showed over 200 publications. The majority 
of these studies focus on brain microdialysis in rats and mice with the purpose of 
characterisation of neurotransmitters, but there are a few examples of microdialysis being 
employed in the brains of mice and rats to determine the pharmacokinetic profiles of drugs146–
149. There are a number of publications using microdialysis in the bone and pulmonary 
epithelial lining fluid (PELF) of pigs150–152.  Human microdialysis has been conducted in the 
brain with relation to neurotransmitters 153,154, skin for topical agents 155,156, one example of a 
study where linezolid was dialysed in soft tissue 157 but most relevant to this PhD is a  
microdialysis study conducted to better understand the pharmacokinetics of levofloxacin 
especially penetration into cavities of patients with multi-drug resistant TB 158.  Microdialysis 
has been conducted in guinea pigs, primarily in relation to the effects of nerve agents, but there 
are limited publications using this species between 2014 to 2019 and none identified that used 
microdialysis to study pharmacokinetics of drugs in the internal organs 159–161. 
Microdialysis involves the insertion of a hollow fibre probe with a semi permeable membrane 
tip into peripheral or soft tissue. Although the probe insertion can be invasive (primarily 
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dependent upon the site of implantation), the probe is so small that even multi-slice CT 
scanning cannot detect the probe in situ 141. This small size also enables the different 
compartments of complex organs to be distinguished  as the concentrations of drugs 
(antimicrobials) may vary between these compartments 141. Multiple probes can be used in 
different tissues simultaneously which enables drug distribution information to be collected 
within the same animal although this cannot be conducted in a freely moving animal.  
The concept of microdialysis is based upon the passive diffusion of analytes across a semi-
permeable membrane driven by a concentration gradient. The constant perfusion of the probe 
with a ‘perfusion fluid’  (a physiological salt solution)   means that drugs of a certain size can 
pass into this fluid (dialysate) across the membrane of the probe tip, which has a molecular 
weight cut off that is dependent upon the pore size162. A schematic is shown in  Figure 1.5. 
Following a variety of analytical techniques, most notably LC-MS/MS, the in vivo recovery of 
the drug can be calculated from the collected dialysate145. 
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FIGURE 1.5: SCHEMATIC DRAWING OF THE CONCEPT OF MICRODIALYSIS METHODOLOGY CENTRED AROUND THE PROBE. Perfusion fluid is pumped from the syringe 
pump into the probe. The probe has a semi permeable membrane tip that is inserted into the tissue.  As shown in the enlarged diagram of probe tip, the white 
arrows (and circles) indicate the direction and movement  of the perfusion fluid. The black arrow (and triangles) indicate the movement of the unbound active 
drug or analyte. These molecules pass through the semi permeable membrane and the resulting dialysate is transported out to  a collection tube via the outlet 
tubing.  
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1.4.3 MICRODIALYSIS METHODOLOGY 
 It is vitally important that meticulous in vitro experiments are carried out with each potential 
drug (or analyte) to determine the efficiency of the probe and optimisation of other 
microdialysis parameters including the analytical method,  probe, perfusion fluid, tubing as 
well as tissue factors in order to calculate the relative recovery (described in Section 1.4.3.2). 
1.4.3.1 ANALYTICAL METHODS  
Initially the analytical methodology and the sensitivity of this methodology (the lower limit of 
quantitation (LLOQ)) to measure the drug concentrations in the dialysate needs to be 
identified. This is because the subsequent flow rate of perfusion fluid and sampling interval 
can only be optimised once it has been ensured that sufficient sample volume (and drug 
concentration) is available for the analytical methodology of choice163. The first step of the 
analysis is the separation of analytes that are in the dialysate, and (ultra) high performance 
liquid chromatography ((U)HPLC) is the most commonly used method164,165. Following 
separation of the analytes in the dialysate, a valid detection method needs to be employed and 
this is usually conducted using mass spectrometry (MS). MS can be used to analyse drug or 
analyte concentrations with very low detection limits; however, limitations can arise due to 
ion suppression as the sample matrix of the dialysate has a high ionic strength. However, 
specialist perfusion fluids can be created to eliminate the problems associated with the high 
salt concentrations found in microdialysis samples.  
Most microdialysis samples are stored and analysed at a later date in order to calculate the 
concentration and recovery of the drug, especially during in vivo studies. Sample storage is 
important to ensure stability of the drug and to reduce the potential for losses such as 
evaporation prior to analysis. Fortunately, microdialysis generates protein-free samples due 
to the molecular weight cut-off of the probe, therefore reducing the likelihood of enzymatic 
degradation during storage as well as reducing time required for sample preparation prior to 
analysis 166.   
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Once the analysis and sample storage methods have been chosen and the required sample 
volume identified, the other in vitro factors that can affect relative recovery can be taken into 
account (as discussed in Chapter 3).  
1.4.3.2 RECOVERY & CALIBRATION 
The recovery of the drug is dependent upon a variety of experimental conditions which can be 
trialled including flow rate, membrane surface area, the material of the membrane, tubing 
materials and dimensions, temperature, tissue factors and the perfusion fluid 143,167,168. 
Changing any one of these parameters can either increase or decrease the relative recovery of 
the probe and hence the resulting drug concentration in the dialysate.  
The recovery is the relation between the concentrations of the drug in the periprobe fluid (the 
fluid surrounding the probe, and therefore concentration in the organ) and that in the collected 
dialysate169.  These concentrations will be different because the constant flow of perfusion fluid 
means that a concentration equilibrium cannot be established, and hence the concentration of 
the drug in the dialysate is always a fraction of the actual drug concentration in the organ. 
Recovery  can be calculated using the following equation: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) = (𝐶𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 ÷ 𝐶𝑝𝑒𝑟𝑖𝑝𝑟𝑜𝑏𝑒)×100 
Cperiprobe is the concentration of drug in the fluid surrounding the probe; Cdialysate is the 
concentration of drug in dialysate. The resulting percentage generated by the equation shows 
how efficiently the probe is recovering the drug. Once the recovery has been established this 
percentage can then be used as a correction factor and applied to the collected drug 
concentrations in order to calculate the concentration of drug in the organ. It is recommended 
that relative recoveries are over 20%170. 
The flow rate directly affects the efficiency of the probe as shown in Figure 1.6. The 
microdialysis probe is more efficient, with a greater recovery of drug in the resulting dialysate, 
at lower flow rates, decreasing from 100% at 0.1µl/min. However, these slow flow rates may 
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not give the desired temporal resolution or not produce sufficient sample volume for analytical 
methodology.  
As mentioned, the continuous perfusion of the microdialysis probe with perfusate means that 
only a fraction of the drug concentration in the extracellular fluid is reflected in the dialysate, 
and therefore it is essential to understand at what efficiency the probe is extracting the drug 
from the tissue extracellular fluid. This is crucial for determination of true extracellular tissue 
concentrations.  Calibration is initially performed in vitro; however, the in vitro recovery must 
be verified in vivo due to different tissue characteristics. There are a variety of methods for 
calibration.  
One of the calibration methods to calculate relative recovery is the extraction efficiency 
method166. The perfusion fluid contains no drug and the probe is placed into a drug containing 
solution, with or without tissue, and the relative recovery of the probe is calculated and the 
error propagated over a series of experiments to calculate probe efficiency (how efficiently the 
probe is extracting the drug from the tissue). The main advantage to this methodology is that 
parameters can be changed to improve the relative recovery in a step-wise manner. The 
disadvantages are that it can be time consuming, requires dedicated analysis facilities and each 
drug will need to be trialled in the system and have a probe efficiency attributed to it. This was 
the method used in this PhD, as described in Chapter 3. 
The most commonly used calibration method is retrodialysis in which the drug of interest is 
added to the perfusion fluid at a known concentration, and the in vivo loss of the drug from the 
perfusion fluid can be used as a measure for in vivo recovery171. The No Net Flux Method (also 
known as the ‘Difference Method’) involves the consecutive perfusion of varying 
concentrations of the drug into the perfusion fluid and measuring the resulting dialysate 
concentrations. The difference between the analyte concentrations in the perfusion fluid and 
the dialysate are calculated and regression analysis performed to calculate the perfusate 
concentration 145,143,172. Although this method is time-consuming, it is the gold standard for 
microdialysis calibration.  
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Other calibration techniques include the ‘zero flow’ and ‘ultraslow flow rate’ methods; the 
‘extended or dynamic no net flux’ method which in contrast to the ‘no net flux’ uses only one 
selected perfusion concentration of the drug173. There is also the ‘internal standard’ technique 
whereby an internal standard (urea or glucose) is added to the perfusion fluid174,175  and the 
‘combined retrodialysis by drug or calibrator’ technique which is a combination of 
retrodialysis and the internal standard method167.  
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FIGURE 1.6: THE RELATIONSHIP BETWEEN FLOW RATE, SAMPLE VOLUME AND PROBE EFFICIENCY. As the flow rate increases from 1 to 5µl/min the sample volume 
increases as indicated by dashed line. The black (10min), blue (15min), green (20min) and red (30min) lines illustrate that decreasing the flow rate increases  
the probe efficiency and that increasing sample collection duration (from 10 to 30 min) means higher sampl e volume but decreased probe efficiency.  Slow 
flow rates give good probe efficiency but small sample volumes for analysis . The converse is true for fast flow rates.  Credit: Stuart Armstrong.
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1.4.3.3 PROBES, TUBING AND PERFUSION FLUID 
Microdialysis probes, which are commercially manufactured for various peripheral or soft 
tissues and brain, have a variety of characteristics that need to be considered. The most 
important factor is the molecular weight (Mw) cut-off of the probe membrane. It is imperative 
to know, before choosing a probe, the molecular masses of any drugs being investigated to 
ensure that the drug will be able to pass through the pores in the semi-permeable membrane. 
The main advantage of microdialysis is that the unbound portion of the drug is collected, if a 
Mw cut-off is too large it may allow serum proteins through, therefore both protein-bound and 
unbound drug would be collected. The probe membrane material must also be considered, as 
the drug of interest may interact or adsorb to the membrane, which therefore would affect the 
flow of perfusate and consequently the recovery of the drug.  However, as the majority of 
probes used are commercially bought, it is not straightforward to change the probe membrane 
material. The membrane surface area is an additional characteristic to consider, as the surface 
area is proportional to the drug recovery; an increase in probe membrane surface area (an 
increase in the length of the probe) will increase recovery. However, the probe membrane may 
be too long to fit into the organ of interest.  
The volume of dialysate collected in the desired time period can also be affected by the length 
of the inlet and outlet tubing.  The tubing needs to be of sufficient length to incorporate 
parameters required for in vivo experiments such as the length of the harness spring. This 
highlights the need to perform in vitro studies incorporating all parameters that will be used 
for in vivo experiments. The material used in the manufacture of the tubing also needs 
consideration with respect to the adherence of drug to the tubing surface as well as the 
diameter and dimensions with regards to static and pulsatile pressures. The commercially 
bought CMA20 microdialysis probe comes pre-assembled with the tubing attached and 
therefore there is little choice in tubing material, hence other parameters will need to be 
altered to improve relative recoveries if the CMA20 probe is to be used.  
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The perfusion fluid must be similar in ionic strength, composition and pH to the surrounding 
extracellular fluid. It must also be compatible with the organ system and the drug being 
measured. There are commercially available perfusion fluids formulated for either brain or soft 
tissue microdialysis, yet Ringers Solution is often cited in the literature as the chosen perfusion 
fluid. Other components can be added to the perfusion fluid to increase recovery, such as 
Bovine Serum Albumin which can be used to block non-specific binding meaning that less drug 
will be adsorbed to tubing surfaces. It has been suggested that flushing the entire system with 
the drug eliminates the problem of loss due to adherence to plastic surfaces and that has been 
shown to be the case for rifampicin 176. 
1.4.3.4 MATHEMATICAL PRINCIPLES 
Mathematical principles can be applied to microdialysis to further understand the system. The 
principles of microdialysis are governed by an adaptation of Ficks Law of Diffusion and 
therefore predictions about how the drug will behave in the microdialysis system can be 
made168: 
𝐽 = (∆𝐶1−3) ÷ 𝑅1−3 
Flux (J) which is the moles of drug in solution transported over the area of diffusion is 
calculated by dividing the overall concentration difference (C) between the three media 
(perfusate (1), probe membrane (2) and tissue (3)) by the resistance to diffusion of the drug 
through the each of the media (R). The factors that guide diffusion differ in each media 
therefore each concentration profile will differ and therefore all must be taken into account. 
Bungay et al developed  ‘mass transfer resistance’ to calculate Ed which ‘describes the 
proportional difference in analyte concentration between undisturbed external medium and 
perfusate’ as a measure of probe efficiency. This calculation incorporates differential resistance 
and concentration gradient in tissue as well as gradient across width of the probe.  This 
framework also incorporates additional factors that affect diffusion in tissue under steady-
state conditions and hence can affect recovery such as degradation of the drug, reversible 
binding, hindrance and tortuosity of the tissue177.  
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1.4.3.5 IN VIVO FACTORS 
A good understanding and knowledge of the physiology of the organ to be dialysed is 
imperative since a number of factors including blood flow to and from the tissue, the ability of 
the drug to bind to cell surface proteins and also the complexity and tortuosity (diffusional 
path) of the organ will affect recovery. The geometry of the probe membrane means that an 
evenly distributed area of tissue is in contact with the probe membrane, which also acts as a 
physical barrier between the perfusion fluid and tissue protecting the tissue from the flow of 
the perfusate. Insertion of the probe into the tissue requires surgery, which can vary in 
invasiveness dependent upon which organ or area of the organ is being dialysed. Studies have 
investigated the effects of surgery and anaesthesia on microdialysis recovery, finding little 
evidence of any effect especially if a guide cannula is used to prevent damage to the probe 
membrane141,178. It has been shown that there is evidence of tissue trauma associated with 
probe insertion with probes inserted longer than 12 hours; this is associated with tissue 
necrosis, however linear probes are less damaging179. It is important to perfuse the 
microdialysis probe in situ for at least half an hour before beginning the microdialysis 
experiment to calibrate to the surrounding interstitial fluid180.  
Temperature is a key environmental parameter that needs to be taken into consideration when 
performing a microdialysis experiment. It has been reported that the higher the temperature, 
the greater the drug recovery, with a 1-2% increase in the diffusion coefficient observed for 
every 1°C increase in temperature168. de Lange demonstrated that microdialysis recovery at 
room temperature underestimated the in vivo recovery of the drug180. Therefore, it is of critical 
importance that the in vitro calibration studies which are conducted prior to the 
commencement of microdialysis in vivo are conducted at the specific body temperature of the 
species to be dialysed. This is also true of the perfusion fluid which should be warmed to the 
same body temperature before use.  
As described in these sections, the development of the microdialysis methodology can be 
broken down into an almost sequential series of experiments. The experiments are conducted  
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in order to calculate and optimise the relative recovery and ultimately the efficiency of the 
probe associated with different drugs by changing different experimental parameters.  
Thompson and Shippenberg168 published a series of 11 steps that should be followed to design 
and conduct a successful microdialysis experiment, and these 11 steps were adapted to 7 steps 
for the purposes of this PhD as described in Chapter 3.
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1.5 HYPOTHESIS AND AIMS 
New drugs and shorter, less toxic drug regimens are urgently needed to control TB. Pre-clinical 
tools that are predictive of human responses to drugs are essential to ensure that drugs 
entering clinical development are optimised with respect to human-relevant PK/PD. This PhD 
sought to address the need for relevant, predictive pre-clinical tools by refinement of a pre-
existing methodology to determine the PK of anti-TB drugs in guinea pigs and to develop and 
optimise the microdialysis technique in order to describe the organ-specific PK of drugs in the 
lung, the target organ for TB.  
The hypotheses to be tested were: 
1. Microdialysis methodology can be established to measure the concentration of drugs 
in the lung.  
2. The concentrations and concentration-time curves (PK curves) of anti-TB drugs within 
the blood will be significantly different to the concentrations and PK curves in the 
lungs. 
To address these hypotheses, the project had the following aims to:  
• Establish PK of TB drugs (rifampicin, isoniazid etc) in peripheral blood (Chapter 2). 
• Develop the microdialysis methodology in vitro; evaluation of probes, perfusion fluid 
and flow rates, development of calibration techniques and optimisation of analytical 
methods (mass spectrometry) with the overarching aim of calculating probe efficiency 
(Chapter 3). 
• Investigate and optimise parameters for in vivo microdialysis including evaluation and 
selection of suitable organ for probe implantation, considerations and method 
development for surgery and pre-/ post- operative care including analgesia and 
housing requirements (Chapter 4). 
• Determine the feasibility of measuring drug concentrations in organs (Chapter 4). 
• Use optimised microdialysis methodology to determine organ-specific PK for TB drugs 
and compare PK profiles with those obtained in blood (Chapter 5).  
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• Investigate the potential for microdialysis to reproducibly measure concentrations of 
drug in organs of a single animal over a time course thus reducing the overall number  
of guinea pigs required for PK studies, addressing the 3Rs. 
Development of microdialysis in the guinea pig model will give critical information to enable 
the PK of anti-TB drugs to be measured in the organs of disease and thereby generating an 
improved pre-clinical tool for dose and potentially regimen optimisation. 
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CHAPTER 2   
PK PARAMETERS OF ANTI-TB DRUGS IN BLOOD 
2.1 INTRODUCTION 
Prior to the studies to establish the in vitro parameters (i.e. flow rate, probe type, perfusion 
fluid) for microdialysis, it was necessary to determine the concentration of drugs to be used in 
developing the microdialysis methodology. It was important that the concentration was in a 
range that was relevant to that which would be present in vivo.  
Although there are similarities in biochemical, physiological and anatomical processes 
between species, there are also a number of differences. Hence for in vivo drug studies, the dose 
of drug to be administered to animal species must be optimised to be equivalent to human 
doses in order to model human drug exposure. There are various methods available to optimise 
doses between species and the primary method is allometric scaling based on weight. Although 
this method has been used with success, there are drugs whose behaviour is not well- predicted 
by allometric scaling, including drugs that have a molecular weight over 300Da and those that 
are excreted via the biliary route, such as rifampicin. This has led to the development of 
pharmacokinetically guided approaches to dose optimisation 135.  
Physiology-Based PK (PBPK) models can be used to predict the PK of drugs in humans using 
pre-clinical data136. This is done by adjusting the model parameters to incorporate human-
specific features following confirmation of PK in an animal species. These PBPK models can 
simulate and make predictions about drug behaviour in other species and can also enable 
doses to be scaled between species and within the same species (i.e. for specific populations) 
based on physiological data.  An alternative PK guided approach is to choose a dose for use in 
an animal species based on the AUC0-t (area under the concentration-time curve) in humans132. 
Different doses are applied in animal species in order to achieve the equivalent AUC0-t in 
humans. The AUC0-t is a measure of total systemic exposure to the drug integrated with time. 
For the front-line anti-TB drugs, the AUC0-t is strongly associated with efficacy in pre-clinical 
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models and the PK/PD parameter that best describes the antimicrobial efficacy of the four 
drugs is AUC:MIC104 though the Cmax: MIC is also associated with efficacy of rifampicin181.  The 
PK parameter(s) which best associate with efficacy are therefore used as a benchmark to 
bridge between species, testing different doses of the drug in animals in order to achieve (if 
available), the equivalent human PK value. This approach was taken in these studies and the 
target was to achieve human-equivalent AUC0-24.      
2.1.1 ANIMAL MODELS OF TUBERCULOSIS 
There are several different mammalian models that are used for TB drug development, this is 
because no one model recapitulates all the features of human TB disease182. The choice of 
animal model used is dependent upon the research question asked.  
These same animal species have also been used for microdialysis studies, although not 
associated with TB research. 
2.1.2 MOUSE 
Mouse (Mus musculus) models are routinely used for TB drug evaluation and there are many 
different mouse models that can be used dependent upon the research question. There are 
models that can be used to show sterilisation183 or early bactericidal activity184 (EBA) or 
whether drugs can prevent disease relapse185. Mice can be genetically modified to ‘humanise’ 
the internal anatomy in order to more fully replicate TB disease in humans186. Pathologically, 
unlike humans,  lung granulomas in mice lack structural organisation and rarely advance to 
caseous necrosis and cavitation, and although the presence of granulomas hinders bacterial 
growth, the disease does not reach a latent state and is associated with a progressive, chronic 
course of infection187. Mice can also maintain a high bacterial load throughout the disease time 
course188.  
Extensive studies have been conducted in various mouse models to characterise the PK of the 
anti-TB drugs with different parameter estimates being achieved for different strains. For 
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example, when the same dose of rifampicin was administered to three different mouse models, 
the terminal half-lives were reported as 4.4 hours for BALB/C mouse189, 7.6  hours for the Swiss 
mouse190 and 6.6 hours in C57BL/6137.  
Due to the small size of the mouse, the majority of microdialysis studies in mice have involved 
probe insertion into the brain as opposed to peripheral organs147,191.  
2.1.3 RABBIT 
Rabbits (Oryctolagus cuniculus) are the largest small animal model used in TB research and are 
used to recapitulate the spectrum of disease outcomes and pathologies in humans. Upon 
infection with M. tuberculosis, rabbits form lung lesions with the human-associated features of 
necrosis, caseation and cavitation192. This species has been useful to demonstrate drug activity 
and penetration into lesions with novel imaging techniques193. These imaging techniques have 
also been used for drug distribution studies 192,194. Similar to humans, rabbits have a varying 
level of resistance to M. tuberculosis disease although the commonly available strains of rabbit 
tend to be resistant (without pre-sensitisation) and this, along with the disadvantage of the 
larger size and cost of housing these animals at high containment, means that rabbits are less 
preferred for drug and method development studies.  
Microdialysis has been routinely performed in the brain and the eye of the rabbit 195.  
2.1.4 NON-HUMAN PRIMATE 
Non-human primate (NHP) species are used for TB research due to their physiological, genetic 
and immunological similarities to humans. The most common species used are Cynomolgus 
(Macaca fascicularis) and Rhesus (Macaca mulatta) macaques. Upon infection with M. 
tuberculosis, macaques like humans, can present with the full spectrum of TB disease including 
acute and chronic progression as well as latent disease 196. Imaging techniques for anti-TB drug 
distribution have been used in baboons (Papio) and a key finding of this study was that lung 
concentrations of total (bound and unbound) rifampicin were found to be 10 times above M. 
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tb MIC 115. Drug doses administered to NHPs can be selected based on allometric scaling (based 
on weight) from the dose administered to humans due to the close similarity between the two 
species.  The PK profiles of the current anti-TB drugs are very similar between humans and 
NHPs especially in relation to AUC0-t. NHPs  also show evidence of the fast/slow acetylator 
status associated with human isoniazid metabolism 197. This highlights the relevance of this 
species in terms of anti-TB drug PK and associated toxicities. NHPs are rarely used for 
development of new methods such as microdialysis, especially without trials in smaller animal 
species first due to ethical reasons.  
Microdialysis has been performed in NHPs, primarily in the brain, and the technique has been 
used successfully to add a wealth of data to the neuroscience field 198. 
2.1.5 RAT 
Although rats (Rattus) are used frequently for PK/PD studies, they are not frequently used in 
tuberculosis research due to their inherent resistance to the bacteria with few publications of 
studies with anti-TB drugs199. There are many examples of studies where rats have been used 
for microdialysis, primarily in the brain, for drugs (ie. Fluconazole148, clozapine200, 
ciprofloxacin201) and for other compounds (ie. Nicotine202, antibodies203, glutamate204). It is 
evident that the majority of the commercial microdialysis equipment has been developed for 
use with rats 165.  
2.1.6 GUINEA PIG 
Guinea pigs (Cavia porcellus) have been used in TB research since 1881 and they are still  
commonly used for TB pathogenesis studies and vaccine evaluation205. Disease progression, 
upon aerosol infection with M. tuberculosis in guinea pigs closely replicates several features of 
human TB, including the presence of caseous necrosis, granulomatous inflammation and 
occasionally pulmonary cavitation 206. These lesions, which are hall marks of TB disease, have 
an influence on the bioavailability and penetration of drugs as well as on the mechanism of 
drug action. Similar to humans, guinea pigs show a concentration-dependant response with 
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rifampicin and isoniazid and also demonstrate the superior sterilising activity of rifampicin 
over isoniazid207. Additional advantages to the guinea pig model in relation to their similarities 
to humans, are that Dunkin-Hartley guinea pigs (the strain most commonly used for TB 
research) are genetically outbred which means there is heterogeneity associated with disease 
progression.  Additional similarities are that guinea pigs have susceptibility to low dose aerosol 
infection 19 and show weight loss throughout disease progression, however, key differences 
between guinea pig and human disease is that upon aerosol infection all guinea pigs will have 
active disease progression (no latent disease) which is unlike humans, and that in the rare 
event of pulmonary cavitation in guinea pigs, which can be a common occurrence in human 
disease,  the guinea pig usually dies before any small cavities can become larger and liquefy208. 
Despite the many advantages of the guinea pig model to study TB, guinea pigs have a very 
sensitive gut flora which means they are not an ideal model for drug studies. Drugs 
administered to guinea pigs often have to be co-administered with a lactobacillus probiotic 
which can change the gut microbiota and enzyme activities within the gut, ultimately affecting  
PK parameters209. Other disadvantages include the lack of accessible peripheral veins for blood 
collection; the marginal ear vein is the most easily accessed, but blood can also be collected 
from the tarsal vein and lateral saphenous vein. Blood collection from these venous sites are 
non-terminal procedures however only small volumes of blood can be collected, with no more 
than 1% of the guinea pigs blood volume or more than 4 blood samples removed over a 24 
hour period. The collected blood also has a rapid coagulation time which can prove problematic 
when collecting small volumes for PK analysis210.   
There are almost 150 publications where microdialysis has been performed in guinea pigs. The 
majority of these studies involve microdialysis in the brain, inner ear and skin for numerous 
xenobiotics including drugs211,212,213, nerve agents214 and nerve agent treatments215 as well as 
endogenous compounds such as serotonin216.  Guinea pigs were the species of choice for this 
PhD with the intention of improving this model for anti-TB drug evaluation. Characterising the 
PK of novel and existing drugs in this model, with microdialysis, would be valuable to better 
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understand drug PK in this important model of TB disease and therefore to potentially predict 
effective drug concentrations for humans. 
2.1.7 DEFINING BASIC PK PARAMETERS VIA BLOOD SAMPLING 
Using guinea pigs as the species of choice, the studies described below were designed to 
understand and define drug doses in the guinea pig in order to achieve the equivalent human 
AUC0-t. The aim was to describe human-relevant drug exposures of the four frontline anti-TB 
drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) delivered as single drugs or in 
combination. These studies were conducted within the PreDiCT TB project (Chapter 1; 1.2.6). 
The short half-lives of the anti-TB drugs means that it was possible to describe the PK profile 
after one single oral dose137. External partners of the PreDiCT TB consortium contributed to 
this work with respect to the processing and UPLC-MS/MS analysis of blood samples to 
measure drug concentrations (GSK) and the analysis and interpretation of the data in R to 
generate AUC0-t data of the anti-TB drugs (University of Liverpool). The sample analysis and 
resulting data analysis were a central resource for the PreDiCT TB project to ensure 
harmonisation between the different partners within the consortium.  
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2.2 METHODS 
EQUIPMENT AND REAGENT LIST 
Equipment Comments Source 
2ml syringe Oral administration of drug BD574/GS576; Appleton Woods 
Ltd, Birmingham, UK 
Scalpel Ear bleeds No. 15A; Product Code: 0320; 
Swann Morton, Sheffield, UK 
20, 21, 23 gauge needles Various uses Terumo Agani, Surrey, UK 
Chemical and Reagent Comments Source 
0.1% Acetic Acid in HPLC 
water 
Chromatographic Solvent 1005706; Sigma Aldrich Co LTD 
Dorset, UK 
0.1% Heptafluorobutyric Acid Chromatographic Solvent 52411; Sigma Aldrich Co LTD 
Dorset, UK 
Acetonitrile Chromatographic Solvent PHR1551-3X1.2ml; Sigma 
Aldrich Co LTD Dorset, UK 
Apple and Banana fruit puree To help palatability of drugs 
for oral administration 
Ella’s Kitchen, Henley-on-
Thames, UK 
Butylhydroxytoluene  B1215000; Sigma Aldrich Co, 
Dorset, UK 
Dimethyl sulfoxide (DMSO)  D2650; Sigma Aldrich, Dorset, 
UK 
Ethambutol  E4630-25G; Sigma Aldrich Co 
LTD, Dorset, UK 
HPLC (High Performance 
Liquid Chromatography) 
Grade Water 
Many uses including diluting 
drug to create ‘dose solution’ 
This water is free from organic 
and inorganic compounds and 
has no UV absorbance. 
270733-1L-M; Sigma Aldrich Co 
LTD, Dorset, UK 
Isoniazid  I3377-250G; Sigma Aldrich, 
Dorset, UK 
Midozolam Internal Standard BP722; Sigma Aldrich Co, 
Dorset, UK 
Pyrazinamide  P7136 100G; Sigma Aldrich, 
Dorset, UK 
Reserpine Internal Standard 43530-4-5ML-F; Sigma Aldrich 
Co, Dorset, UK 
Rifampicin  R3501-1G; Sigma Aldrich, 
Dorset, UK 
UPLC/MASS SPECTROMETRY 
GlaxoSmithKlein R&D, 
Diseases of the Developing 
World, Tres Cantos, Madrid, 
Spain 
(UPLC) Aquity System with 
Sampler Manager 
Waters, Hertford,  UK (UPLC) Column; Aquity UPLC 
BEH C18 50x2.1mm, 1.7µm 
column 
(Mass Spectrometer) API4000 Sciex, Warrington, UK 
(Data Collation) Mass Lynx Waters, Hertford,  UK 
 
 
66 
 
2.2.1 ETHICS STATEMENT 
All of the guinea pig procedures were approved by UK Home Office legislation for animal 
experimentation as well as being approved by Public Health England, Porton Down local 
animal welfare and ethical review body (AWERB). All in vivo work was carried out under 
Project Licence: PPL NO. 30-3236. As far as possible principles of randomisation, non-bias and 
blinded analyses were adhered to, for example by using identification microchips. 
2.2.2 GUINEA PIGS 
Female full barrier-reared, out-bred Dunkin-Hartley guinea pigs (weighing between 200 and 
250g; Envigo UK) arrived on site at least 72 hours prior to commencement of the first 
procedure. Throughout the duration of the study, guinea pigs were kept in a controlled 
environment and had access to food (Global Guinea Diet; Envigo, Enrichment Feed: Forage Mix; 
Envigo) and water ad libitum.  
2.2.3 PREPARATION OF DRUGS FOR ORAL ADMINISTRATION 
The drugs were orally administered and for the purpose of these studies as monotherapy, 
rather than in combination. The doses trialled were: isoniazid: 50mg/kg; rifampicin: 50 or 75 
mg/kg; ethambutol: 100 or 250mg/kg. Animals were weighed immediately prior to 
administration of the drugs to the ensure accuracy of the dose. Due to the small volume of drug 
required per animal, a larger volume homogenous solution of the drug was prepared, with 
multiple doses created from the same stock solution. Solutions for administration were mixed 
with an apple and banana fruit puree, to make the drug more palatable for the guinea pigs.  The 
drug and puree mixture was divided into 2ml volumes (in syringes) for administration.  
2.2.4 ORAL ADMINISTRATION OF DRUGS TO GUINEA PIGS 
Guinea pigs were gently restrained by hand and the syringe placed into the mouth, until the 
syringe end was at the rear of the buccal cavity. In a controlled manner 0.2ml of formulation 
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(drug+ puree) was administered into the back of the mouth. This was repeated until all the 
formulation had been consumed by the guinea pig. If the guinea pig was not consuming the 
formulation with ease, the syringe was removed from the mouth and a smaller volume of 
formulation introduced. Enough time was given for the guinea pig to consume the formulation. 
It was important to ensure that the guinea pigs were ingesting the formulation and not holding 
it in their cheeks. After all of the formulation had been consumed the time was recorded and 
the subsequent time of sample (blood and/or microdialysis fraction) collection was calculated 
from this point (t0). 
2.2.5 COLLECTION OF BLOOD FROM PERIPHERAL VEIN IN EAR 
Blood was collected from the peripheral vein in the ear at 0.25, 0.5, 1, 2, 4, 7, 10 and 24 hours 
post drug administration. 12 guinea pigs were ear bled (2 blood sampling occasions each) for 
the studies detailed in this chapter.  The guinea pig was gently restrained by hand and the ear 
gently held and rubbed with fingers to ensure maximum blood flow. A small incision was 
carefully made in a peripheral vein in the guinea pig ear using a scalpel. A 100µl sample was 
collected into a tube containing 200µl HPLC water. The blood was mixed thoroughly with the 
water using a vortex, placed into liquid nitrogen and stored at -80°C until protein precipitation 
and analysis. Residual blood flow from the vein was stopped using a sterile tissue. 
2.2.6 UPLC-MS/MS SAMPLE ANALYSIS 
The blood samples from these PK studies were analysed at GlaxoSmithKlein, Tres Cantos, 
Spain. A deliverable of the PreDiCT TB consortium was that all the in vivo samples be analysed 
in a harmonised and centralised resource, this was provided by GSK. The UPLC- MS/MS (Ultra-
high Performance Liquid Chromatography-Mass Spectrometry/Mass Spectrometry) protocol 
and details of sample analysis given below was shared by Dr Fatima Ortega-Muro (Principal 
Scientist, GSK).  
The UPLC system consisted of an Aquity UPLC System with Sampler Manager. The column used 
was an Aquity UPLC BEH C18 50x2.1mm, 1.7µm column. The mass spectrometer used was an 
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API4000 with electrospray ionisation source (ESI). Data were collected and processed using 
MassLynx. The chromatographic conditions are shown in Table 2.1. 
Gradient 
Acetonitrile 
0.1% 
heptafluorobutyric 
acid 
+ 0.1% acetic acid in 
HPLC grade water 
Time (Min) %A %B 
0 0.1 99.9 
0.2 3 97 
1.2 50 50 
1.6 99 1 
2 99 1 
3.55 0.1 99.9 
Flow Rate: 350µl/min 
Column 
Temperature: 
5°C 
Injection 
Volume: 
10µl 
TABLE 2.1: CHROMATOGRAPHIC CONDITIONS USED AT GSK for the rifampicin, isoniazid and 
ethambutol. The total run time was 3.55 minutes.  
1mg/ml stock solutions of the front-line anti-TB drugs were made in 50:50 Methanol: Water. 
1mg/ml internal standards reserpine and midazolam were prepared in dimethyl sulfoxide 
(DMSO) and further diluted in acetonitrile/methanol (80:20 v/v) to create 200ng/ml and 
50ng/ml working standards respectively. Butylhydroxytoluene (1% w/v) was added as 
antioxidant agent. 
Using the ESI, the mass spectrometer (MS) was operated in the positive ionisation mode 
(Nebuliser gas (NEB) 50PSI, Curtain gas (CUR) 10PSI, Collisionally Activated Dissociation 
(CAD) 5PSI, Ion-spray Voltage (IS) 2550V, Temperature of ion source (TEM) 500°C). The 
determined multiple reaction monitoring (MRM) transitions (m/z) were 138.02/120.98 for 
isoniazid, 205.4/115.9 for ethambutol and 823.5/791.2 for rifampicin.  For the internal 
standards transitions were 609.61/194.97 for reserpine and 326.41/291.21 for midazolam. 
Mass spectrometry parameters are shown in Table 2.2. 
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Compound 
De-
clustering 
Potential 
(V) 
Entrance 
Potential 
(V) 
Collision 
Energy 
(Electron-
volt) 
Collision 
Cell Exit 
Potential 
(V) 
Retention 
Time 
(Minutes) 
Rifampicin 56 10 23 24 2.02 
Isoniazid 26 10 21 6 1.26 
Ethambutol 76 10 15 6 1.44 
Reserpine 76 10 35 6.3 1.90 
Midazolam 76 10 35 6.3 1.77 
TABLE 2.2: MASS SPECTROMETRY PARAMETERS FOR DRUGS AND INTERNAL STANDARDS AT GSK.  
The UPLC-MS/MS methodology was validated by adherence to the  following acceptance 
criteria; the signal in the blank sample was <20% of the signal of the lowest calibration 
standard, the internal standard area in calibration standards did not differ from the area in 
unknown samples by more than 30%, definition of the upper limit of quantitation ((ULOQ) 
which was the calibration standard that met the acceptance criteria immediately above the 
highest concentration sample) and lower limit of quantitation ((LLOQ) which was the lowest 
calibration standard which meets the acceptance criteria if the signal is 10-fold of the signal to 
noise ratio). 
2.2.7 DATA ANALYSIS 
The concentrations of drug measured in the blood samples at GSK were analysed using PK 
Solver which is a freely available add-in programme for Microsoft Excel (2003-2010) designed 
by Zhang et al217. It was developed for a range of PK/PD analyses including non-compartmental 
analysis for extravascular administration and compartmental analysis of concentration-time 
data.  
The data (concentration in ng/ml inputted as µg/L (ng/ml=µg/L)) for each of the drugs were 
input into Microsoft Excel 2010. The PK Solver add-in programme was installed, and the 
concentration against time data was selected for analysis within the programme using the non-
compartmental analysis following an extravascular dose. The results are shown in Figure 2.1 
and Table 2.3.  
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The PK Solver add-in for Microsoft Excel can be found in the online version of the publication: 
doi:10.1016/j.cmpb.2010.01.007 
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2.3 RESULTS 
The data shown in Figure 2.1 are the concentration-time curves generated in PK Solver, for 
each drug and dose.  The concentrations of drug  from three guinea pigs bled at each time point 
were averaged. PK Solver was also used  to generate the associated AUC0-t (0-24 hours) and 
AUC0-inf (AUC extrapolated to infinity time) using the linear trapezoidal method, these and  
other PK parameters are shown in Table 2.3. 
 
FIGURE 2.1: PK PROFILES GENERATED IN PK SOLVER. The concentrations of  isoniazid (50mg/kg), 
rifampicin (50mg/kg vs 75mg/kg (no rifampicin measured after 10 hours post drug 
administration)) and ethambutol (100 vs 250 mg/kg) in blood over 24 hours.  
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Non-Compartmental Analysis 
Drug   Rifampicin Isoniazid Ethambutol 
Dose mg/kg 50 75 50 250 100 
h t1/2 16.68 3.75 9.2 7.61 7.77 
h Tmax 1 2 1 0.25 0.5 
mg/L Cmax 4.3 0.5 1.9 3.4 4.8 
mg/L*h 
AUC0-24 5.66 1.51 7.06 16.43 14.42 
AUC0-inf 7.07 1.98 9.61 18.42 17.77 
TABLE 2.3: PK PARAMETERS  FOR RIFAMPICIN, ISONIAZID AND ETHAMBUTOL CALCULATED FROM CONCENTRATION IN GUINEA PIG BLOOD .  The parameters shown, 
calculated using PK Solver are t1/2 (half-life of the drug), Tmax (time at which maximum concentration occurs), Cmax (maximum concentration). AUC0-t and 
AUC0-inf  are shown (mg/L*h).   
Species Drug Dose (mg/kg) 
Median AUC
0-24 
(mg/L*h) 
AUC
0-24 
Range 
(mg/L*h) 
Cmax 
(mg/L) 
(Range) 
Median Tmax 
(h) 
t1/2 
(h) 
(Range) 
Reference 
Human 
  
Rifampicin (Median) 9.8 35.4 26.8-49.9 9.0 (6.6-12.8) 3.0 1.6 (1.4-1.8) 
218 
Isoniazid (Median) 4.9 4.4 1.3-15.0 1.9 (1.0-3.5) 1.0 1.9 (0.9-4.0) 
Ethambutol (Median) 17.2 12 5.4-28.2 1.8 (0.9-3.7) 4 3.3 (2.5-7.4) 130 
TABLE 2.4:  PK PARAMETERS OF RIFAMPICIN, ISONIAZID AND ETHAMBUTOL IN HUMANS. Published data (from Burhan et al and Denti et al) calculated from measured 
drug concentrations in blood.  
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2.3.1. ISONIAZID 
The concentration-time curve for isoniazid showed a biphasic profile and the AUC0-24 with a 
dose of 50mg/kg was 7.06mg/L*h, which was within the range of AUC0-24 data obtained in 
humans with a median dose of 4.9mg/kg. The Tmax and Cmax values for isoniazid in guinea 
pigs were 1h and 1.9mg/L respectively which are similar values as those obtained in the human 
study. The t1/2 value obtained from the guinea pig data (9.2h) was greater than that measured 
in humans (1.9h).    
 2.3.2. RIFAMPICIN 
At a dose of 50mg/kg, the PK properties of rifampicin in guinea pigs were different to the 
published human data. The AUC0-24 was  5.65mg/L*h which was lower than the value obtained 
in humans (35.4mg/L*h).   The Cmax of rifampicin was also lower in guinea pigs (4.3mg/L) 
than in humans. The Tmax  occurred later in the human PK profile than in the guinea pig profile 
(3 hours vs 1 hour) and the half-life (t1/2) was longer (16.6h) in guinea pigs than humans (1.6h). 
A higher dose of rifampicin (75mg/kg) given to guinea pigs, did not result in an increase in the 
AUC0-24 , or Cmax, compared with the 50mg/kg dose, the values obtained were lower with the 
higher dose, which is an unexpected result.    
2.3.2. ETHAMBUTOL 
Following a 100mg/kg dose of ethambutol, the AUC0-24 was 14.4mg/L*h and with a 250mg/kg 
dose the AUC0-24 was 16.4mg/L*h and these values were within the range of values obtained in 
humans dosed with 17mg/kg. The Cmax values were 4.8mg/L and 3.4 mg/L respectively for 
the 100mg/kg and 250mg/kg doses and these values obtained in guinea pigs were around the 
higher end of the range of values obtained in humans. The t1/2 in guinea pigs was also similar 
to values obtained in humans but at the higher end of the range. The Tmax occurred earlier in 
guinea pigs (0.25 and 0.5 h for the 100 and 250mg/kg doses respectively) than in humans 
(3.3h).  
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2.4 DISCUSSION AND CONCLUSIONS 
The PK profiles and parameters of each drug in the guinea pig were compared with published 
data for humans as described by Burhan et al218 and Denti et al130 . A summary of these 
parameters are shown in Table 2.5. 
 
AUC0-24 
mg/L*h 
Cmax 
mg/L 
Tmax 
h 
t1/2 
h 
Guinea 
Pig  
Human 
(Range) 
Guinea 
Pig  
Human 
Guinea 
Pig  
Human 
Guinea 
Pig  
Human 
(Range) 
Isoniazid 7.06 
1.3-
15.0 
1.9 
1.0-3.5 
(median:1.9) 
1 1 9.2 0.9-4 
Rifampicin 
50mg/kg  
5.66 
26.8-
49.9 
4.3 
6.6-12.8 
1 
3 
16.68 
1.4-1.8 
Rifampicin 
75mg/kg  
0.5 0.5 2 3.75 
Ethambutol 
250mg/kg 
16.43 
5.4-
28.2 
3.4 
0.9-3.7 
0.25 
4 
7.61 
2.5-7.4 
Ethambutol 
100mg/kg 
14.42 4.8 0.5 7.77 
TABLE 2.5: SUMMARY PK PARAMETERS AS GENERATED IN BLOOD FOR GUINEA PIGS compared to PK 
parameters generated in humans as identified in the literature. 
These publications describe studies to evaluate the PK of the anti-TB drugs in populations who 
were patients with pulmonary TB and provided a data set with which to compare the PK 
parameters between species, based upon concentrations of drug measured in the blood. 
Of the PK parameters examined, the AUC0-24 and Cmax were the ones which were most  similar 
between the human data and the data from guinea pigs at the doses given. This was particularly 
the case for isoniazid and ethambutol. With the exception of t1/2 , which was longer in guinea 
pigs than in humans, the PK parameters obtained when guinea pigs were given a dose of 
50mg/kg of isoniazid were closely matched to those described in humans dosed at 4.9mg /kg. 
In humans, isoniazid concentrations were modelled using a two-compartment model130 and 
these data in guinea pigs were modelled using a non-compartmental analysis, so the t1/2 
measured in guinea pigs most likely overestimates the initial apparent half-life. These data 
collectively demonstrate that allometric scaling is not appropriate for identifying the most 
appropriate doses for an animal species. Generally, in order to achieve human-like exposures, 
the drug dose required for guinea pigs was much greater than that which would have been 
predicted by scaling based upon weight. 
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The AUC0-24 and Cmax for rifampicin were the least closely matched between humans and 
guinea pigs with 50mg/kg and 75mg/kg doses in guinea pigs resulting in much lower values 
for these PK parameters than a human dose of 9.8mg/kg. Additionally, the 75mg/kg dose not 
only failed   to increase systemic exposure (AUC0-24) but resulted in a decrease. The differences 
in t1/2 between 50mg/kg and 75mg/kg rifampicin doses were most likely an artefact of the 
unusual profile associated with 75mg/kg dose.  The higher dose of rifampicin was tested after 
a one- week washout period in the same guinea pigs that received the 50mg/kg dose of 
rifampicin.  The reduction in the systemic exposure could be explained by the auto-induction 
of rifampicins’ metabolism. Auto-induction, whereby a drug induces enzymes that enhance its 
metabolism, is known to occur following secondary exposure to rifampicin, resulting in a more 
rapid clearance even though a higher dose was administered219. Auto-induction has not 
previously been reported in the guinea pig after a single dose or when dosed to a steady state220 
although auto-induction following rifampicin administration has been identified in mice137.  
Studies to investigate whether human-like exposures could be achieved with doses of 
rifampicin higher than 50mg/kg were not pursued due to potential toxicity of this drug in 
guinea pigs. Antibiotic-associated enteritis was observed in some of the animals, a 
phenomenon also observed by Ahmad et al. After 14 days of treatment with rifampicin, 7/61 
guinea pigs were culled following colon distension and a directly toxic effect on the GI tract 207. 
It has been reported that a dose of 100mg/kg rifampicin in guinea pigs achieved a median AUC0-
24  of 71.0mg/L*h which indicates that exposures equivalent to or even higher than the human 
range of AUC0-24 can be achieved220 but this comes with a risk of toxicity, especially in the GI 
tract which can limit the bioavailability of rifampicin.  
 The data generated in the studies described in this Chapter enabled key parameters to be 
established prior to initiating microdialysis method development and subsequent 
investigations of anti-TB drug PK in disease-relevant tissue. These data were: 
• Identification of drug doses for guinea pigs that are relevant to human exposures and 
that can be used as a starting point for set-up and optimisation of the in vitro 
parameters of microdialysis, such as flow rate, selection of probe and perfusion fluid.  
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A dose of 50mg/kg isoniazid and the doses of ethambutol (100 and 250mg/kg) were 
selected because these gave human-like exposures in guinea pigs and the rifampicin 
dose of 50mg/kg was chosen although it did not achieve a human-like AUC, to ensure 
minimal adverse drug effects.   
• Concentration-time curves for the drugs to define post-drug sampling time points and 
other aspects of study design (taking into account 3Rs principles) to measure and 
compare concentrations of drug in blood and  tissues sampled using microdialysis. For 
example, it was shown for both rifampicin and isoniazid that the Tmax occurred before 
the four hour time point, and therefore a four hour dialysis period would be sufficient 
for microdialysis studies in guinea pigs. 
• Blood PK parameters for the anti-TB drugs which serve as comparative data to evaluate 
consistency between guinea pigs that have undergone microdialysis or not and against 
which to compare tissue PK . 
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CHAPTER 3 
IN VITRO MICRODIALYSIS METHOD DEVELOPMENT 
3.1 INTRODUCTION 
The main principles of microdialysis, including a detailed overview of the factors that can affect 
the relative recovery of drug, was described in Chapter 1. Microdialysis is a continuous 
sampling technique and therefore describes the pharmacokinetic (PK) behaviour of drugs 
within organs and tissues as opposed to the traditional PK data collection site (blood) and 
importantly can be used to quantify the amount of unbound pharmacologically active drug. For 
the anti-TB drugs, where the target site for drug action is the lung, PK data obtained by 
microdialysis are thus more clinically relevant than data from the blood.  
Thompson and Shippenberg168 published a series of 11 steps that should be followed to design 
and conduct a successful microdialysis experiment. An adaptation of these 11 steps was 
devised and used to guide the progression of experiments performed in this PhD project, this 
adapted scheme is shown in Figure 3.1. Thompson and Shippenberg168  suggested that these 
steps be followed sequentially; however, in practice, the process of setting-up microdialysis for 
use with the anti-TB drugs was cyclical. For instance, whilst optimising the sensitivity of the 
analytical equipment; probe type (Mw cut-off) and membrane length, flow rate, perfusion fluid 
and other factors, including drug- specific and tissue- specific factors, needed to be considered 
to improve the efficiency of recovery.   
The initial in vitro experiments described here aimed to characterise the microdialysis system 
through testing different probes (different membrane lengths and molecular weight (Mw) cut-
offs), perfusion fluids and flow rates. These experiments were conducted in order to optimise 
the efficiency of microdialysis recovery for each of the drugs (ETH, INH, RIF). The data 
generated from these in vitro experiments enabled the calculation of the probe efficiency (a 
correction factor applied to organ drug concentrations recovered in vivo).  Optimisation of the 
bioanalytical methods for the three drugs (ETH, INH and RIF) was also completed. These 
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studies provided the data to enable an understanding of the factors that affect the recovery of 
drugs both in vitro and in vivo. 
The microdialysis system for all in vitro experiments was set up as shown in Figure 3.2. The 
syringe pump was fitted with a 1ml syringe that contained the perfusion fluid. The syringe was 
connected to the CMA 20 microdialysis probe using a Luer lock needle and tubing connector. 
The probe was placed in the dose solution (drug (volume µg or mg) + HPLC water). The 
refrigerated fraction collector was connected to the probe via the probe outlet tubing to collect 
the resulting dialysate. Samples were collected every 30 minutes for 4 hours to align with the 
in vivo PreDiCT TB experiments (Chapter 2). The collected dialysate was analysed via Liquid 
Chromatography- Mass Spectrometry/ Mass Spectrometry (LC-MS/MS) to calculate the 
relative recovery and ultimately the probe efficiency. 
The aspects of the microdialysis system optimised in this Chapter are those related to Steps 1 
through 4 of Figure 3.1. Prior to the description of the studies that relate to steps 1-4, the 
methods used to calculate %relative recovery and %co-efficient of variation (Section 3.2.1) as 
well as the initial calibrations of the syringe pump (Section 3.3) and an overview of 
microdialysis parameters (Section 3.3.2) are described. An equipment list which details all the 
equipment, materials and reagents used for these in vitro studies is shown in Section 3.2.  
The drugs used in this Chapter were ethambutol (ETH), isoniazid (INH) and rifampicin (RIF) 
(3 of the 4 front-line anti-TB drugs). It was vitally important that meticulous in vitro 
experiments were carried out with each drug before moving into in vivo experiments.  
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FIGURE 3.1: PROJECT SPECIFIC ADAPTATION OF ‘AN OVERVIEW OF MICRODIALYSIS’  TO REFLECT THE STEPS OF THIS PROJECT. This chapter details the results from 
steps 1 to 4. Black solid boxes represent results shown in Chapter 4, black das hed box represents results shown in Chapter  5. 
1. Calculating and improving relative recoveries by optimisation of: 
• Flow Rate 
• Probe Type (Mw cut-off; Membrane length)  
• Perfusion Fluid 
 
2. Sensitivity of Analytical 
Equipment (LC-MS/MS) 
for ETH, INH and RIF. 
Determination of LLOQ. 
3. Determining loss of drug 
through microdialysis 
system. 
Drug-specific factors.  
• Molecular weight 
(Mw) 
• Lipophilicity (LogP) 
4. in vitro assay. 
Tissue-specific factors.  
 
• Drug binding to tissues. 
• Mw of binding proteins. 
Calculation and optimisation of relative recovery. 
5. in vivo microdialysis 
pilot study.  
 
6. Organ for dialysis, surgery considerations (including analgesia), post-operative care and 
housing. 
7.  
8.  
 
7. in vivo 
microdialysis 
experiment. 
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FIGURE 3.2: IN VITRO MICRODIALYSIS EQUIPMENT SET-UP. The syringe pump was fitted with a 
syringe (60mm stroke length) that was connected to the microdialysis probe. The probe was 
submerged in the dose solution. The refrigerated fraction collector was connected to the 
probe via outlet tubing to collect resulting dialysa te in 300µl microdialysis tubes. 
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3.1.2 CALCULATING RELATIVE RECOVERY AND ERROR 
The  relative recovery (also known as the extraction efficiency) is the relation between the 
concentrations of the drug in the periprobe fluid (the fluid surrounding the probe) and that in 
the collected dialysate169. Recovery can be calculated using the following equation: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) = (
𝐶𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒
𝐶𝑝𝑒𝑟𝑖𝑝𝑟𝑜𝑏𝑒
) ×100 
Cdialysate is the concentration of compound in dialysate, Cperiprobe is the concentration of 
compound in the fluid surrounding the probe (for these in vitro experiments the dose solution 
in which the microdialysis probe was sat). 
As part of the characterisation of the microdialysis system, the experiments that determined 
the relative recovery of the probes were repeated three times (as a minimum) to enable a mean 
to be calculated and to obtain an error on these measurements. The recoveries of the replicate 
experiments were propagated to determine the efficiency (and associated error) of the probe. 
Subsequently, the relative recoveries obtained following in vivo microdialysis were corrected 
for using this calculated probe efficiency. 
The co-efficient of variation was calculated to assess the reproducibility of the assay and with 
adequate calibration of the microdialysis probe, the within-probe co-efficient of variation for 
microdialysis measurements should be around 20% depending on the analyte 221. 
𝐶𝑜𝑉 (%) = (𝑆𝑡𝑑𝐷𝑒𝑣 (𝐴𝑙𝑙 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠) ÷ 𝑀𝑒𝑎𝑛 (𝐴𝑙𝑙 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠))×100 
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3.2 IN VITRO EQUIPMENT LIST 
Equipment Comments Source 
300µl collection tubes Compatible with refrigerated 
fraction collector. 
Polypropylene. 
(1000/pack) 743110; Linton 
Instruments, Norfolk, UK. 
CMA 20 Probe Various molecular weight cut-
offs; 4mm or 10mm membrane 
length. 
(Various) CMA Microdialysis 
AB, Kista Sweden; Distributed 
by Linton Instruments, Norfolk, 
UK. 
CMA 402 Rev D Syringe Pump Designed for pulse-free low 
flow rates. 
CMA Microdialysis AB, Kista 
Sweden. 
CMA 470 Refrigerated fraction 
collector 
Automatically changes tubes 
after desired collection period; 
maintains samples at 4°C. 
CMA 8002770; CMA 
Microdialysis AB, Kista 
Sweden; Distributed by Linton 
Instruments, Norfolk, UK. 
FEP Tubing Fluorinated Ethylene 
Propylene; attached to probe. 
BFEP-T22Q; Instech, Plymouth 
Meeting, USA; Distributed by 
Linton Instruments, Norfolk, 
UK. 
Luer stubs blunt needle Connect syringe to probe. Fisnar QuantX 8001101; 
Ellsworth, Germantown, USA. 
Tubing connectors  CMA 3409500; CMA 
Microdialysis AB, Kista 
Sweden; Distributed by Linton 
Instruments, Norfolk, UK. 
Perfusion Fluid Composition Source 
CNS 
Designed for microdialysis in 
central nervous system 
NaCl 147 mmol/L, KCl 2.7 
mmol/L, CaCl2 1.2 mmol/L, 
MgCl2 0.85 mmol/L 
 
Harvard Apparatus, Holliston, 
USA distributed by Linton 
Instruments, Norfolk, UK 
 
Ringers Solution +0.2% BSA 
 
NaCl 147 mmol/L, KCl 4 
mmol/L, CaCl2 2.25 mmol/L 
 
BSA: Bovine Serum Albumin; 
A2058, Sigma Aldrich, Dorset, 
UK. 
 
T1 
Designed for microdialysis in 
soft tissues. 
NaCl 147mmol/L, KCl 
4mmol/L, CaCl2 2.3mmol/L 
CMAP000034; Harvard 
Apparatus, Holliston, USA 
distributed by Linton 
Instruments, Norfolk, UK 
Reagent Use Source 
0.1% Formic Acid Aqueous Chromatographic Solvent 5438040100; Sigma Aldrich Co 
LTD, Dorset, UK 
Acetonitrile Chromatographic Solvent PHR1551-3X1.2ml; Sigma 
Aldrich Co LTD Dorset, UK 
Dextromethorphan (DXT) Internal standard 1180503-2G; Sigma Aldrich, 
Dorset, UK 
Dimethyl sulfoxide (DMSO)  D2650; Sigma Aldrich, Dorset, 
UK 
Ethambutol  E4630-25G; Sigma Aldrich Co 
LTD, Dorset, UK 
HPLC Grade Water Many uses including diluting 
drug to create ‘dose solution’ 
270733-1L-M; Sigma Aldrich Co 
LTD, Dorset, UK 
Isoniazid  I3377-250G; Sigma Aldrich, 
Dorset, UK 
Rifampicin  R3501-1G; Sigma Aldrich, 
Dorset, UK 
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HPLC/ MASS SPECTROMETRY 
Q3 Analytical, 
Porton Science Park, Porton 
Down, Salisbury, Wiltshire, 
SP4 0JG 
(HPLC) Agilent 1100 Pump, 
Column heater, Degasser 
Aligent, Cheadle, UK 
(HPLC) CTC HTS Autosampler Presearch, Basingstoke, UK 
(HPLC) Column; Ethambutol; 
Ascentis Express C8 50x2.1MM 
Phenomenex, Macclesfield, UK 
 
(HPLC) Column; Rifampicin; 
Kinetex C8 50x2.1MM, 5µm 
(HPLC) Column; Isoniazid; 
Kinetex C18 150x2.1MM, 5µm 
(Mass Spectrometer) API3000 Sciex, Warrington, UK 
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3.3 INITIAL SET UP OF MICRODIALYSIS SYSTEM 
3.3.1 CALIBRATION OF THE SYRINGE PUMP BY WEIGHT 
The volume of dialysate available for analysis is dependent upon the flow rate, therefore the 
syringe pump required calibration to ensure it was flowing at the expected flow rate (as 
described in Chapter 1). The initial stages of calibration of the syringe pump involved weighing 
of dialysate samples (every 10 minutes) as the syringe pump flowed at various rates (1, 2, 5, 
10 µl/min). Deviations in the weight of the dialysate samples can indicate changes in the flow 
rate which can therefore affect the efficiency of the probe and therefore the concentration of 
drug in the dialysate. 
It was evident that the syringe pump was flowing at a constant rate and was working as 
expected (Figure 3.3). The linearity of the data points indicate that the flow was continuous, 
and this was further emphasised by the cumulative weight of the samples being consistent with 
the flow rate. There were differences observed in sample collection at the different flow rates, 
and a faster flow rate resulted in an appropriately heavier sample being collected. All of this 
was indicative that the syringe pump was working as expected.  
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FIGURE 3.3: INITIAL SYRINGE PUMP CALIBRATIONS. Weight of samples collected at different flow 
rates over a 60-minute period.  
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3.3.2 OVERVIEW OF PROBES, PERFUSION FLUIDS AND FLOW RATES 
Figure 3.4 shows a basic flow diagram of the microdialysis parameters (probe type, perfusion 
fluid and flow rate) which were evaluated and optimised with each drug (ETH, INH and RIF).  
These parameters were optimised with the aim of improving the relative recovery and hence 
calculating the probe efficiency associated with each of the different drugs.  
For example, ethambutol was dialysed with a new CMA 20 probe (4mm membrane length, 
molecular weight cut-off of 20kDa) using T1 perfusion fluid at flow rates of 1 and 2µl/minute. 
As shown in Figure 3.4 the majority of the optimisation was completed with rifampicin; in total 
four different probes were evaluated, each had either a 4mm or 10mm membrane length with 
two different molecular weight cut-offs (20kDa or 100kDa), probes that had been re-used 
following previous exposure to the drug (rifampicin) after storage in demineralised water 
were also evaluated. Three different perfusion fluids and four different flow rates were tested.  
The following parameters were evaluated and optimised to improve recoveries for the three 
drugs: 
• Ethambutol; 4mm 20kDa probe, T1 perfusion fluid, 1 and 2µl/minute flow rates. 
• Rifampicin; 4mm & 10mm, 20kDa & 100kDa probes (including previous exposure to 
rifampicin), T1, CNS and Ringers Solution (+BSA) perfusion fluids, 1, 2, 5 &10µl/minute 
flow rates. A rifampicin system flush was also evaluated. 
• Isoniazid; 10mm 20kDa & 100kDa probes, T1 perfusion fluid, 2µl/minute flow rate. 
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FIGURE 3.4: FLOW DIAGRAM SHOWING WHICH PROBES, PERFUSION FLUIDS AND FLOW RATES WERE TESTED WITH EACH DRUG. Orange arrows= rifampicin, purple 
arrows= isoniazid, blue arrows= ethambutol. BSA; bovine serum albumin, CNS; central nervous  system. New; used directly, Previous exposure; re -used probe 
following primary exposure to drug.
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3.4 SENSITIVITY OF ANALYTICAL EQUIPMENT 
As shown in Figure 3.1, the first step in designing a microdialysis experiment is selection of 
analytical equipment. To quantify drug concentrations in dialysate fractions LC-MS/MS (Liquid 
Chromatography-Mass Spectrometry/Mass Spectrometry) was used. Sample analysis was 
conducted at Q3 Analytical (Porton Science Park). Each of the three drugs were analysed using 
a triple quadrupole mass spectrometer which was selected because of its high sensitivity and 
the potential to measure multiple compounds at the same time 222. 
The LC-MS/MS system at Q3 Analytical consists of an HPLC (High Performance Liquid 
Chromatography) system comprised of an Agilent 1100 pump, column heater and degasser 
with a CTC HTS auto-sampler. The HPLC column used is specified for each drug. The mass 
spectrometer (MS) was an API 3000 with an ESI (Electro-spray Ionisation) source. Using ESI 
source, the MS was operated in the positive ionisation mode (Nebuliser Gas (NEB) 14PSI, 
Curtain Gas (CUR) 14PSI, Collisionally Activated Dissociation (CAD) 4PSI, Ion-spray Voltage 
(IS) 5500V,  Temperature of ion source (TEM) 350°C) for all three drugs. The parent ion was 
observed in Q1(Quadrupole 1) and following collision-induced dissociation the product ion 
was observed in Q3 (Quadrupole 3). 
Stock solutions of the drugs were made in dimethyl sulfoxide (DMSO) and further diluted to 
10µg/ml in acetonitrile/0.1% formic acid to tune the MS. 10µl dextromethorphan (DXT) was 
added to stock solutions and samples as the internal standard. The multiple reaction 
monitoring (MRM) transition for DXT was 272.4/215.2 and DXT had an approximate retention 
time of 3.8 minutes. The chromatogram in Figure 3.5 shows the DXT peak.   
Prior to beginning these in vitro studies, each drug was trialled in the LC-MS/MS system. Due 
to the resolution of the peak (shown in Figure 3.5) ethambutol was selected as the initial drug 
for optimisation studies. The HPLC column used for ethambutol analysis was an Ascentis 
Express C8 50 x 2.1MM. For ethambutol, the MRM transition was 205.3/116.4 and the 
approximate retention time was 3.2 minutes.  
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FIGURE 3.5: A; CHROMATOGRAM FOR THE INTERNAL STANDARD DXT. B; CHROMATOGRAM FOR ETHAMBUTOL. A; Peak at 3.8 minutes (x axis), peak intensity 7.64e4cps 
(y axis). B; peak at 3.2 minutes, peak intensity 5.04e4cps.  
 
 
 
TABLE 3.1: MASS SPECTROMETRY PARAMETERS FOR ETHAMBUTOL AND DXT USED AT Q3 ANALYTICAL. DP; de-clustering  potential (v), FP; focussing potential (v), 
CE; collision energy (electro-v), CXP; collision cell exit potential  (v).   
A B 
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3.5 ETHAMBUTOL IN VITRO MICRODIALYSIS 
3.5.1 SELECTION OF ETHAMBUTOL CONCENTRATION FOR INITIAL 
MICRODIALYSIS STUDIES 
The two ethambutol doses administered to the guinea pigs (100 and 250mg/kg) were used for 
initial in vitro microdialysis experiments. The microdialysis system was set up as shown in 
Figure 3.2. The probe used was a CMA 20 (4mm; 20kDa) with T1 perfusion fluid.   A 2µl/min 
flow rate was chosen in the first instance, as recommended by Kloft and Simmel, in order to 
achieve adequate drug recovery as well as sufficient sample volume for analysis 170. Samples 
were collected every 30 minutes for four hours, in duplicate.  
Whilst conducting these experiments a sample was not collected at 30 minutes. This was 
potentially because of the lag time and dead space within the probe inlet and outlet tubing. The 
lag time for sample collection could be calculated as it was known that the dead volume of the 
inlet and outlet tubing was 1.8µl per 10cm. For these in vitro calibrations, the length of the inlet 
and outlet tubing was 20cm. Hence, the total dead volume was 7.2µl and using a flow rate of 
2µl/minute meant there was a lag time of 3 minutes 36 seconds indicating that lag time and 
dead space within the system may not account for the lack of 30 minute sample collection.  
However, to negate any further issues associated with the lack of sample collection at 30 
minutes, the syringe pump needed to continually flow for at least 30 minutes with the probe in 
a blank (no drug) solution prior to the collection of dialysate fractions for analysis.  The fraction 
collector kept the samples at 4°C, for no longer than 4 hours,  until they were stored at -80°C 
until analysis.  Sample analysis was conducted as described above (Section 3.4) with the 
chromatographic conditions for ethambutol shown in Table 3.2. Concentrations of ethambutol 
above 10µg/ml cannot be quantified as this is above the upper limit of quantitation 
(2000ng/ml); therefore, the samples were diluted prior to analysis. Relative recovery and the 
co-efficient of variation were calculated as described in Section 3.1.2. The results from these 
initial experiments with ethambutol are shown in Table 3.3. Also shown in Table 3.3 is the 
concentration of ethambutol measured in each fraction and dose solution (mg/ml), the % 
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relative recovery and mean % relative recovery, the standard deviation (SD) and %Co-efficient 
of Variation (%CoV).  
For these initial experiments the dose solutions used were chosen to reflect the oral dose of 
ethambutol that was administered to the guinea pigs in vivo.  In vitro microdialysis conditions 
should be as close to in vivo as is practically possible and therefore the dose solutions should 
have been at the concentrations of ethambutol that were identified in the peripheral blood.    
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Gradient 
 
Time (Min) 
0.1% Formic Acid (Aqueous) 
 
%A 
0.1% Formic Acid (in 
Acetonitrile) 
%B 
0 95 5 
1 95 5 
4 5 95 
5 5 95 
5.1 95 5 
8 95 5 
Flow Rate 250µl/minute 
Column Temperature 40˚C 
Injection Volume 5µl 
TABLE 3.2: CHROMATOGRAPHIC CONDITIONS used for ethambutol analysis following 
microdialysis. Mass spectrometry parameters are shown in Table 3.1 .  
 
  
Dose 
Time 
(Min) 
Conc 
(mg/ml) 
% 
Relative 
Recovery 
Mean 
% RR 
SD %CoV 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
 
: 9
1
m
g/
m
l 
60 16 17.6 
35 11.93 34.4 
90 45.5 50.0 
120 45.3 49.8 
150 18.6 20.4 
180 35.7 39.2 
210 30.2 33.2 
240 28 30.8 
C
o
n
c 
o
f 
D
o
se
 
So
lu
ti
o
n
: 5
6
.5
m
g/
m
l 60 14 24.8 
20 3.60 18.8 
90 12 21.2 
120 10 17.7 
150 11.4 20.2 
180 7.81 13.8 
210 12.5 22.1 
240 13.9 24.6 
TABLE 3.3: ETHAMBUTOL RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS.  Two drug 
concentrations were compared (250mg/kg and 100mg/kg) over a period of 240 minutes using 
a flow rate of 2µl/minute.  Conc (mg/ml); concentration of ethambutol measured in each 
fraction, SD; Standard Deviation, %CoV; Co-efficient of Variation.   
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3.5.2 REFINEMENT OF ETHAMBUTOL CONCENTRATION FOR INITIAL IN 
VITRO MICRODIALYSIS STUDIES 
The median blood concentration of ethambutol as collected in vivo (Chapter 2) was 1.29µg/L 
(Cmax: 7214µg/L) following a 250mg/kg dose which indicated that a 1mg/ml solution of 
ethambutol was closer to the concentration of ethambutol expected in the organs. This lower 
concentration (1mg/ml) was therefore used for further in vitro experiments with ethambutol. 
An additional advantage to this lower starting concentration of ethambutol was that all 
fractions would contain less than 10µg/ml ethambutol which negates the need for the dilution 
series conducted prior to MS analysis, thereby reducing errors.  
The equipment was set up as shown in Figure 3.2 and the probe used was a CMA 20 (4mm; 
20kDa) with T1 perfusion fluid. Samples were collected using the same flow rate and collection 
period described in Section 3.5.1. Again, as in Section 3.5.1, no sample was collected at 30 
minutes. Therefore, in order to collect a sample at 30 minutes for all future experiments, the 
syringe pump needed to continually flow for 60 minutes (as opposed to the 30 minutes 
mentioned in Section 3.5.1) with the probe in a blank (no drug) solution prior to collection of 
dialysate fractions for analysis. Relative recovery and the co-efficient of variation were 
calculated as described in Section 3.1.2. The results are shown in Table 3.4.  
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Replicate Dose  
Time 
(Min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
1 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
 1
.2
4
m
g/
m
l 
60 0.54 43.8 
41.7 4.4 11.6 
90 0.54 43.1 
120 0.54 43.4 
150 0.47 37.7 
180 0.48 38.4 
210 0.57 46.2 
240 0.40 32.4 
2 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.9
9
5
m
g/
m
l 
60 1.58 159.1 
59.3 52.0 89.4 
90 1.31 132.0 
120 0.28 28.5 
150 0.27 27.6 
180 0.30 29.9 
210 0.29 29.1 
240 0.38 38.0 
3 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
 : 
1
.1
7
m
g/
m
l 
60 0.44 37.2 
33.6 6.5 19.4 
90 0.41 35.2 
120 0.48 41.3 
150 0.46 39.4 
180 0.41 35.1 
210 0.37 31.3 
240 0.33 28.5 
TABLE 3.4: ETHAMBUTOL RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS. A dose 
solution of 1mg/ml ethambutol was used and dialysed with CMA20 probe (4mm, 20kDa). 
Samples were collected every 30 minutes for a period of 240 minutes in triplicate.  Conc 
(mg/ml); concentration of ethambutol measured in each fraction, SD; Standard Deviation, 
%CoV; Co-efficient of Variation.  
All the dose solutions were close to the expected 1mg/ml concentrations (0.995-1.24mg/ml) 
that were being aimed for. There was little effect of the different concentrations on %relative 
recovery demonstrating linear extraction efficiency over a concentration range. The % relative 
recoveries are sufficiently high as shown by the consistent collection of ethambutol in the 
individual fractions above the MS LLOQ of ethambutol (0.625µg/ml). The reproducibility of 
these experiments was generally good over the three replicates. These results indicated that 
the microdialysis parameters selected for use with ethambutol were fit for purpose.  
The % relative recoveries for 2 samples were above 100% (Replicate 2; 159.1 & 132%) as the 
concentrations of these samples exceeded the concentration of the dose solution. This was 
indicative that there was residual ethambutol within the dialysis tubing or around the probe 
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membrane tip. This was confirmed by the fact that 101µg/ml of ethambutol was recovered 
within the ‘flush’ sample. The ‘flush’ sample is one that was collected after a brief flow of 
demineralised water at a 25µl/minute flow rate with the probe submerged in demineralised 
water. An additional reason for the above 100% relative recoveries (in Replicate 2) was that 
there was ‘carry-over’ of ethambutol between samples within the mass spectrometer, this was 
corroborated when a blank sample, in which only the internal standard DXT was present and 
no ethambutol, measured 0.0876µg/ml of ethambutol (data not shown).  
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3.5.3 FLOW RATE OPTIMISATION 
Following optimisation of the concentration of the dose solution and adequate relative 
recoveries over the three replicates, the next parameter to be tested and optimised was flow 
rate. This was to understand if the probe was working more efficiently at a slower flow rate 
and whether sufficient sample volume was obtained for analysis (as described in Chapter 1). 
The experiment described in the previous section was repeated using a 1mg/ml dose solution 
and a 1µl/min flow rate. The other parameters remained the same; CMA 20 probe (4mm; 
20kDa) and T1 perfusion fluid. The results are shown in Table 3.5. 
Replicate Dose 
Time 
(Min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
1 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
 : 
0
.9
7
6
m
g/
m
l 
30 0.55 56.8 
53.8 9.7 19.2 
60 0.75 76.9 
90 0.53 53.8 
120 0.51 51.9 
150 0.50 51.4 
180 0.50 50.8 
210 0.42 43.4 
240 0.44 44.9 
2 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.9
1
3
m
g/
m
l 
30 1.27 139.1 
105.3 29.2 29.6 
60 1.21 132.5 
90 1.15 126.0 
120 1.02 111.7 
150 0.98 107.0 
180 0.87 95.6 
210 0.82 89.3 
240 0.38 41.2 
3 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.8
1
6
m
g/
m
l 
30 0.67 81.5 
65.6 11.0 17.9 
60 0.64 78.8 
90 0.63 76.6 
120 0.53 64.7 
150 0.49 60.0 
180 0.48 58.2 
210 0.43 53.1 
240 0.43 52.1 
TABLE 3.5: ETHAMBUTOL RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS USING A 
1µL/MIN FLOW RATE. A 1mg/ml dose solution with CMA20 (20kDa) probe and T1 perfusion 
fluid were used. Conc (mg/ml); concentration of ethambutol measured in each fraction, SD; 
Standard Deviation, %CoV; Co-efficient of Variation.  
The dose solutions have similar concentrations for all three experimental replicates and, in 
these experiments a 30 minute sample was collected. Consistent with the data obtained for the 
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2µl/min flow rate (shown in Table 3.4) five of the %relative recoveries were over 100% adding 
strength to the observation that carry-over of ethambutol in the MS was occurring.   
As the flow rate decreased (from 2µl/min to 1µl/min) the sample volume also decreased but 
there was still sufficient sample available for analysis. As expected when the flow rate was 
decreased to 1µl/min the %relative recovery increased, from 41%, 59% and 33% (mean 
relative recoveries at 2µl/min (Table 3.4)) compared with 53%, 105% and 65% (mean relative 
recoveries at 1µl/min). These data confirm what was stated in the literature in relation to 
slower flow rates leading to higher probe efficiencies145.  However, over the 4 hour time period 
the concentration of ethambutol recovered using the 1µl/min flow rate decreased within all 
three experimental replicates. This trend is not shown with the 2µl/min flow rate experiments 
and therefore a 2µl/min flow rate was used for all future in vitro and in vivo microdialysis 
experiments.  
3.5.4 OVERVIEW OF ETHAMBUTOL IN VITRO MICRODIALYSIS 
In summary (as shown in Table 3.6), microdialysis with ethambutol was successful in 
recovering drug. There are no reports of suitable parameters for ethambutol (or any other TB 
drug) microdialysis and therefore these data are informative for future studies of ethambutol 
or any physiochemically similar drugs. 
Concentration 
of Dose 
Solution 
Probe 
Perfusion 
Fluid 
Flow Rate 
(µl/minute) 
Recovery Comments 
91mg/ml 
(=250mg/kg) 
CMA 20 
4mm 20kDa 
T1 
2 
Yes 
 
Dose 
Solutions too 
high 
56.5mg/ml 
(=100mg/kg) 
2 
1mg/ml 2&1 
System 
performing 
as expected. 
TABLE 3.6: SUMMARY TABLE SHOWING WHICH PARAMETERS WERE TESTED WITH ETHAMBUTOL TO 
CALCULATE RELATIVE RECOVERIES. 
The main parameters tested with ethambutol were optimisation of the dose solution and flow 
rate. It was shown that ethambutol was recovered across a range of concentrations and the 
reproducibility of the %relative recoveries were good and not influenced by concentration of 
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dose solution. As expected, the flow rate did have an impact with slower flow rates leading to 
increased recovery. However, the concentration of ethambutol recovered decreased over the 
four hour time course when using the 1µl/minute flow rate as there was less ethambutol in the 
dose solution to collect as time increased (i.e. the increased recovery meant more drug was 
removed from the dose solution earlier in the time course, so there was less available to collect 
later in the time course). These experiments also defined the initial experimental parameters 
to be used for in vitro microdialysis of isoniazid and rifampicin. It was concluded that all further 
in vitro experiments would be conducted with 1mg/ml dose solutions at a 2µl/minute flow 
rate.   
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3.6 ISONIAZID IN VITRO MICRODIALYSIS 
Isoniazid is one of the four front-line anti-TB drugs and is used mono-therapeutically for the 
treatment of those infected with latent TB infection as discussed in Chapter 1. Isoniazid shares 
many physiochemical properties with ethambutol (Chapter 1) and hence the %relative 
recoveries with isoniazid should be similar to those achieved with ethambutol. The importance 
of isoniazid in the treatment of TB and the anticipated high recoveries (based on 
physiochemical properties) indicated that isoniazid could be an important drug to dialyse in 
vivo and PK data generated from blood sampling, as described in Chapter 2, would provide a 
comparator for PK data generated in organs, therefore isoniazid was characterised within the 
microdialysis system.   
3.6.1 INITIAL IN VITRO EXPERIMENTS WITH ISONIAZID 
Isoniazid in vitro microdialysis experiments were conducted using a 2µl/min flow rate using a 
dose solution of 1mg/ml of isoniazid as shown in Figure 3.2. These experiments were 
conducted using the left-hand side (LHS) and right-hand side (RHS) of the syringe pump and 
tested two probe types: Mw cut-off 20kDa, 10mm length and 100kDa, 4mm length. Replicates 
1 and 2 for the same probe type used the LHS and RHS of the syringe pump. The perfusion fluid 
used was T1 perfusion fluid. Prior to beginning in vitro microdialysis with isoniazid the probes 
were placed in demineralised water for one hour using a 10µl/min flow rate which enabled 
samples to be reproducibly collected at 30 minutes. This was a refinement based on the results 
of the ethambutol in vitro experiments. 
The samples were analysed as described in Section 3.4, and the column used for isoniazid 
analysis was a Kinetex C18 150x2.1mm, 5µm column. The MRM transition was 137.9/120.9 for 
isoniazid and the approximate retention time was 3.1 minutes. The chromatographic 
conditions used are shown in Table 3.7 and the chromatogram shown in Figure 3.6. Isoniazid 
mass spectrometry parameters are shown in Table 3.8. The LLOQ for isoniazid was 1ng/ml. 
The calibration curve was constructed as described in Section 3.7.1. DXT mass spectrometry 
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parameters are found in Section 3.4. The relative recoveries of isoniazid were calculated as 
described in Section 3.1.2. The results are shown in Table 3.9.
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TABLE 3.7: CHROMATOGRAPHIC CONDITIONS FOR ISONIAZID. 
 
Compound DP FP CE CXP 
Isoniazid 31 270 19 2 
 
TABLE 3.8: MASS SPECTROMETRY PARAMETERS USED WITH ISONIAZID.  
FIGURE 3.6: ISONIAZID CHROMATOGRAM FOLLOWING A 2000NG/ML 
ISONIAZID INJECTION. The peak is at 3.1 minutes (x axis) and the 
intensity of the peak is 1.25e4 (y axis). Additional peaks represent 
background interference. 
Gradient 
 
Time (Min) 
0.1% Formic Acid (Aqueous) 
 
%A 
0.1% Formic Acid (in 
Acetonitrile) 
%B 
0 95 5 
5 95 5 
10 5 95 
15 5 95 
15.1 95 5 
20 95 5 
Flow Rate 400µl/minute 
Column Temperature 40˚C 
Injection Volume 5µl 
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TABLE 3.9: ISONIAZID RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS. Two different probes (Mw cut off 20kDa with 10mm membrane length and Mw 
cut off 100kDa with 4mm membrane length) and the left-hand side and right-hand side of the syringe pump were used.  Conc (mg/ml); concentration of 
isoniazid measured in each fraction, SD; Standard Deviation, %CoV; Co -efficient of Variation.
20kDa Cut Off (10mm)  100kDa Cut Off (4mm) 
Replicate Dose 
Time 
(Min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean %RR SD %CoV Replicate Dose 
Time 
(Min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean %RR SD %CoV 
1 
LHS 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.9
4
9
m
g/
m
l 
30 0.339 35.7 
40.9 10.1 24.7 
 
1 
LHS 
 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
1
.0
7
0
m
g/
m
l 
30 0.146 13.7 
45.8 26.2 57.3 
60 0.553 58.3 60 0.795 74.3 
90 0.504 53.1 90 0.98 91.5 
120 0.447 47.1 120 0.664 62.1 
150 0.371 39.1 150 0.505 47.2 
180 0.329 34.7 180 0.358 33.5 
210 0.296 31.2 210 0.263 24.6 
240 0.267 28.1 240 0.206 19.3 
2 
RHS 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.9
9
2
m
g/
m
l 
30 0.582 58.7 
44.3 11.2 25.3 2 
RHS 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
1
.8
0
4
m
g/
m
l 
30 0.272 25.1 
21.3 9.8 46.1 
60 0.566 57.1 60 0.457 42.2 
90 0.494 49.8 90 0.308 28.5 
120 0.521 52.5 120 0.228 21 
150 0.422 42.6 150 0.183 16.9 
180 0.339 34.2 180 0.151 13.9 
210 0.289 29.2 210 0.134 12.4 
240 0.3 30.2 240 0.114 10.5 
3 
LHS 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
1
.0
0
2
m
g/
m
l 
30 0.645 64.4 
64.4 5.8 9.1 3 
LHS 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
1
.1
2
8
m
g/
m
l 
30 0.259 23 
22.7 5.8 25.4 
60 0.738 73.7 60 0.37 32.8 
90 0.664 66.3 90 0.327 29 
120 0.7 69.8 120 0.296 26.3 
150 0.661 65.9 150 0.228 20.2 
180 0.561 55.9 180 0.192 17 
210 0.642 64.1 210 0.177 15.7 
240 0.556 55.5 240 0.201 17.8 
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The relative recoveries, as anticipated, due to the similar physiochemical properties were 
similar to those achieved with ethambutol (Table 3.4).  The Mw cut-offs of the probes seem to 
have an effect on %CoV (24.7, 25.3 and 9.1% for 20kDa cut-off probe vs 57.3, 46.1, 25.4% for 
100kDa cut-off probe) yet little effect on %relative recovery; as the lower Mw cut-off probe 
recovered more isoniazid in replicates 2 and 3, but less in replicate 1 (Table 3.9). As expected, 
use of the 10mm (longer) membrane resulted in increased recovery with a mean % relative 
recovery of 49% and a mean % relative recovery of 30% associated with the 4mm membrane.  
Use of the LHS or RHS of the syringe pump had no effect on %relative recoveries which means 
that both sides can be used simultaneously enabling dialysis of two guinea pigs at the same 
time when dialysing in vivo.   
The use of the higher Mw cut-off probe (100kDa) seemed to have little effect on relative 
recovery of isoniazid in these in vitro microdialysis experiments. There are no proteins in these 
in vitro samples, however if used in vivo this larger Mw cut-off would allow serum proteins 
(Mw of albumin in guinea pigs= ~64.9kDa223)  to enter the dialysate. The isoniazid collected in 
the dialysate therefore could still be bound to proteins. As discussed in Chapter 1, a key 
advantage of the microdialysis methodology is the ability to collect only the pharmacologically 
unbound portion of the drug. Use of the 100kDa probe with isoniazid does not exclude the 
proteins and therefore may collect both unbound and bound drug.  The lower Mw cut-off 
probes were sufficient to recover unbound isoniazid (Mw 137.14Da) and rifampicin (Mw 
822.94Da). Therefore the 20kDa probes were used for all future microdialysis experiments as 
the lower Mw cut-off excluded all proteins from the dialysate thereby ensuring only the 
unbound portion of the drug was collected. An additional advantage to protein exclusion was 
that no additional sample processing was required prior to analysis.   
The increased relative recovery associated with the longer membrane length was due to the 
larger surface area.  The 10mm membrane should therefore recover more drug than the 4mm 
membrane when the probe was placed in the organ of interest in vivo. 
 
 
104 
 
The surface area of the probe membrane tip, even at the longer length, still fitted within the 
proposed organs for dialysis. It was preferable to use the longer membranes for all further in 
vitro and in vivo experiments due to the larger surface area for diffusion to occur (Chapter 1).  
The co-efficient of variations for the lower Mw cut-off/ longer membrane probe were 
approximately 20% (Table 3.9), indicating that these results were reproducible and that no 
additional optimisation to improve isoniazid recoveries using a 1mg/ml isoniazid dose 
solution was required.  
3.6.2 CONCLUSIONS OF IN VITRO MICRODIALYSIS WITH ISONIAZID 
The main parameters tested for isoniazid were the probe membrane length and Mw cut-off. An 
additional parameter tested was use of the LHS and RHS of the syringe pump. The probes tested 
had a 10mm membrane, the first time this longer membrane had been tested within these 
studies. Relative recoveries associated with this longer membrane were higher than those 
associated with 4mm membrane. An additional parameter tested was molecular-weight cut-
off of the probe membrane. The Mw cut-off appears to have no discernible differences in 
relation to isoniazid recovery. 
Concentration 
of Dose 
Solution 
Probe 
Perfusion 
Fluid 
Flow Rate 
(µl/minute) 
Recovery Comments 
1mg/ml 
CMA 20 
10mm 
20kDa 
T1 2 
Yes 
 
Longer 
membrane 
has higher 
recovery. 
CMA 20 
4mm 
100kDa 
Mw cut-off, 
no obvious 
effect on 
recovery.  
TABLE 3.10: SUMMARY OF PARAMETERS TESTED FOR INITIAL IN VITRO MICRODIALYSIS WITH 
ISONIAZID. 
Additional studies were performed using physiologically relevant dose solutions which 
showed that isoniazid could be recovered at these lower concentrations, with and without the 
presence of an organ. These studies have not been described here but can be found in the 
Appendix (A1). Therefore, the in vitro microdialysis parameters were optimised for use with 
isoniazid for preparation to move to in vivo experiments.  
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3.7 RIFAMPICIN IN VITRO MICRODIALYSIS 
In previous in vivo studies (PreDiCT TB project) guinea pigs were orally administered 
rifampicin either mono-therapeutically or in combination with other drugs. An associated 
adverse effect of rifampicin administration, in some guinea pigs, was antibiotic related enteritis 
which resulted in animals being culled for welfare reasons. Further to this, studies described 
in Chapter 2 showed that a dose of 50mg/kg, which was largely well-tolerated was not 
sufficient to achieve human-equivalent exposures in the blood. This raised the issue that to 
obtain human- like exposures, as related to blood, the guinea pigs would need a higher dose of 
rifampicin which could not be tolerated. The question that remained is whether concentrations 
of rifampicin in the blood reflect those in the tissues and whether drug doses could be 
optimised more efficiently by measuring this drug in organs rather than blood. Therefore, to 
better understand rifampicin pharmacokinetics and answer this key question, rifampicin was 
used and optimised in the in vitro microdialysis system to enable this drug to be dialysed in the 
guinea pig in vivo.  
Parameters for rifampicin microdialysis were evaluated using the systems described in Section 
3.3 and equipment was set up as shown in Figure 3.2. 
3.7.1 CHROMATOGRAPHIC CONDITIONS & MASS SPECTROMETRY 
PARAMETERS FOR RIFAMPICIN 
The LC-MS/MS system used was the same as described in Section 3.4. The column used for 
rifampicin analysis was a Kinetex C8 50x2.1mm, 5µm column. The MRM transition was 
823.6/95.3 for rifampicin and the approximate retention time was 4.3 minutes. The 
chromatographic conditions are shown in Table 3.11 and chromatogram shown in Figure 3.7. 
The mass spectrometry parameters for rifampicin are in Table 3.12. DXT mass spectrometry 
parameters are found in Section 3.4. 
To prepare the standard curve a stock standard solution of 1mg/ml RIF was made in DMSO. 
Stock standard solutions were further diluted in DMSO to make final concentrations of 400, 40, 
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20, 10, 5, 2, 1, 0.5, 0.2, 0.1 and 0.02µg/ml. These dilutions were further diluted with T1 
Perfusion Fluid (190µl T1 Perfusion Fluid to 10µl standard) to final concentrations of 2000, 
1000, 500, 250, 100, 50, 25, 10, 5 and 1ng/ml. 10µl DXT was added to all samples as the internal 
standard. The calibration curves were made in 300µl microdialysis tubes following 
determination of rifampicin loss across passaging experiment (Section 3.8).   
The HPLC-MS/MS methodology was validated by adherence to the  following acceptance 
criteria; the signal in the blank sample was <20% of the signal of the lowest calibration 
standard, the internal standard area in calibration standards did not differ from the area in 
unknown samples by more than 15%, definition of the upper limit of quantitation ((ULOQ) 
which was the calibration standard that met the acceptance criteria immediately above the 
highest concentration sample if the standards gave a linear response) and lower limit of 
quantitation ((LLOQ) which was the lowest calibration standard which meets the acceptance 
criteria if the signal is 2 to 3 fold of the signal to noise ratio). 
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TABLE 3.11: CHROMATOGRAPHIC CONDITIONS FOR RIFAMPICIN. 
 
 
FIGURE 3.7: RIFAMPICIN CHROMATOGRAM FOLLOWING A 2000NG/ML 
RIFAMPICIN INJECTION. The peak is at 4.3 minutes (x axis) and the 
intensity of the peak is 1500 cps (y axis).  
TABLE 3.12: MASS SPECTROMTERY PARAMETERS USED WITH RIFAMPICIN. 
 
Gradient 
 
Time (Min) 
0.1% Formic Acid (Aqueous) 
 
%A 
0.1% Formic Acid (in 
Acetonitrile) 
%B 
0 95 5 
1 95 5 
4 5 95 
5 5 95 
5.1 95 5 
8 95 5 
Flow Rate 250µl/minute 
Column Temperature 40˚C 
Injection Volume 5µl 
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3.7.2 INITIAL IN VITRO EXPERIMENTS WITH RIFAMPCIN 
Initial rifampicin in vitro experiments were conducted using the parameters that were 
optimised for ethambutol as described in Section 3.5.4.  Briefly, the probe used was a CMA 20 
(4mm; 20kDa) submerged in a 1mg/ml dose solution of rifampicin. T1 perfusion fluid flowed 
at a 2µl/min flow rate and the results are shown in Table 3.13. 
Replicate Dose 
Time 
(Min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
1 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
:  
0
.0
8
7
m
g/
m
l 
30 No Sample 
1.37 0.82 60 
60 <0 - 
90 <0 - 
120 <0 - 
150 <0 0.4 
180 0.002 1.9 
210 0.001 1.0 
240 0.003 2.2 
2 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.1
6
2
m
g/
m
l 
30 No Sample 
15.1 7.1 51.0 
60 <0 - 
90 0.010 12.0 
120 0.017 19.0 
150 0.013 15.2 
180 0.019 21.6 
210 0.017 19.6 
240 0.017 19.2 
3 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.1
2
5
m
g/
m
l 
30 <0 - 
10.1 6.1 63.8 
60 0.005 3.0 
90 0.011 6.9 
120 0.015 9.5 
150 0.022 13.4 
180 0.025 15.5 
210 0.024 14.8 
240 0.030 18.2 
TABLE 3.13: RIFAMPICIN RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS IN 
TRIPLICATE. A 1mg/ml rifampicin dose solution was used with T1 perfusion fluid flowing at 
2µl/min flow rate. Samples were collected every 30 minutes for a total of 240 minutes.  Conc 
(mg/ml); concentration of rifampicin measured in each fraction, SD; Standard Deviation, 
%CoV; Co-efficient of Variation, <0 = below lower limit of quantitation.  
Following LC/MS-MS analysis of the rifampicin-containing dialysate samples, there were three 
key results. The first of these was that the dose solutions were lower (mean dose solution = 
0.124±0.03mg/ml) than the expected 1mg/ml (shown in Table 3.13) and only one 30 minute 
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sample was collected.  Secondly, as time increased (between 0-240 minutes) the concentration 
of rifampicin recovered in the dialysate also increased. This was shown with all three 
experimental replicates. Thirdly there were 6 %relative recoveries which were below the 
lower limit of quantitation (5ng/ml), which was unexpected, but as these samples were 
collected at earlier time points it is indicative that there was not any rifampicin in the samples 
to measure due to the length of time taken for the rifampicin to move through the microdialysis 
tubing because of the physiochemical properties of the drug. 
There were several possibilities for the measured concentrations of the dose solutions being 
lower than the concentration prepared; the (in)solubility of rifampicin in solution, a 
miscalculation whilst the dose solutions were prepared and a dilution of the dose solution with 
the constant perfusion of the perfusion fluid. This dilution of the dose solution potentially 
occurred because 60µl of T1 perfusion fluid passed through the probe into the dose solution 
every 30 minutes whilst a flow rate of 2µl/minute was used. However, this would not be unique 
to the rifampicin dose solutions and therefore given the concentrations of the dose solutions 
associated with isoniazid and ethambutol, this seems an unlikely explanation. Another 
possibility for the lower dose solution was that due to the lipophilic nature of rifampicin (LogP 
-3.85), it adhered to the Eppendorf which contained the dose solution.  
The increased rifampicin concentration in the dialysate observed over time could also be due 
to adherence of rifampicin to the plastic of the Eppendorf and FEP tubing. The increased 
concentrations of rifampicin over time suggested that saturation of binding sites in the 
Eppendorf and the FEP tubing plastics with rifampicin had occurred leading to no further 
binding of rifampicin to the plastics. This subsequently allowed more rifampicin to flow 
through the tubing and be collected. This saturation of binding sites may not have occurred till 
after 60 minutes which is why no 30 minute sample was collected in replicates 1 and 2 and 
when a sample was collected at 30 minutes in replicate 3, the measured rifampicin was below 
the LLOQ.  A visible crystallisation around the probe tip may have led to recoveries below the 
LLOQ and therefore highlighted the need to perform a flush with demineralised water prior to 
beginning dialysis in all future experiments.  
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It was evident from the co-efficient of variations that these experiments were variable and 
would need repeating before the true %relative recoveries could be calculated, but the mean 
%relative recoveries were close to the acceptable 20% recovery for replicates two and three 
(15.13% and 10.13% respectively). A probe efficiency greater than 20% is sufficient as this 
would recover rifampicin at concentrations above the LLOQ for MS analysis (5ng/ml). 
3.7.3 REPEAT OF INITIAL EXPERIMENTS WITH RIFAMPICIN; IMPACT OF 
DOSE SOLUTION 
In light of the results in Section 3.7.2, the experiment was repeated using a different method to 
prepare the dose solution.  The same probe (CMA 20 (4mm; 20kDa)) and probe tubing used 
for the experiment described in Section 3.7.2 was used again for the repeat experiments. T1 
perfusion fluid was used. To make the 1mg/ml solution, 10mg of rifampicin was added to 10ml 
of HPLC water to alleviate any errors associated with weighing out small amounts of drug. The 
absorbance of rifampicin for a 1mg/ml solution is 0.337nm and this was checked prior to 
commencing the experiments. The rifampicin solution was heated to 25°C to ensure 
solubilisation. The results of this repeat experiment are shown in Table 3.14. 
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Replicate Dose 
Time 
(Min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
1 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
:  
0
.6
5
2
m
g/
m
l 
30 
No Sample 
6.3 0.4 7 
60 
90 0.047 7.2 
120 0.041 6.2 
150 0.040 6.1 
180 0.040 6.1 
210 0.042 6.4 
240 0.039 6.0 
2 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.7
2
4
m
g/
m
l 
30 0.0263 3.6 
7.9 2.0 26.6 
60 0.082 11.3 
90 0.061 8.5 
120 0.058 7.9 
150 0.056 7.7 
180 0.057 7.8 
210 0.057 7.8 
240 0.060 8.2 
3 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
0
.7
0
5
m
g/
m
l 
30 No Sample 
8.3 0.6 7.4 
60 0.064 9.1 
90 0.064 9.0 
120 0.058 8.3 
150 0.056 7.9 
180 0.056 7.9 
210 0.059 8.4 
240 0.053 7.4 
TABLE 3.14: RIFAMPICIN RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS with a 
1mg/ml dose solution. A 2µl/min flow rate was used. A different method of preparing dose 
solutions was used following low relative recoveries in initial experiment.  Conc (mg/ml); 
concentration of rifampicin measured in each fraction, SD; Standard Deviation, %CoV; Co -
efficient of Variation. 
 
The relative recoveries were still lower than expected, when taking into account the relative 
recoveries obtained with ethambutol. The reproducibility of these experiments was increased 
compared to the initial rifampicin in vitro results (CoV: 60%, 51% and 63.82% for initial 
rifampicin experiments (Table 3.13)).  
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3.7.4 SUMMARY OF INITIAL RIFAMPICIN IN VITRO MICRODIALYSIS 
These initial experiments showed that, when using the microdialysis parameters optimised for 
ethambutol, it was possible to recover rifampicin, although not consistently or at 
concentrations far enough above the LLOQ to be confident that this drug would be recovered 
in vivo. This indicates that parameters established for one drug are not necessarily optimal for 
use with another.  
Concentration 
of Dose 
Solution 
Probe 
Perfusion 
Fluid 
Flow Rate 
(µl/minute) 
Recovery Comments 
1mg/ml 
CMA 20 
4mm 20 
kDa 
T1 
2 
Yes 
Low 
recovery 
when 
compared to 
ethambutol 
Ringers + 
0.2% BSA 
No Not repeated 
TABLE 3.15: SUMMARY OF PARAMETERS TRIALLED FOR INITIAL IN VITRO MICRODIALYSIS WITH 
RIFAMPICIN. 
  
With the aim of improving rifampicin relative recoveries, an additional perfusion fluid 
(Ringers+0.2% BSA) was tested, however, as all samples had concentrations of rifampicin 
below the limit of detection (Lower Limit of Quantitation (LLOQ): 5ng/ml) following MS 
analysis, this perfusion fluid was not used again.  
As rifampicin was the focus for in vivo microdialysis, additional optimisation of microdialysis 
parameters needed to be conducted to improve rifampicin relative recoveries.   
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3.8 DETERMINING LOSS OF ANALYTE TO IMPROVE RIFAMPICIN 
RECOVERIES 
To further understand why the recoveries of rifampicin had been so low (when compared to 
ethambutol and isoniazid) and with the intention of improving them, the first aim was to 
determine the loss of the analyte.  
As shown in Figure 3.1, a key step in development of the microdialysis methodology is 
determination of the loss of drug within the microdialysis system. Whilst performing in vitro 
experiments with rifampicin, the relative recoveries were lower (mean recovery=9.54%) and 
more variable (mean %CoV=31.54%) than the relative recoveries generated with ethambutol 
(Table 3.4) and isoniazid (Table 3.9).  A hypothesised reason for these lower relative recoveries 
is that rifampicin is a lipophilic drug and can adhere or non-specifically bind to the plastics 
within the microdialysis system.  To better understand the properties of rifampicin and how 
rifampicin interacts with the microdialysis system, a series of experiments were conducted.  
3.8.1 EVALUATION OF RIFAMPICIN ADHERANCE 
To test the hypothesis that the lipophilicity of rifampicin was the cause of the lower relative 
recoveries, 1mg/ml rifampicin solutions were made in a plastic vessel (whereby rifampicin is 
expected to adhere to the plastic) and in a glass vessel (limited adherence of rifampicin).  The 
plastic and glass vessels were left on the laboratory bench (not covered) for 8 hours at ambient 
temperature (approximately 20 °C). 25µl of 1mg/ml rifampicin solution was sampled from 
each vessel at 0, 0.25, 0.5, 1 ,2 ,4, 6 and 8 hours and analysed by LC-MS/MS as described in 
Sections 3.4 and 3.7.1. The results are shown in Figure 3.8 and represent a single experiment.
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FIGURE 3.8: RIFAMPICIN CONCENTRATIONS MEASURED IN GLASS AND PLASTIC VESSLES. This experiment was conducted over an 8-hour period to identify if there 
was adherence of rifampicin to plastic.  Pink circles are rifampicin concentrations measured using a glass vessel, blue squares are rifampicin concentrations 
measured using a plastic vessel.  Each point represents a single sample.
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In both the glass and plastic vessels, the measured rifampicin concentration at time zero was 
higher than at all other time points (Figure 3.8). This could be attributed to the incomplete 
dissolution of rifampicin. This explanation is corroborated by observations during the analysis 
process of a visible precipitate in some of the samples.  
There was little difference (especially up to the four-hour time point; the length of a 
microdialysis experiment) between rifampicin concentrations measured in a glass or plastic 
vessel. An extension of this experiment was preparation of a 5µg/ml rifampicin solution by 
serial dilution or as a single dilution in both plastic and glass vessels. There were no discernible 
differences identified between the rifampicin concentrations recovered between the serial 
dilution and the direct dilution in either the plastic or glass vessels (data not shown).   
To further investigate rifampicin non-specific binding, a passage experiment was conducted 
whereby a 10µg/ml rifampicin solution was made in T1 perfusion fluid and 200µl of this 
solution was passaged across 10 tubes sequentially (using a different polypropylene pipette 
tip each time). The 10 tubes used for the passage were either standard polypropylene 
Eppendorfs, glass vials or 300µl polypropylene microdialysis tubes. After passaging through 
10th tube, 50µl rifampicin solution from each tube type was added to 50µl 1µg/ml DXT in DMSO 
in an HPLC glass vial and analysed via LC-MS/MS (as described in Sections 3.4 and 3.7.1). The 
amount of rifampicin recovered is related to the 10µg/ml RIF starting solution. These data 
were calculated by comparing peak area ratios (PAR; an example of which is seen in Figure 3.7) 
which can be done using HPLC. Three replicates of each passage through the different tube 
types were conducted and a mean (+standard deviation) PAR calculated. This average (mean) 
was then related to the starting concentration (10µg/ml) to calculate the percentage of 
rifampicin that  had been recovered.  Results are shown in Table 3.16. 
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Mean 
PAR 
SD 
% of Starting 
Rifampicin 
Concentration 
10µg/ml RIF in T1 Perfusion Fluid  1.607 0.098 100 
10µg/ml RIF in Eppendorf (Polypropylene) 0.002 0.000 0.125 
10µg/ml RIF in Glass Tube 0.030 0.004 1.85 
10µg/ml RIF in 300µl Microdialysis Collection 
Tubes  
0.470 0.042 29.3 
TABLE 3.16: RIFAMPICIN MEASURED (% RECOVERED OF 10µG/ML SOLUTION) IN THREE DIFFERENT 
TUBE TYPES FOLLOWING SEQUENTIAL PASSAGE THROUGH TEN TUBES. 
 
29.3% of the starting rifampicin concentration (10µg/ml) was recovered in the microdialysis 
tubes which was the highest observed recovery. This recovery was most likely associated with 
the smaller surface area of these 300µl tubes as there was less surface for rifampicin 
adherence.   
All in vitro experiments with rifampicin, isoniazid and ethambutol were completed using 
plastic Eppendorfs for the dose solutions. The data indicated that there were no differences in 
adherence using glass or plastic (Figure 3.8), so plastic Eppendorfs were used for all remaining 
in vitro experiments.  These data shown in Table 3.16 indicated that by using the 300µl 
microdialysis tubes to collect fractions the associated adherence of rifampicin to plastics was 
minimised. Hence, the 300µl collection tubes were used for all future in vitro optimisation 
experiments and in vivo microdialysis experiments with rifampicin.  
3.8.2 FURTHER OPTIMISATION OF MICRODIALYSIS PARAMETERS TO 
IMPROVE RIFAMPICIN RECOVERIES 
Having investigated loss of drug, a series of three experiments were completed (Experiments 
1, 2 and 3). Each experiment was designed to test different parameters (probes, perfusion 
fluids, flow rates) in order to improve rifampicin recoveries.  
For all three experiments, the dose solutions in which the probe(s) were submerged were 
1mg/ml rifampicin. For each experiment, four flow rates were tested (1, 2, 5 and 10µl/minute). 
The tubing was cleared after each flow rate (throughout experiments 1-3) by flowing with 
demineralised water at a 25µl/min flow rate for 10 minutes. Samples were collected for 
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LC/MS-MS analysis (as in Section 3.4 and 3.7.1) every 30 minutes for 2 hours. Relative 
recoveries were calculated as described in Section 3.1.2.  
Experiment 1 used two previously exposed CMA20 cut-off 20kDa, 4mm probes, cleared with 
demineralised water at a 25µl/min flow rate for 10 minutes. T1 perfusion fluid was used for 
the 10 and 5µl/min flow rates. CNS perfusion fluid was used for the 2 and 1µl/min flow rates. 
The results from this experiment are shown in Table 3.17.  
Experiment 2 used two new CMA20 probes with different Mw cut-offs (20kDa or 100kDa), but 
the same membrane length (4mm). CNS perfusion fluid was used for all flow rates. Results are 
shown in Table 3.18. 
Experiment 3 used one previously exposed CMA20 (20kDa, 4mm) probe, flushed with 1mg/ml 
rifampicin solution at a 10µl/min flow for at least 10 minutes. This experiment was devised 
following a publication in which rifampicin concentrations were measured in the human brain 
using microdialysis. To alleviate the issue of non-specific binding, a flush of the tubing with 
rifampicin was conducted by Mindermann et al (1998)224.  T1 perfusion fluid was used for all 
flow rates. Flushes with rifampicin were conducted prior to beginning each new flow rate 
(1mg/ml solution of rifampicin flushed through probe and tubing at a 10µl/min for 10 
minutes). Results are shown in Table 3.19. No rifampicin was detected in the dialysate at the 
1µl/minute flow rate (all samples below LLOQ (5ng/ml)).  
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Experiment 1 
 
 
 
PF 
Flow 
Rate  
Time 
(min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
T
1
  
1
0
µ
l/
m
in
 
0  
0.28 
  0.43 
30 0.01 3.17 
3.8 0.6 17.0 
60 0.01 3.43 
90 0.01 4.06 
120 0.01 4.61 
30 0.01 3.26 
2.9 0.5 19.8 
60 0.01 2.40 
90 0.02 3.60 
120 0.01 2.50 
5
µ
l/
m
in
 
0  
0.52 
  0.53 
30 0.02 3.11 
5.1 1.2 26.4 
60 0.03 5.95 
90 0.03 5.90 
120 0.03 5.35 
30 0.05 9.27 
6.8 1.4 24.3 
60 0.03 6.50 
90 0.03 5.75 
120 0.03 5.81 
C
N
S 
 
2
µ
l/
m
in
 
0  
0.36 
  0.47 
30 0.06 17.66 
17.3 2.9 19.5 
60 0.05 12.68 
90 0.07 18.34 
120 0.07 20.72 
30 0.04 8.89 
15.3 5.5 41.1 
60 0.05 11.15 
90 0.09 19.18 
120 0.10 22.05 
1
µ
l/
m
in
 
0  
0.26 
  0.31 
60 0.08 29.99 
50.6 17.9 36.3 90 0.14 56.54 
120 0.17 65.21 
30 0.07 22.00 
34.0 7.3 24.8 
60 0.11 34.23 
90 0.13 40.77 
120 0.12 38.83 
 
TABLE 3.17: RIFAMPICIN RELATIVE RECOVERIES CALCULATED FROM RIFAMPICIN CONCENTRATIONS 
COLLECTED DURING EXPERIMENT ONE. 2 previously exposed (to rifampicin) CMA 20 probes 
(4mm, 20 kDa) were tested at 4 different flow rates (1, 2, 5 and 10 µl/ minute) with two 
different perfusion fluids (T1 and CNS). PF; perfusion fluid, Conc (mg/ml); concentration of 
rifampicin measured in each fraction, SD; Standard Deviation, %CoV; Co -efficient of Variation.  
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Experiment 2 
PF 
Flow 
Rate  
Time 
(min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
C
N
S 
1
0
µ
l/
m
in
  
0  
0.491         
0.177         
30 0.003 0.6 
1.3 0.6 52.7 
60 0.004 0.8 
90 0.010 1.9 
120 0.009 1.9 
30 0.002 0.3 
3.7 0.6 52.3 
60 0.007 1.4 
90 0.009 1.8 
120 0.009 1.8 
5
µ
l/
m
in
  
0  
0.143         
0.155         
30 0.002 0.51 
9.5 1.3 55.1 
60 0.016 3.18 
90 0.019 3.78 
120 0.017 3.55 
30 0.013 2.65 
8.8 0.2 7.4 
60 0.015 2.99 
90 0.014 2.89 
120 0.013 2.55 
2
µ
l/
m
in
  
0  
0.173         
0.185         
30 0.034 6.96 
15.4 2.5 54.1 
60 0.005 1.05 
90 0.032 6.52 
120 0.035 7.20 
30 0.057 11.63 
37.0 1.9 16.1 
60 0.070 14.27 
90 0.083 16.91 
120 0.064 12.98 
1
µ
l/
m
in
  
0  
0.214       
  
0.244     
  120 0.080 16.26 37.2 
30 0.061 12.43 
48.7 7.0 33.5 
60 0.139 28.32 
90 0.125 25.57 
120 0.150 30.53 
 
TABLE 3.18: RIFAMPICIN RELATIVE RECOVERIES CALCULATED FROM RIFAMPICIN CONCENTRATIONS 
COLLECTED DURING EXPERIMENT TWO. Two different Mw cut-off probes (20kDa or 100kDa; 
4mm membrane). CNS perfusion fluid was used over four different flow rates.  PF; perfusion 
fluid, Conc (mg/ml); concentration of rifampicin measured in each fraction, SD; Standard 
Deviation, %CoV; Co-efficient of Variation.  
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Experiment 3 
PF 
Flow 
Rate 
Time 
(min) 
Conc 
(mg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
Rif 
Flush 
1
0
µ
l/
m
in
 
10m 0.1941         
10m 0.2356         
T
1
  
0 
0.2866         
0.2998         
30 0.0062 2.18 
0.9 0.8 97.7 
60 0.0016 0.56 
90 0.0010 0.33 
120 0.0014 0.48 
30 0.0014 0.48 
0.2 0.1 78.3 
60 0.0004 0.13 
90 0.0005 0.16 
120 0.0004 0.12 
Rif 
Flush 
10m 0.1813         
10m 0.1552         
T
1
  
5
µ
l/
m
in
  
0 0.3371         
30 0.3036 90.08 
34.1 39.7 142.7 60 0.0352 10.43 
90 0.0061 1.81 
120 ND         
T
1
 
2
µ
l/
m
in
  
0 0.2479         
30 0.3238 130.62 
63.3 45.7 83.3 
60 0.1637 66.01 
90 0.1344 54.20 
120 0.0058 2.35 
 
TABLE 3.19: RIFAMPICIN RELATIVE RECOVERIES CALCULATED FROM RIFAMPICIN CONCENTRATIONS 
COLLECTED DURING EXPERIMENT THREE. One previously exposed CMA 20 probe (20kDa 4mm) 
was flushed with 1mg/ml rifampicin before use. T1 perfusion fluid was used over 4 different 
flow rates. ND: no drug detected. PF; perfusion fluid, Conc (mg/ml); concentration of 
rifampicin measured in each fraction, SD; Standard Deviation, %CoV; Co -efficient of Variation. 
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All three experiments showed that as the flow rate decreased from 10µl/min to 1µl/min, the 
relative recovery of rifampicin increased. This is a known characteristic of the microdialysis 
system. Another observation was that as the flow rate decreased the percentage co-efficient of 
variation increased highlighting that lower flow rates were associated with less 
reproducibility.  
Reviewing the results in Table 3.17 in conjunction with Table 3.18, a comparison of perfusion 
fluids can be made. The T1 perfusion fluid and CNS perfusion fluid, although similar, do have 
different compositions (see Section 3.2). There seemed to be no pattern in relation to the 
relative recoveries and the perfusion fluid used. For the 10µl/ min flow rates, relative 
recoveries were higher with T1 (3.814% (T1) 1.313% (CNS)), yet for 5µl/min flow rate, the 
relative recoveries were higher with CNS perfusion fluid (5.0% (T1) 9.5% (CNS)). T1 perfusion 
fluid is designed specifically for microdialysis in peripheral tissues and demonstrated good 
recovery with ETH and INH, hence there was no rationale in selecting CNS over T1. T1 
perfusion fluid was selected for use for all further in vitro and in vivo experiments.   
Using the data in Table 3.13 in which a new 20kDa (4mm) probe was used with T1 perfusion 
fluid at a 2µl/min flow rate, the mean relative recoveries across the three experiments was 
8.85%. The previously exposed probes (20kDa (4mm)) used with CNS perfusion fluid at a 
2µl/min flow rate increased the relative recoveries to a mean of 16.37% (Table 3.17). The 
%relative recovery was higher with the probes that had been previously exposed to rifampicin 
and the results were less variable (mean %CoV with probes that had previous exposure to 
rifampicin: 35.1%; mean %CoV with new probes: 58.2%) , however this was an average (mean) 
of only two replicates as opposed to three.  
The concept that higher recoveries were associated with probes that had previously been 
exposed to rifampicin were strengthened with use of the 10µl/min flow rate (Table 3.17) which 
showed a mean recovery over 2 hours of 3.35%. When comparing these results with those 
shown Table 3.18, in which a new probe was used and other parameters remained the same, 
the % relative recoveries were lower with the new probe (2.5%).  
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This increased % relative recovery associated with the probe which had been previously 
exposed to rifampicin was expected because of the lipophilic nature of rifampicin. It is likely 
that the prior use with rifampicin, would result in saturation of binding to the surfaces, hence 
when the probe was re-used there were no (or minimal) binding sites for the rifampicin to non-
specifically bind (adhere) to, resulting in more drug being collected in the dialysate. For all 
further microdialysis experiments with rifampicin, probes were previously exposed to 
rifampicin.  When performing in vivo microdialysis, the probe required flushing with rifampicin 
to ensure  previous exposure176, and due to the requirement of aseptic technique this flush was 
conducted in situ. 
The effect on relative recovery in relation to the molecular weight cut-offs of the probes can be 
identified by comparing results in Table 3.17 (20kDa) and Table 3.18 (100kDa). The relative 
recovery for the 100kDa probe was 3.65% which was approximately 1% higher than the 2.94% 
for the 20kDa Mw probe. It is important to note here that the membrane length (4mm) and the 
length of the tubing (20mm) used was the same for both probes. As discussed in Section 3.6.1, 
use of the 100kDa probe would prove to be problematic when conducting microdialysis in vivo. 
In guinea pigs, rifampicin is 69.5% plasma protein bound, binding to α-1-acid glycoprotein 
(Mw: 23.2kDa), albumin (Mw: 64.9kDa) as well as serum proteins (Mw: ranges between 70 to 
250kDa)117. Evidently, the 100kDa cut-off probe would allow many of these proteins into the 
dialysate, therefore, the 20kDa cut-off probe was used for the remainder of the studies 
reported in this thesis.  
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3.9 RIFAMPICIN IN VITRO MICRODIALYSIS WITH PHYSIOLOGICALLY 
RELEVANT DOSE SOLUTIONS 
The previous experiments (Sections 3.7 and 3.8) used a 1mg/ml rifampicin solution in order 
to optimise the parameters to increase %relative recovery. It was important that in vitro 
microdialysis experiments were conducted closer to the concentration of drug that was 
expected in the guinea pigs’ organs following oral drug administration. Using the data 
generated in Chapter 2, the Cmax (maximum concentration) measured in blood following a 
50mg/kg oral dose of rifampicin was 6µg/ml. Therefore, a more physiologically relevant 
concentration of 10µg/ml was used as the dose solution for these experiments. A 100µg/ml 
dose solution was also used. These experiments were conducted to ascertain if the 
microdialysis system and the analytical equipment were sensitive enough to detect these lower 
concentrations of rifampicin collected in the dialysate. 
Initially, a 100µg/ml rifampicin solution was dialysed with parameters optimised throughout 
this Chapter: CMA 20 probes (20kDa, 10mm tip) which had previously been exposed to 
rifampicin, T1 perfusion fluid and a flow rate of 2µl/min. The dose solution was heated to and 
maintained at 39.2°C (guinea pig body temperature) to replicate in vivo conditions. Samples 
were analysed as discussed in Section 3.7.1, and relative recoveries calculated as discussed in 
Section 3.1.2. The results are shown in Table 3.20. 
 
 
 
 
 
 
 
 
 
 
124 
 
Replicate Dose 
Time 
(Min) 
Conc 
(µg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
1 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
2
4
.2
µ
g/
m
l 
30   
60 4.57 18.9 
15.9 2.0 14.0 
90 4.29 17.7 
120 3.85 15.9 
150 3.69 15.3 
180 3.57 14.7 
210 3.07 12.7 
240         
2 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
: 
3
0
.0
4
µ
g/
m
l 
30 2.06 6.9 
11.6 6.0 51.7 
60 6.83 22.7 
90 4.57 15.2 
120 1.97 6.5 
150 4.35 14.5 
180 1.93 6.4 
210 4.23 14.1 
240 1.97 6.5 
 
TABLE 3.20: RIFAMPICIN RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS WITH A 
100µG/ML DOSE SOLUTION. A previously exposed probe was used (20k Da 10mm) at 2µl/min 
flow rate with T1 perfusion fluid . Conc (µg/ml); concentration of rifampicin measured in each  
fraction, SD; Standard Deviation, %CoV; Co-efficient of Variation.  
The %relative recoveries for the 100µg/ml dose solution were similar to %relative recoveries 
when a 1mg/ml solution of rifampicin was used (Table 3.17). The dose solutions were below 
the expected concentrations (30µg/ml and 24µg/ml) of 100µg/ml. An explanation for the 
lower than expected dose solution was described in Section 3.7.2 and with a 100µg/ml dose 
solution, 6µg of rifampicin was removed every 30 minutes (across 4 hour experiment) 
ultimately lowering the concentration by at least 48µg.  As the relative recoveries for the 
individual fractions were related to the starting dose solution, the %relative recovery 
remained the same.  
These experiments were repeated with the same parameters and a 10µg/ml dose solution was 
also dialysed. The results for both the 100 and 10µg/ml dose solutions are in Table 3.21. The 
concentrations of rifampicin in the dose solutions (132 & 82.8 µg/ml) were closer to the 
100µg/ml dose solution that was aimed for. The dose solutions for 10µg/ml calibrations were 
similar between both experimental replicates. The mean relative recoveries were higher with 
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100µg/ml dose solution.  One 30-minute sample had a rifampicin concentration much higher 
than the rest of the samples (Table 3.21; 10µg/ml Replicate 2; 19.9µg/ml). This high value 
could be due to rifampicin crystallisation on the probe or carry-over of rifampicin during MS 
analysis as 30-minute samples were analysed immediately after the dose solution. Recovering 
rifampicin from these low dose solutions via in vitro microdialysis gave confidence that the 
proposed rifampicin concentrations expected in the organs (based upon the concentration of 
rifampicin measured in blood) could be recovered during in vivo microdialysis.  Therefore, no 
further optimisation for rifampicin microdialysis was conducted. 
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Replicate Dose 
Time 
(Min) 
Conc 
(µg/ml) 
%Relative 
Recovery 
Mean 
%RR 
SD %CoV 
1 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
 (
2
4
0
 
m
in
s)
: 1
3
2
µ
g/
m
l 
30 No Sample 
27.0 5.3 18.2 
60 37.3 28.1 
90 47.5 35.8 
120 42.7 32.2 
150 36.0 27.2 
180 25.7 19.4 
210 30.3 22.9 
240 30.6 23.1 
2 
C
o
n
c 
o
f 
D
o
se
 S
o
lu
ti
o
n
 (
2
4
0
 
m
in
s)
: 8
2
.8
µ
g/
m
l 
30 51.6 62.3 
47.9 9.6 21.7 
60 46.2 55.8 
90 43.2 52.2 
120 24.7 29.8 
150 36.0 43.5 
180 37.4 45.2 
210 38.1 46.1 
240 No Sample 
1 
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: 
1
9
µ
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l 
30 2.4 12.9 
8.6 4.3 54.5 
60 2.9 15.4 
90 1.7 8.7 
120 0.6 3.0 
150 1.5 8.1 
180 1.8 9.6 
210 0.5 2.6 
240 No Sample 
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: 
2
1
.7
µ
g/
m
l 
30 19.9 91.5 
11.0 28.6 55.9 
60 4.7 21.6 
90 3.7 17.0 
120 0.9 4.2 
150 2.3 10.8 
180 1.7 7.8 
210 1.5 6.8 
240 1.9 8.8 
 
TABLE 3.21: RIFAMPICIN RELATIVE RECOVERIES FOLLOWING IN VITRO MICRODIALYSIS WITH 
PREVIOUSLY OPTIMISED PARAMETERS USING 100µG/ML AND 10µG/ML DOSE SOLUTIONS. A 
previously exposed probe was used (20kDa 10mm) at 2µl/min flow rate with T1 perfusion 
fluid . Conc (µg/ml); concentration of rifampicin measured in each fraction, SD; Standard 
Deviation, %CoV; Co-efficient of Variation  
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3.9.1 PROBE EFFICIENCIES 
Table 3.22 shows all the calculated mean %relative recoveries gained for rifampicin in vitro 
microdialysis. These data were propagated to determine the efficiency (and associated error) 
of the probe. Subsequently, the in vivo microdialysis recoveries were corrected for using this 
calculated probe efficiency. Error was propagated using the method described in ‘An 
Introduction to Error Analysis’225. Errors were propagated using standard error of the mean of 
relative recoveries. The equation used to calculate error was:  
√ (a)2+ (b)2+……. + (z)2 
The error was then divided by mean %relative recovery to get the fractional uncertainty.  
The results table column  in Table 3.22 shows which results table (in Chapter 3) the %relative 
recovery data was obtained from. For 4 of the concentrations, the data is not shown in this 
Chapter. This is because a set of samples were analysed at the University of Liverpool. It was 
decided to include these data as the concentrations of the dose solutions and the associated 
%relative recoveries were very similar to those results shown in Table 3.21 hence these 
relative recoveries were included to strengthen the calculated probe efficiency.  
Across all of the dose solutions (19µg/ml-724µg/ml; Table 3.22) the probe efficiency with 
rifampicin was calculated to be 15%±32%. This meant the associated error (CI) was ±32% 
which was very high. However, it was assumed (based on blood concentrations) that the 
expected in vivo organ concentration of rifampicin was going to be less than or close to 
50µg/ml, and at these concentrations the probe efficiency was calculated to be 21%±9%. The 
probes used at these lower concentrations (19-30µg) were CMA20 (Mw cut-off 20kDa, 10mm 
membrane length) probes which were optimised for use in vivo. A probe efficiency greater than 
20% is sufficient as this would enable rifampicin to be consistently recovered at concentrations 
above the LLOQ (5ng/ml) and hence it was concluded that no further optimisation would be 
required. Therefore, recovered rifampicin collected during in vivo microdialysis could be 
confidently corrected with this figure (21±9%).  
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Rif 
Conc 
(µg/ml) 
%RR Results Table 
Probe 
Efficiency 
19 8.6% Table 3.21 
21%±9% 
21.7 11% Table 3.21 
22 21% Not Shown 
24.2 15% Table 3.20 
30 25% Not Shown 
30.04 11% Table 3.20 
82 47% Table 3.21 
19%±10% 
87 15% Table 3.13 
132 27% Table 3.21 
162 10% Table 3.13 
173 15% Table 3.18 
185 37% Table 3.18 
249 16% Not Shown 
16%±15% 355 17% Table 3,17 
466 15% Table 3.17 
589 10% Not Shown 
8.12%±25% 
652 6% Table 3.14 
705 8% Table 3.14 
724 8% Table 3.14 
 
TABLE 3.22: ALL MEAN RELATIVE RECOVERIES ASSOCIATED WITH RIFAMPICIN PROPAGATED TO 
DETERMINE EFFICIENCY OF THE PROBE. An efficiency of 21±9% could be attributed to the probe 
as the concentration of rifampicin in the organs were expected to be less or approximately 
equal to 50µg/ml. Results table column shows where in this document the relative recoveries 
can be found. Data not shown is data that is not described in this document due to the samples 
being analysed at the University of Liverpool.  
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3.9.2 CONCLUSIONS FOLLOWING OPTIMISATION OF PARAMETERS TO 
IMPROVE RIFAMPICIN RECOVERIES 
In this section the main aim was to improve rifampicin relative recoveries from those 
determined in Section 3.7. The main parameters tested were probes, perfusion fluid and flow 
rate. Initially, adherence and non- specific binding of rifampicin to plastics (an unavoidable 
component of the microdialysis system) were investigated. It was found that rifampicin 
concentrations were highest following passage through the 300µl microdialysis tubes, so these 
tubes were used throughout the remainder of this project. The other parameters tested are in 
Table 3.23. 
Concentration 
of Dose 
Solution 
Probe 
Perfusion 
Fluid 
Flow Rate 
(µl/minute) 
Recovery Comments 
1mg/ml 
CMA 20 
4mm 20kDa 
Previously 
Exposed 
CNS 1&2 
Yes 
 
Previously 
exposed 
probes had 
higher 
recovery 
than new 
probe. 
T1 5&10 Yes  
CMA 20 
4mm 20kDa 
New 
CNS 1, 2, 5 &10 
Yes 
Low. 
Perfusion 
fluid had no 
effect on 
recovery.  
CMA 20 
4mm 
100kDa 
Yes 
Mw cut-off, 
no effect on 
recovery.  
CMA 20 
4mm 20kDa 
Rifampicin 
Flush; T1 
1, 2, 5 &10 Variable 
Useful in 
relation to 
exposing the 
probe to 
rifampicin.  
TABLE 3.23: SUMMARY TABLE OF PARAMETERS TESTED TO IMPROVE RIFAMPICIN RECOVERIES. 
The probes that had been previously exposed to rifampicin meant that higher concentrations 
of rifampicin were recovered, and the method for exposing sterile probes in vivo to rifampicin 
to ensure previous exposure was confirmed.  
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There were no discernible improvements in recoveries associated with CNS perfusion fluid, 
therefore T1 perfusion fluid was used for all future calibrations as it was optimised for use in 
peripheral tissues. 
In vitro experiments were also conducted with more physiologically relevant concentrations 
(100 & 10µg/ml) of rifampicin with parameters optimised throughout this Chapter; Previously 
exposed probes (10mm, 20kDa), T1 perfusion fluid and 2µl/min flow rate were used. 
Rifampicin was recovered via microdialysis at these concentrations using these parameters, 
which enabled the probe efficiency associated with rifampicin to be calculated. The probe 
efficiency associated with rifampicin at the concentrations expected in the organs was 21±9% 
and this figure was used as a correction factor when microdialysis was conducted in vivo.  
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 3.10 ORGAN EFFECTS ON %RELATIVE RECOVERY 
All in vitro calibrations up to this point were conducted with dose solutions made of drug and 
water, however another factor that could affect relative recovery is the tissue in which the 
microdialysis will occur as shown in Figure 3.1.  Hence, for the final in vivo microdialysis 
preparations, the equipment was set up as in  Figure 3.2 and the probe was submerged in a 
drug and organ homogenate dose solution as opposed to a drug and HPLC water dose solution.  
3.10.1 IN VITRO MICRODIALYSIS WITH ORGAN HOMOGENATES SPIKED 
WITH RIFAMPICIN 
Three sets of guinea pig lungs, livers and skeletal muscles (organs of interest for probe 
insertion) were defrosted at room temperature and weighed on an analytical balance. To every 
0.2g tissue, 1ml Ringers solution was added192. An Ystral homogeniser was used and post 
homogenisation the organ was spiked with 10µg/ml rifampicin. These spiked samples were 
vortexed for at least 2 minutes and maintained at 39.2°C in a water bath whilst the CMA20 
microdialysis probe (20kDa; 10mm) which had been previously exposed to rifampicin were 
submerged into the homogenate. T1 perfusion fluid was used with a 2µl/minute flow rate and 
dialysate fractions were collected every 30 minutes for 4 hours. Samples were analysed as 
discussed in Section 3.7.1. Rifampicin was measured in all dialysate samples which gave 
reassurance that these low drug concentrations were able to be collected and analysed via LC-
MS/MS in the presence of tissue homogenate.  
The results are shown in Figure 3.9 and each point on the graph represents an average of three 
different replicates.
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FIGURE 3.9: CONCENTRATIONS OF RIFAMPCIN RECOVERED IN FRACTIONS FOLLOWING MICRODIALYSIS IN ORGAN HOMOGENATES. Lungs, livers and skeletal muscle 
were spiked with 10µg/ml rifampicin in triplicate.  Each point represents an average of three replicates.  Additional line on graph show 21% (36ng) of the 
proposed unbound concentration of rifampicin (180ng) .
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Initially the unbound drug proposed to be in the spiked homogenates was calculated based 
upon plasma protein binding in blood which is 69.5% for rifampicin in guinea pigs. On this 
basis it was assumed that there was 0.18µg (180ng) of unbound rifampicin available in the 
homogenate for collection via microdialysis. Using the calculated probe efficiency of 21±9% 
(Table 3.22) and the proposed unbound drug in the homogenate, a line was drawn on the 
graphs in Figure 3.9 which shows 21% of 180ng which is 36ng.   
It was evident in Figure 3.9, that over the time course, the probe was not consistently 
recovering 21±9% of the hypothesised unbound rifampicin. The reasons for this may be as this 
was a static system with no blood flow and the organs were spiked with the drug. However, at 
the 30 and 60-minute time points within the lung and skeletal muscle, the probe was working 
as expected recovering approximately 21% of the expected unbound rifampicin. The lower 
values at the later time points, as evidenced in the skeletal muscle, could be explained due to 
the static system whereby the majority of the unbound drug may have been already removed.  
The lung results were more variable when compared to the skeletal muscle, as between 60 and 
210 minutes the probe was recovering below the hypothesised 21%. This can be explained by 
the associated volume of blood that is present in the lungs, that when homogenised, could 
decrease the amount of unbound drug available to collect due to protein binding as well as 
potentially diluting the available drug. Within the liver, the probe was working close to the 
proposed 21% efficiency especially from 180 minutes onwards.  
Rifampicin was recovered at approximately the expected probe efficiency (21%) from organ 
homogenates (30 and 240 minutes for lung, 60 minutes skeletal muscle and between 180 and 
240 minutes in liver). Although these data were variable, the aforementioned limitations of the 
static system and use of homogenised tissue most likely contributed to this variability and 
hence these data support the use of 21±9% as the correction factor for probe efficiency for  the 
rifampicin microdialysis data generated in vivo.  
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3.11 IN VITRO CONCLUSIONS PRIOR TO MOVING IN VIVO 
This chapter describes the in vitro microdialysis experiments conducted with ethambutol, 
rifampicin and isoniazid with the overarching aim of calculating the efficiency of the probes to 
recover each drug prior to performing in vivo microdialysis. To calculate probe efficiency, the 
relative recovery of the drug was measured with probe. Recovery was optimised and improved 
by changing various parameters such as flow rate, perfusion fluid and probe type. Table 3.24 
shows the parameters that were tested. 
Drug Concentration Probe 
Perfusion 
Fluid 
Flow Rate 
(µl/min) 
Recovery 
ETH 
91mg/ml 
(=250mg/kg) 
CMA 20 (4mm; 
20kDa) 
 
T1 
 
2 
Yes- Very 
High 
56.5mg/ml 
(=100mg/kg) 
Yes- Very 
High 
1mg/ml 
 
Yes 
1 Yes 
RIF 
1mg/ml 
 
CMA 20 (4mm; 
20kDa) 
 
T1 
2 
Yes- Very 
low 
Ringers 
+0.2%  
Bovine 
Serum 
Albumin  
No 
Previously Exposed 
CMA 20 (4mm; 
20kDa) 
 
CNS 1 & 2 
Yes- Very 
low 
T1 5 & 10 Yes 
CMA 20 (4mm; 
20kDa) 
CNS 
1, 2, 5 & 10 
 
Yes- Low 
CMA 20 (4mm; 
100kDa) 
Yes 
Flushed with 
rifampicin; CMA 20 
(4mm; 20kDa) 
T1 
 
1, 2, 5 & 10 Variable 
100µg/ml 
Previously Exposed 
CMA 20 (10mm; 
20kDa) 2 
 
Yes 
 
10µg/ml 
Previously Exposed 
CMA 20 (10mm; 
20kDa) 
INH 
1mg/ml 
 
CMA 20 (10mm; 
20kDa) T1 
 
2 
 
Yes 
CMA 20 (4mm; 
100kDa) 
Yes 
 
TABLE 3.24: ALL PARAMETERS (PROBE TYPE, PERFUSION FLUID, FLOW RATE) THAT WERE TESTED 
IN THIS CHAPTER TO ENABLE PROBE EFFICIENCIES TO BE CALCULATED. 
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The calculated probe efficiency for rifampicin was 21±9% at the concentrations expected in 
the organs. An in vitro assay was conducted, primarily to understand matrix (organ) effects on 
the recovery of rifampicin. The recoveries for rifampicin were close to the expected 21±9% 
and these experiments gave confidence that the microdialysis methodology could recover low 
concentrations of the drug in the presence of organ/tissue components. 
Therefore, the parameters that were proposed to be used for in vivo microdialysis were a 
previously exposed CMA 20 probe (20kDa, 10mm), T1 perfusion fluid and 2µl/minute flow 
rate. 
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CHAPTER 4 
IN VIVO MICRODIALYSIS METHOD DEVELOPMENT 
4.1 INTRODUCTION 
Drug doses for in vitro microdialysis and for oral administration to guinea pigs were defined in 
Chapter 2.  The key parameters for microdialysis, such as probe type, perfusion fluid and flow 
rate were defined during the in vitro studies detailed in Chapter 3. The aims of the studies 
described in this Chapter were to define the organ into which the microdialysis probe was to 
be implanted and to establish the in vivo microdialysis methodology. This methodology is 
comprised of in vivo study design and surgical considerations, as well as pre- and post- 
operative care including analgesia and housing requirements. 
4.2 SELECTION OF ORGAN FOR MICRODIALYSIS 
4.2.1 LIVER 
The lungs (main target site for drug delivery during TB disease) were the original organ of 
interest to recover unbound (UB) anti-TB drug concentrations via microdialysis. The feasibility 
of microdialysis in the lung of an awake freely moving guinea pig was limited and could not be 
successfully conducted without the use of a specially designed proprietary MetQuant ‘floppy’ 
microdialysis probe (Thomas Cremers, Brains On-Line 226, Personal Communication). The liver 
was therefore proposed as an alternative organ to dialyse, primarily because of its large size 
and seemingly straightforward location for probe insertion.  
Isoniazid and rifampicin are both metabolised in the liver, and are also associated with high 
levels of hepatotoxicity, which gave further justification for the liver as the site of probe 
implantation. Isoniazid is known to cause severe liver failure in 1% of people who are 
administered this drug, especially those with the slow acetylator status127,128. This toxicity is 
most likely associated with the bioactivation of the pro-drug into its reactive metabolites227  
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(Chapter 1). The practicality of microdialysis probe implantation into the liver of guinea pigs 
was investigated post mortem. A guinea pig was culled via an intra-peritoneal injection of 
sodium pentobarbitone as described later in this Chapter and then was laid on its right- hand 
side. The surgery area was prepared in advance by ensuring the table used was clean and 
covered. The area into which the probe was to be implanted was close clipped and cleaned. An 
incision was made along the midline of the guinea pig to expose the peritoneum. The xiphoid 
process was used as an anatomical ‘land mark’ and needle (23Ga x 5/8" 0.6x16mm) was 
inserted approximately 1mm below the xiphoid process, but above the ribs. An incision was 
made along the peritoneum to determine if the needle had entered the liver without disturbing 
or disrupting other internal anatomy of the guinea pig. The initial insertion did enter the liver 
of the guinea pig; however, it also exited out the other side. To ensure maintenance of the probe 
membrane and comfort for the guinea pig, the probe must be anchored in position with 
sutures. There were no suitable anchor points (points to suture the probe to) within the liver.  
It was clear that insertion of the probe into the liver was a non-recoverable procedure and 
therefore would not be fit for the purpose of this project.  As highlighted in this section, probe 
implantation into the liver or the lung was not feasible, hence an alternative tissue was 
investigated for probe implantation as detailed in the following sections. 
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4.3 SKELETAL MUSCLE AS A SURROGATE FOR LUNG 
4.3.1 INTRODUCTION 
It was identified that unbound drug concentrations within the lung and skeletal muscle were 
similar for gatifloxicin228 and cefpodoxime229. Both of these drugs share physiochemical 
properties with isoniazid, and it was therefore decided to design an experiment to identify if 
the concentrations of anti-TB drugs were similar between lung (site of TB disease and 
therefore the most relevant organ for microdialysis) and skeletal muscle or if not, whether 
there was a correlation. Similar or correlated drug concentrations between the lung and 
skeletal muscle would enable the skeletal muscle to be used as a surrogate for lung 
microdialysis in the guinea pig. This experiment and the subsequent results are described in 
the following section. 
An investigation into the feasibility of probe implantation into the skeletal muscle was also 
conducted (Section 4.4.5).  The sacrospinalis is a large skeletal muscle that is located next to 
the spine, and due to its size, strength and proximity to the dermis there were anatomical 
advantages for probe implantation. There are several examples of microdialysis in the skeletal 
muscle 215,228,229 using minimally invasive surgical protocols, which ensured that animals can 
be awake and freely moving. 
 For the first investigation, skeletal muscle was collected from the hind leg (biceps femoris) of 
the guinea pig, because for the purposes of PK/PD modelling, skeletal muscle is not 
distinguished by anatomical location.
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4.3.2 STUDY DESIGN AND METHODS 
Following the methods described in Chapter 2, six guinea pigs were administered one oral dose 
of isoniazid (50mg/kg) or rifampicin (50mg/kg) and blood samples were taken from the ear, 
following the schedule in Table 4.1. Guinea pigs were cardiac bled and necropsied to remove 
lung, liver and skeletal muscle. The samples were processed via protein precipitation (Chapter 
4) and analysed at Q3 Analytical, following the methods described in Chapter 3. 
 
TABLE 4.1: STUDY DESIGN TO INVESTIGATE THE RELATIONSHIP BETWEEN DRUG CONCENTRATIONS 
IN THE LUNG AND SKELETAL MUSCLE. Six guinea pigs were administered a single oral dose 
(50mg/kg) of isoniazid or rifampicin and ear bled either at 1 and/or 2 hours post drug 
administration. Cardiac bleeds and necropsies (lung, liver, skeletal muscle removed) were 
performed either at 1, 2 or 4 hours post drug administration.
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4.3.3 EQUIPMENT LIST FOR INVESTIGATION OF RELATIONSHIP 
BETWEEN LUNG AND SKELETAL MUSCLE DRUG CONCENTRATIONS 
Equipment Comments Source 
2ml/10ml syringe Oral administration of 
drug/cardiac bleed 
BD574/GS576; Appleton 
Woods Ltd, Birmingham, UK. 
Scalpel Ear bleeds No. 15A; Product Code: 
0320; Swann Morton, 
Sheffield, UK 
Sterilin plates Necropsy Procedure SC274; Appleton Woods Ltd, 
Birmingham, UK 
Various gauge needles Various uses Terumo Agani, Surrey, UK 
Drug, Chemical or 
Reagent 
Comments Source 
0.1% Formic Acid Aqueous Chromatographic Solvent 5438040100; Sigma Aldrich 
Co LTD, Dorset, UK 
Acetonitrile Chromatographic Solvent PHR1551-3X1.2ml; Sigma 
Aldrich Co LTD Dorset, UK 
Apple and Banana fruit 
puree 
To help palatability of drugs 
for oral administration 
Ella’s Kitchen, Henley-on-
Thames, UK 
Dextromethorphan (DXT) Internal standard 1180503-2G; Sigma Aldrich, 
Dorset, UK 
Dimethyl sulfoxide (DMSO)  D2650; Sigma Aldrich, 
Dorset, UK 
HPLC Grade Water  270733-1L-M; Sigma Aldrich 
Co LTD, Dorset, UK 
Isoniazid  I3377-250G; Sigma Aldrich, 
Dorset, UK 
Isopropyl alcohol (IPA) Necropsy Procedure I0398; Sigma Aldrich, Dorset, 
UK 
Rifampicin  R3501-1G; Sigma Aldrich, 
Dorset, UK 
Sodium pentobarbitone Dolethal 200mg/ml Vetoquinol UK Ltd 
HPLC/MASS SPECTROMETRY 
Q3 Analytical, 
Porton Science Park, Porton 
Down, Salisbury, Wiltshire, 
SP4 0JG 
(HPLC) Agilent 1100 Pump, 
Column heater, Degasser 
Aligent, Cheadle, UK 
(HPLC) CTC HTS 
Autosampler 
Presearch, Basingstoke, UK 
(HPLC) Column; Rifampicin; 
Kinetex C8 50x2.1MM, 5µm 
Phenomenex, Macclesfield, 
UK 
(Mass Spectrometer) 
API3000 
Sciex, Warrington, UK 
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4.3.4 CARDIAC BLEED AND NECROPSY PROCEDURE 
Guinea pigs were euthanised via 2ml injection of 200mg/ml sodium pentobarbitone. Blood 
samples were withdrawn once the pedal withdrawal reflex was absent.  A syringe with needle 
was used to withdraw 1ml of blood from the heart, which was then added to 2ml HPLC water. 
The tubes were closed, vortexed and snap frozen in liquid nitrogen. The guinea pig was then 
placed on its back and an incision made in the abdomen and thorax to remove the lungs and 
liver. The skeletal muscle from the hind leg (biceps femoris) was removed after removing the 
fur on the left hind leg and using the scissors to cut away the muscle from the bone. Organs 
were placed on Sterilin plates to remove excess connective tissue, weighed on an analytical 
balance and snap frozen.  
4.3.5 SAMPLE PROCESSING FOR ANALYSIS OF ISONIAZID AND 
RIFAMPICIN CONCENTRATIONS IN BLOOD AND TISSUE 
This method was adapted from Kjellson et al192.  
Blood, liver, lung and skeletal muscle samples were thawed at room temperature. To every 
0.2g of tissue (as weighed at point of necropsy) 1ml of PBS was added. Each tissue was 
homogenised (Ystral) and the blade was cleaned between every sample with isopropyl alcohol 
and then demineralised water to ensure no carry-over of tissue or drug. Methanol (10µl) was 
added to 50µl of homogenate or blood and vortexed thoroughly. 440µl acetonitrile (containing 
0.3µg/ml dextromethorphan (internal standard for LC-MS/MS (Chapter 3)) was added  to the 
samples and vortexed for two minutes then centrifuged in a microfuge at 10,000g for 10 
minutes. The supernatant was removed and stored at -80°C until samples were thawed, 
transferred to HPLC tubes and the liquid evaporated from samples (Genevac evaporator). 
When dry, 20µl of 0.1% formic acid was added to each HPLC tube and these samples were 
injected directly into the HPLC for analysis. 
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4.3.6 COMPARISON OF DRUG CONCENTRATIONS IN LUNG AND SKELETAL 
MUSCLE 
The mean concentrations (µg/ml) of rifampicin and isoniazid in lung and skeletal muscle from 
six guinea pigs were plotted (GraphPad Prism V7) against one another as shown in Figure 4.1.  
These data represent both the bound and unbound (total) drug concentrations. 
The concentration of rifampicin measured in the skeletal muscle was significantly lower than 
that found in the lung (Wilcoxon test; P=0.0313). The mean concentration of rifampicin in the 
lung was 22.67µg/ml (Standard Deviation (SD): 22.6) and in the skeletal muscle was 6.19µg/ml 
(SD:6.9). This meant that the concentration of rifampicin in the lung was approximately 3 times 
higher than in the skeletal muscle.  
The concentration of isoniazid measured in the skeletal muscle was lower than that found in 
the lung (Wilcoxon test; P=0.1563). The mean concentration of isoniazid in the lung was 
30.3µg/ml (SD: 36.9) and in the skeletal muscle was 6.01µg/ml (SD: 5.8). This meant that the 
concentration of isoniazid in the lung was approximately 5 times higher than in the skeletal 
muscle. 
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FIGURE 4.1: A) MEAN ORGAN CONCENTRATION OF RIFAMPICIN (BOUND AND UNBOUND) IN LUNG AND SKELETAL MUSCLE. B) MEAN ORGAN CONCENTRATION OF ISONIAZID (BOUND AND 
UNBOUND) IN LUNG AND SKELETAL MUSCLE.  Six guinea pigs were dosed with either 50mg/kg of rifampicin or isoniazid and the concentration of drug in the lung and hind leg 
skeletal muscle were measured. Error bars represent standard deviation (SD).
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4.3.7 RELATIONSHIP BETWEEN LUNG AND SKELETAL MUSCLE 
CONCENTRATIONS OF ISONIAZID 
As the isoniazid concentrations in the lung and skeletal muscle were not sufficiently similar, 
the concentrations in the two organs were analysed to identify if there was a relationship or 
correlation between them that would enable the concentration in the lung to be derived from 
the skeletal muscle. There was no relationship identified between lung and skeletal muscle 
drug concentrations in animals dosed with isoniazid (Pearson R2 value =0.1857 (P = 0.3936)). 
The data are shown in Figure 4.2.  
 
FIGURE 4.2: ISONIAZID CONCENTRATIONS MEASURED IN THE LUNG AND SKELETAL MUSCLE. There 
is no relationship between the concentrations of isoniazid within the two organs . The data 
from six guinea pigs is plotted.  
Under the conditions tested (doses and timescale), it does not appear that lung concentrations 
of isoniazid could be estimated from skeletal muscle and therefore microdialysis of the 
sacrospinalis would not be a suitable for this drug. Further investigations would be required 
to optimise the methodology for in vivo microdialysis experiments with isoniazid.  
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4.3.8 RELATIONSHIP BETWEEN LUNG AND SKELETAL MUSCLE 
CONCENTRATIONS OF RIFAMPICIN 
As the concentrations of rifampicin differed between the lung and skeletal muscle (P=0.0313), 
the individual animal data were analysed to identify if there was a relationship between the 
quantity of drug in the two tissues. The rifampicin concentrations in the lung and skeletal 
muscle were plotted and tested for correlation (Pearson correlation test) which generated an 
R2 value of 0.8718 (p=0.0065).   
A second order polynomial (quadratic function) (Figure 4.3) was used to fit all data points, 
generating an R2 of 0.964 (Sy.x=4.5) highlighting the strength of the fit.  
The use of a second order polynomial with these data (Figure 4.3) generated the following 
equation: 
𝑌 = 𝐵0 + 𝐵1 ∗ 𝑋 + 𝐵2 ∗ 𝑋^2 
where Y is the concentration of rifampicin in the lung, B0=-7.254, B1=7.848 and B2=-0.2361 
(equation constants generated in GraphPad Prism) and X is concentration of rifampicin in the 
skeletal muscle. This meant that rifampicin concentrations measured in the skeletal muscle 
could be used to calculate rifampicin concentrations in the lung.  
The second order polynomial was used to account for the data point at 20.1µg/ml in skeletal 
muscle and 55µg/ml in the lung. This data point was from a guinea pig that was culled two 
hours post drug administration. To understand if the time at which the samples were collected 
had an effect on the relationship between drug concentrations in the lung and skeletal muscle, 
the ratio of rifampicin concentrations between lung and skeletal muscle were plotted over time 
(Figure 4.4).  The ratio varied minimally which indicated that the relationship of drug 
concentrations between the lung and skeletal muscle was true regardless of sampling 
timepoint and therefore suggested that differing rates of distribution following oral drug 
administration could be accountable for this apparent outlier. 
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These data provided confirmation that the sacrospinalis was a potentially suitable tissue to 
dialyse in order to estimate concentrations of rifampicin in the lung due to the strength of the 
relationship (R2 =0.8718) between lung and skeletal muscle concentrations. Rifampicin was 
therefore selected for in vivo microdialysis studies using the sacrospinalis for probe insertion 
with the assumption that this relationship (between lung and skeletal muscle rifampicin 
concentrations) would remain true for unbound rifampicin concentrations as collected via 
microdialysis.   
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FIGURE 4.3: CORRELATION BETWEEN RIFAMPICIN CONCENTRATIONS IN THE LUNG AND SKELETAL 
MUSCLE. Data points for six guinea pigs were fitted with a second order polynomial.  Each point 
is labelled with hour of collection. The equation Y=B0+B1*X+B2*X^2 where Y is the 
concentration of rifampicin in the lung, B0=-7.254, B1=7.848 and B2=-0.2361 (equation 
constants generated in GraphPad) and X is concentration of rifampicin in the skeletal muscle.  
 
FIGURE 4.4: MEAN RATIO OF RIFAMPICIN CONCENTRATIONS BETWEEN LUNG AND SKELETAL MUSCLE 
PLOTTED OVER TIME. Each point is the mean data of two guinea pigs which were culled 1, 2 or 
4 hours post drug administration . Error bars represent standard deviation.  
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4.4 IN VIVO MICRODIALYSIS STUDY DESIGN & METHODS 
4.4.1 INTRODUCTION TO PILOT STUDY  
Following the determination and optimisation of the microdialysis parameters that best 
recover rifampicin, calculation of the probe efficiency (Chapter 3) and the determination of a 
correlation (R2 =0.8718) between rifampicin concentrations in the lung and skeletal muscle 
(Section 4.3), it was decided that rifampicin was to be administered to the guinea pigs with the 
aim of being recovered via microdialysis in vivo. An initial in vivo microdialysis study with two 
guinea pigs was designed to prove that rifampicin concentrations could be measured via the 
microdialysis methodology from the sacrospinalis over time.  
An essential component of this pilot study was determination of the methods required for in 
vivo microdialysis. The methods described in this section are for the following: 
• Anaesthesia, as guinea pigs required anaesthesia for the implantation of the CMA20 
microdialysis probe into the sacrospinalis. 
• Surgical implantation of the probe into the sacrospinalis. As shown in Section 4.3 the 
sacrospinalis was selected as the site of microdialysis for rifampicin and therefore a 
protocol was devised for the insertion of the selected microdialysis probe (based on 
studies in Chapter 3 (CMA20 10mm 20kDa)) into the sacrospinalis. An important 
component of this pilot study was to determine whether the guinea pig would survive 
the surgical implantation of the probe and thrive thereafter to enable good quality data 
to be generated from healthy animals. 
• Maintenance of the microdialysis probe in situ to ensure patency. The probe was 
flushed twice daily until patency (visible liquid in collection tube) was observed. The 
first flush occurred as soon as was practically possible following the guinea pig being 
placed into the warmed home cage for recovery post-surgery. The probe was flushed 
with a rifampicin containing solution to ensure that the probe had been previously 
exposed to rifampicin to limit non-specific binding of rifampicin to the microdialysis 
system plastics (Chapter 3). 
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Also described are the methods used for post-operative care, entry and exit into the guinea pig 
housing room, urine and faeces collection (as rifampicin is known to be excreted via these 
routes) and ex vivo microdialysis. The overarching in vivo microdialysis study schedule and 
method is shown in Section 4.5.  
As part of this methodology, ear bleed samples were collected at set time points post drug 
administration as described in Chapter 2. These samples were collected to enable blood drug 
concentrations to be related to organ drug concentrations and as a comparator to the PK 
parameters of rifampicin in blood which were generated in Chapter 2. Collection of ear bleeds 
had to comply with the specified limits on frequency of ear bleeds in the Home Office Project 
Licence, which details that each guinea pig can have 2 ear bleeds (maximum blood volume of 
100µl per occasion). An alternative approach for blood sampling was considered, involving 
blood vessel (jugular vein) cannulation so that blood samples could be collected at intervals 
time-matched to the microdialysis fractions. This would require an additional surgical 
procedure and since collection of blood from the peripheral vein in the ear (capillary blood) 
had been used previously (Chapter 2) and shown to be feasible, this less invasive method was 
preferred.  
The lessons learnt from this pilot study are highlighted at the end of this chapter. The results 
from this initial in vivo microdialysis experiment were analysed in conjunction with additional 
data generated from further in vivo microdialysis experiments and these data are shown and 
discussed in Chapter 5.  
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4.4.2 IN VIVO MICRODIALYSIS EQUIPMENT LIST 
Microdialysis Equipment Comments Source 
300µl collection tubes Polypropylene. (1000/pack) 743110; Linton 
Instruments, Norfolk, UK 
CMA 20 Probe 20kDa molecular weight cut-offs; 
10mm membrane length. 
CMA 8010436; CMA 
Microdialysis AB, Kista 
Sweden; Distributed by Linton 
Instruments, Norfolk, UK. 
CMA 402 Rev D Syringe Pump Designed for pulse-free low flow 
rates. 
CMA Microdialysis AB, Kista 
Sweden 
FEP Tubing Fluorinated Ethylene Propylene; 
attached to probe. 
BFEP-T22Q; Instech, Plymouth 
Meeting, USA; Distributed by 
Linton Instruments, Norfolk, 
UK 
Harness To tether guinea pigs CIH95 Covance Infusion 
Harness for Rat; CMA 
Microdialysis AB, Kista, 
Sweden distributed by Linton 
Instruments, Norfolk, UK 
Liquid swivel  CM375KRP; Instech, Plymouth 
Meeting, USA distributed by 
Linton Instruments, Norfolk, 
UK 
Luer stubs blunt needle Connect syringe to probe. Fisnar QuantX 8001101; 
Ellsworth, Germantown, USA 
Split tubing For probe insertion in vivo CMA 8309019; CMA 
Microdialysis AB, Kista, 
Sweden distributed by Linton 
Instruments, Norfolk, UK 
T1 
Designed for microdialysis in 
soft tissues. 
NaCl 147mmol/L, KCl 4mmol/L, 
CaCl2 2.3mmol/L; 
CMAP000034; Harvard 
Apparatus, Holliston, USA 
distributed by Linton 
Instruments, Norfolk, UK 
Tubing connectors  CMA 3409500; CMA 
Microdialysis AB, Kista 
Sweden; Distributed by Linton 
Instruments, Norfolk, UK 
Equipment Comments Source 
Ethicon Sutures Mersilk 3/0 To stitch probe into place. W328H; Ref: GSI003A; Johnson 
and Johnson, New Jersey, USA 
TRENDnet Camera To observe guinea pigs  TRENDnet TV IP310PI Outdoor 
3 MP PoE Day/Night Network 
Camera; Insight, Salford, UK 
Various gauge needles Various uses Terumo Agani, Surrey, UK 
 Comments Source 
Buprenorphine Opioid Analgesic Vetergesic 0.3mg/ml; Ceva 
Animal Health Ltd, UK 
Carprofen NSAID Analgesic Carpreive 5%w/v; Norbrook 
Laboratories, USA 
Chlorhexidine Disinfectant Hibiscrub; 500ml EA; Ref: 
MOLN10008780; VWR 
International, Lutterworth, UK 
Isoflurane Anaesthetic agent (IsoFlo 100% 
w/v inhalation vapour) 
Zoetis UK Ltd 
Vetbond Tissue Adhesive To close incisions 3M 1469sb 
 
Additional equipment used is shown in Section 4.3.2. 
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4.4.3 ANAESTHESIA  
Before any guinea pig was considered for surgical implantation of the microdialysis probe, a 
thorough health check (including acknowledgement of clear eyes, good coat, no swelling, 
normal respiratory sounds, food and water intake and evidence of mobility and activity) was 
undertaken. The weight of the guinea pig was recorded immediately prior to anaesthesia to 
ensure that an accurate dose of isoflurane (2-2.5%/0.4-0.8L/min oxygen) was given. 
Immediately prior to anaesthesia, a subcutaneous injection of buprenorphine ((opioid) 
0.3mg/kg) was administered in order to minimise pain upon recovery from anaesthesia.  
The concentration of isoflurane was gradually increased (starting with 0.5%) to reduce 
adverse reactions such as hypersalivation.  The guinea pigs were placed in a position with their 
head and neck extended to help the airway remain clear and unobstructed, and a rodent sized 
facemask was used for maintenance of the anaesthesia. Following the initial induction of 
anaesthesia, a subcutaneous injection of carprofen ((NSAID) 4mg/kg) was administered to 
relieve any inflammation associated with the surgical procedure.   
Depth of anaesthesia was continually monitored using the pedal withdrawal reflex and an 
absence of this reflex was indicative that the appropriate depth of anaesthesia had been 
achieved. 
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4.4.4 SURGICAL IMPLANTATION OF MICRODIALYSIS PROBE INTO 
SACROSPINALIS OF GUINEA PIG 
Initially a guinea pig cadaver was used to demonstrate the implantation of a microdialysis 
probe (CMA 20, 10mm, 20kDa) into the sacrospinalis muscle (Figure 4.5). Following additional 
refinements on cadavers, this protocol was used to implant probes into anesthetised guinea 
pigs.   
The following surgical procedure was completed in approximately 15 minutes.  
 
 
FIGURE 4.5: LOCATION OF THE SACROSPINALIS MUSCLE WITHIN THE GUINEA PIG BODY (MUSCLE 
LABELLED #22230).  
Surgical procedures were carried out using sterile instruments and following good aseptic 
technique. Guinea pigs were anesthetised as described in the previous section and warmth was 
generated via a heat mat set to 55˚C and maintained via a surgical drape. 
Initially the sacrospinalis was located using the spine as a reference point, and the area around 
the sacrospinalis and between the shoulder blades was close clipped and cleaned with warmed 
chlorhexidine. A scalpel was used to make two incisions, one which was between the shoulder 
m. erector spine; also known as m. sacrospinalis 
Erector muscle of spine (22). 
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blades (approximately 5mm long) and the other incision was made at the side of the spine, 
directly above the location of the sacrospinalis (approximately 1 to 1.5cm long).  
A trocar which functioned as a portal for the subsequent placement of the microdialysis tubing 
was inserted into the incision made directly above the sacrospinalis and tunnelled carefully 
under the skin where it emerged through the incision between the shoulder blades. The inner 
stylet from the lumen of the trocar was carefully removed and the inlet and outlet tubing of the 
microdialysis probe was gently inserted into the trocar. The trocar was then pulled cranially 
through the incision between the shoulder blades so that the inlet and outlet tubing of the 
probe emerged through this incision.  
The spine was used as the point of reference and introducer (comprised of a guide needle 
(21Ga x 11/2" 0.8mm x 40mm) & split tubing) was inserted in a caudal direction at a 45° angle 
into the incision above the sacrospinalis. Resistance was encountered as the myelin sheath was 
pierced. Once the myelin sheath was pierced no more resistance was met and the angle of the 
guide needle was reduced until parallel with the spine.  
The needle was carefully removed, ensuring the split tubing remained in situ, and the 
microdialysis probe was introduced into the sacrospinalis. The split tubing was then carefully 
pulled apart, leaving the microdialysis probe in situ.  
The microdialysis probe was sutured in place via the suture points on the probe to the 
subcutaneous muscle. Once sutured, the remaining suture thread was tied off. Both of the 
incision holes were then sutured closed and sealed with tissue glue.  
At this point, two additional pieces of tubing (full length) were connected to the inlet and outlet 
tubing of the microdialysis probe using modified blue tubing connectors (fluted ends removed) 
which had been previously soaked in ethanol. The probe tubing and additional tubing were 
threaded up through the harness spring and the guinea pig gently placed into the harness as 
shown in Figure 4.6. The harness was tightened gently.  
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FIGURE 4.6: GUINEA PIG WEARING HARNESS FOLLOWING COMPLETION OF SURGICAL PROCEDURE. The close clipped area is visible in this photo as well as the location 
of the sacrospinalis incision. The probe tubing was threaded up through harness spring and is attached to the liquid swivel . 
 
FIGURE 4.7: EXAMPLE OF TRENDNET SURVEILLANCE CAMERA DISPLAY. LHS; day time view of guinea pigs in cages, RHS; night time view of guinea pigs in cages. 
Both cages are clearly visible.  
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4.4.5 ENTRY AND EXIT INTO GUINEA PIG HOUSING ROOM  
Throughout the duration of the experiment guinea pigs were housed in a room that was quiet 
and warm with minimal foot traffic. The guinea pigs being dialysed were the only animals kept 
in the room. As the guinea pigs were tethered, entry and exit into the housing room needed to 
be done in calm and controlled manner to not frighten the guinea pigs and cause them to make 
any sudden movements.  To minimise the entry and exit to the room, guinea pigs were 
monitored via a network surveillance camera allowing them to be monitored throughout the 
time that they were tethered. An example of the TRENDnet display is seen in Figure 4.7.  
4.4.6 POST-OPERATIVE CARE (RECOVERY) 
Immediately following completion of surgery, individual guinea pigs were placed into their 
warmed home cages (30-35°C) which were previously modified to create an anchor point for 
attachment of the harness. Maintenance of temperature was important as a significant amount 
of fur was removed as part of the surgical procedure which increased the risk of hypothermia. 
Therefore, heat was generated via a heat mat placed under the cages and via a ‘hand warmer’ 
inside the cages. Home cages were lined with tray liner and Vetbed (medical grade bedding 
with 28mm pile for warmth and comfort) along the bottom. Guinea pigs had access to food and 
water ad libitum.  
The animals were constantly monitored until fully awake and movement was observed. 
Comprehensive monitoring was conducted via TRENDnet camera and physically to identify 
any post-operative complications.  
The general condition (appearance, posture, coat, vocalisation) and activity/ mobility of the 
guinea pigs were monitored via TRENDnet system as well as physically. The camera was an 
integral component of this experiment in order to observe the natural behaviour of the guinea 
pigs. Being a prey species, they naturally hid discomfort when being physically monitored and 
it was therefore important that they were remotely observed in order to show evidence of 
discomfort.  
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The harness was monitored for fit (tightness or looseness). It was important to strike the right 
balance between ensuring the harness was tight enough as to not allow the guinea pigs access 
to the tubing and ensuring that it was not so tight that it was causing discomfort. The harness 
needed to be tightened throughout the tethered duration as the constant movement of the 
guinea pigs and decrease in swelling (post-surgery) loosened it. The harness straps proved to 
be an irritant (as evidenced via TRENDnet system) as the straps became longer (upon 
tightening) evidenced by the guinea pigs constantly turning their heads to try and reach them. 
The harness straps were trimmed as short as possible to minimise this. Incision wounds were 
also checked for presence of infection. 
Food and fluid intake as well as urine and faeces output were monitored both physically and 
via the TRENDnet system. There was more evidence of guinea pigs eating than drinking so to 
alleviate any potential dehydration, the food was then mixed with water.  Faeces were found 
in the guinea pig cages. It was decided not to remove the faeces because guinea pigs are 
caecotrophs and the faeces are covered in a mucus, that contains vitamins that have benefits 
upon re-ingestion. Note that immediately prior to oral drug administration all faeces were 
cleared from the cages. 
Both buprenorphine (0.03mg/kg) and carprofen (4mg/kg) were administered to the guinea 
pigs prior to surgery (following collection of guinea pig weight) and then every 8-12 hours for 
buprenorphine and every 24 hours for carprofen. Buprenorphine and carprofen were 
administered via subcutaneous injection in a 300µl volume with Ringers Solution. This volume 
of Ringers Solution was selected in order to administer additional fluids to counter 
dehydration and also to maximise the volume of analgesic given in each dose. A smaller total 
volume would require a very small volume of the active ingredient which may be difficult to 
dispense accurately resulting in potential under-dosing. Table 4.2 shows the relative doses of 
each drug based on body weight.  
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Buprenorphine (Vetergesic) Carprofen (Carpreive) 
Guinea 
Pig 
Weight 
(kg) 
Dose of 
Analgesia 
(mg/kg) 
Volume to 
Administer 
(µl) 
Volume 
of 
Ringers 
Solution 
(µl) 
Final 
Dose 
Volume 
(µl) 
Guinea 
Pig 
Weight 
(kg) 
Dose of 
Analgesia 
(mg/kg) 
Volume to 
Administer 
(µl) 
Volume 
of 
Ringers 
Solution 
(µl) 
Final 
Dose 
Volume 
(µl) 
0.2 
0.03 
20 280 
300 
0.2 
4 
16 284 
300 0.3 30 270 0.3 24 276 
0.4 40 260 0.4 32 268 
TABLE 4.2: DOSE OF BUPRENORPHINE AND CARPROFEN ADMINISTERED TO GUINEA PIGS, PRE AND 
POST SURGERY. Doses of carprofen and buprenorphine, and hence Ringers solution, were 
dependant on guinea pig weight. Guinea pigs received buprenorphine every 8 hours  and 
carprofen every 24 hours. 
4.4.7 MAINTENENCE OF MICRODIALYSIS PROBE IN SITU 
20cm (approximately) of sterile FEP tubing was used to connect a 1ml syringe (in the syringe 
pump) via a Luer stubs blunt needle and clear tubing connector to the liquid swivel (Figure 
4.8). The liquid swivel was clipped into the counter balanced lever arm (Figure 4.8). The inlet 
tubing (which exited the top of the tether spring) was looped and attached via a clear tubing 
connector to the rear of the liquid swivel. The outlet tubing (which also exited at the top of the 
tether spring) was placed into a collection tube which was connected to the tether spring via a 
tubing clip (No longer manufactured).  
The syringe contained a warmed (in an oven to approximately 39°C; guinea pig body 
temperature) rifampicin containing solution (10µg/ml in Ringers solution). A 2µl/minute flow 
rate was used, and the flow continued until there was evidence of fluid on the outlet tubing. 
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FIGURE 4.8: SET UP OF MICRODIALYSIS EQUIPMENT. The syringe was connected to the liquid swivel. The liquid swivel was connected to the harness spring 
which contained the inlet and outlet tubing. The inlet tubing was looped to allow movement. The outlet tubing was placed in a collection vial .  
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4.4.8 URINE & FAECES COLLECTION 
During the 4 hour microdialysis experiment, cages were lined with hydrophobic (reflective) 
tray liners. A Pasteur pipette was used to immediately collect all urine and the time (post drug 
administration) and volume (directly measured) recorded. Faeces were collected by sterile 
forceps and the time (post drug administration) recorded. Both urine and faeces samples were 
snap frozen in liquid nitrogen and stored at -80°C until protein precipitation and analysis 
(Section 4.3.5).  
4.4.9 EX VIVO MICRODIALYSIS 
Following removal of lungs at the point of necropsy, lungs were dialysed whole as shown in 
Figure 4.9. The syringe pump was set up as described in Chapter 3 and CMA 20 probe (10mm, 
20kDa) was inserted into the lung. The syringe contained T1 perfusion fluid with a flow rate of 
2µl/min and a single sample was collected at 30 minutes.  
FIGURE 4.9: EX VIVO MICRODIALYSIS SET UP. The syringe pump contained a 1ml syringe 
containing T1 perfusion fluid. The syringe was connected to blue inlet tubing. The CMA20 
probe was inserted into the lungs and the outlet tubing was placed in a collection vial for 30 
minutes.  
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4.5 PILOT IN VIVO MICRODIALYSIS EXPERIMENT 
Prior to performing in vivo microdialysis an additional in vitro calibration was conducted using 
an equipment set-up that reflected that of the final in vivo set-up (including the liquid swivel). 
The lag time was calculated to be 3 minutes 36 seconds (same as Chapter 3). in vivo, the lag 
time is calculated from the point of sample collection within the guinea pig (i.e. the time taken 
for the perfusion fluid to flow down inlet tubing is discounted). As 20cm of additional tubing 
was added to the outlet tubing (to enable tubing to be threaded up through harness spring) the 
total outlet tubing was the same length (40cm) as the combined length of the inlet and outlet 
tubing for in vitro calibrations. This calibration showed that the probe was working at 30% 
efficiency (data not shown) which was concordant with the probe efficiency as calculated using 
the in vitro set up described in Chapter 3 (21±9%).  
The microdialysis equipment was set up as shown in Section 4.4.7. The two guinea pigs arrived 
on site at least 72 hours before the commencement of the procedures. Both guinea pigs 
underwent the surgical protocol under anaesthesia as detailed in Section 4.4.3 for probe 
implantation into the sacrospinalis (Figure 4.10). Guinea pigs were placed into their home 
cages where they remained for the duration of the experiment. Approximately two hours post-
surgical completion, a rifampicin flush was conducted to ensure probe patency and limit non-
specific binding (Section 4.4.7). This was then repeated later that day and twice the following 
day. Eight hours post-surgery (and in subsequent eight hour intervals) guinea pigs were 
administered buprenorphine via subcutaneous injection. 24 hours post-surgery guinea pigs 
were administered carprofen. Throughout this recovery period the guinea pigs were 
constantly observed remotely via a camera and twice- daily health checks were performed in 
person when the microdialysis probes were flushed (Section 4.4.6). 
Guinea pigs were dialysed on day 3 post-surgery following a one hour pre-flush with warmed 
T1 perfusion fluid. Oral drug administration of a single 50mg/kg rifampicin dose (Chapter 2) 
occurred following the one hour pre-flush. The following in vitro optimised microdialysis 
parameters were used: 
 
 
161 
 
 
Probe (in situ) CMA 20, 10mm Membrane, 20kDa Mw Cut-Off  
Perfusion Fluid T1 warmed to approximately 39°C; guinea pig body temperature. 
Tubing (in situ) FEP Tubing for Microdialysis  
Flow Rate 2µl/minute 
Sample Storage Samples were stored on ice throughout the experiment and stored at -80°C 
until point of analysis. 
Pre-collection Flow 1 hour at 2µl/minute prior to drug administration with T1 perfusion fluid. It 
was important not to stop the flow to allow sufficient sample volume for 30 
minute sample. 
Number of samples 8 per guinea pig, samples were collected every 30 minutes. 
TABLE 4.3:MICRODIALYIS PARAMETERS USED FOR IN VIVO EXPERIMENT  
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FIGURE 4.10: STUDY SCHEDULE FOR IN VIVO MICRODIALYSIS EXPERIMENT. Guinea pigs arrived on site at least 72 hours before th e first procedure. On day 1 guinea 
pigs underwent surgery for probe implantation, and on day 3 guinea pigs underwent in vivo microdialysis following oral administration of 50mg/kg rifampicin.  
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During the dialysis period, ear bleeds were collected at set time points post drug 
administration (Section 4.4.1) to provide a control. As guinea pigs were singly housed, all urine 
and faeces from the individual guinea pigs were collected over the four-hour microdialysis 
experiment (Section 4.4.8).  
Following completion of the four-hour dialysis experiment, guinea pigs were euthanised, 
cardiac bled and lungs, liver and skeletal muscle from the hind leg and sacrospinalis removed 
(Section 4.3.4) with the following modification; the guinea pig was initially placed on its front, 
sprayed with IPA and an incision made along the spine. The sacrospinalis was removed using 
sterilised scissors and forceps. Following necropsy, lungs were dialysed prior to 
homogenisation as in Section 4.4.9. Organ samples were processed as in Section 4.3.5, and 
blood, organ samples and microdialysis samples were analysed for drug concentrations as in 
Chapter 3.  
4.5.1 CONCLUSIONS FOLLOWING PILOT STUDY 
Both guinea pigs tolerated the surgery and analgesia well. The recovery period was adequate 
with no need to elongate for future studies. This pilot study also confirmed there was adequate 
healing time to enable handling of guinea pigs for collection of ear bleeds. The Named 
Veterinary Surgeon examined the guinea pigs and had no cause for concern. Rifampicin was 
recovered in all microdialysis fractions following microdialysis in the sacrospinalis of one 
guinea pig which confirmed that the microdialysis equipment and methods established in 
Chapter 3 were applicable in vivo. 
Upon necropsy it was shown that the probe was implanted correctly. For the other guinea pig, 
it was evident that there was no probe patency on day 2 as no liquid was recovered. This guinea 
pig was still administered one oral dose of rifampicin and culled at 2 hours post drug 
administration to add data to the correlation data set (Chapter 5). Upon necropsy it was 
evident that the probe had snapped in situ as shown in Figure 4.11. All organs from both guinea 
pigs contained rifampicin, as did the sample collected via ex vivo microdialysis.  
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FIGURE 4.11: PROBE SNAPPED IN SITU. The red box indicates the head of the probe, the shaft 
and membrane tip are missing, and it was clear as to why the probe showed no evidence of 
patency in Guinea Pig B. 
Following completion of the pilot study, several refinements were made prior to conducting 
subsequent experiments (which are detailed in Chapter 5):  
• Cage sides were covered to ensure they were opaque and cages sides were elongated 
with wire to restrict any possible vertical movement. 
• Cages were truncated to relieve additional pressure on the balance arm. 
• Guinea pigs were handled throughout the pilot experiment to administer analgesia. It 
was decided that for the subsequent study to minimise handling when administering 
analgesia.  
• The ability to handle the guinea pigs throughout the study duration gave confidence 
that the guinea pigs could be handled to conduct ear bleeds without causing them any 
additional pain. 
• Probes were flushed for evidence of patency at point of analgesia administration (every 
8 hours) removing the need for additional entrance into the housing room. 
• Once the guinea pig was secured in the harness, the straps were trimmed, as it was 
shown that the straps were in the guinea pigs eyeline causing irritation.  
• Lower food and water bowls were used to ensure ease of access. 
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CHAPTER 5 
EVALUATION OF RIFAMPICIN PK IN GUINEA PIGS 
USING MICRODIALYSIS 
5.1. INTRODUCTION 
Microdialysis can be used to describe the pharmacokinetic behaviour of drugs in organs as a 
continuous sampling technique, in awake freely moving animals.  Microdialysis is the only 
methodology available to collect the unbound pharmacologically active portion of the drug. 
Traditional methodologies for pharmacokinetic analysis such as blood collection are a 
measurement of total drug concentrations (unbound and bound). The aim of this PhD was to 
develop the microdialysis methodology for use with rifampicin to determine the organ PK of 
this drug over a four-hour time period in an awake freely moving guinea pig and compare the 
results gained via the microdialysis methodology with those gained via traditional methods.  
Meticulous in vitro microdialysis experiments were performed with rifampicin 
before progressing to in vivo experiments because drug recovery (concentration of the drug in 
the tissue related to that in the collected dialysate) is dependent upon a variety of 
experimental and environmental conditions. The impact of flow rate, temperature, perfusion 
fluid, molecular weight cut-off and tubing materials on the recovery of rifampicin at 
physiologically relevant concentrations were determined using mass spectrometry to measure 
rifampicin concentrations in the dialysate (Chapter 3). In vitro calibrations with rifampicin 
have shown that the efficiency of the probe is 21% ± 9%. Rifampicin was recovered from tissue 
homogenates at the concentrations expected and following difficulties associated with 
insertion of the probe into the guinea pig lung and liver, experiments were conducted to 
investigate skeletal muscle as a surrogate for lung microdialysis. A correlation (R2 = 0.8718) 
was identified between rifampicin concentrations in the lung and skeletal muscle with stable 
ratios of drug between the two organs (Chapter 4). It was therefore determined that  using 
microdialysis to quantify the unbound pharmacologically active part of rifampicin in the 
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skeletal muscle would enable the unbound concentration of rifampicin to be quantified in the 
lung, the main target site for drug delivery during tuberculosis disease.  
An initial pilot in vivo microdialysis experiment was conducted with two guinea pigs (Chapter 
4). Guinea pigs tolerated the surgery well and were healthy throughout the duration of the 
experiment. Unbound rifampicin was collected every 30 minutes over a four-hour duration 
from the skeletal muscle (sacrospinalis) of one guinea pig. Rifampicin was detectable in all 
collected fractions. Total rifampicin concentrations measured in the lung and skeletal muscle 
were added to the pre-existing correlation data set (Chapter 4).  
Having proven that the microdialysis technique could be successfully applied, further 
experiments were performed to provide a complete data set in order to determine the PK of 
rifampicin in the target organ (lung) via microdialysis of skeletal muscle to compare organ PK 
profiles with those obtained in peripheral blood. Technical refinements discussed in Chapter 4 
were incorporated into the additional experiments.  
The data presented and analysed in this chapter include the measurements from experiments 
described in Chapter 4.  
5.2. EXPERIMENTAL OVERVIEW 
The experimental schedule shown in Figure 4.10 (Chapter 4) was followed. Each guinea pig 
was attributed a letter (A-F). A total of six guinea pigs underwent surgery to have a 
microdialysis probe (CMA20, 10mm, 20kDa) implanted into the sacrospinalis on Day 1 (as 
described in Chapter 4). The surgery and microdialysis were performed on pairs of guinea pigs. 
All six guinea pigs tolerated the surgery, anaesthesia and recovery well, subcutaneously 
administered buprenorphine (every 8 hours) and carprofen (every 24 hours) was used 
successfully for pain relief with no adverse effects. 
Consistent with the pilot study, all guinea pigs showed evidence of movement, vocalisation, 
food and water intake and urine and faeces output. As previously noted, due to guinea pigs 
being a prey species, when physically in the room with them, guinea pigs limited their 
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movement. Observation of the guinea pigs through the TRENDnet system showed the guinea 
pigs eating, drinking and being significantly more mobile. An additional benefit to observing 
the guinea pigs remotely was that it was possible to observe and rectify any discomfort they 
were experiencing (such as a too tight harness). The guinea pigs were seen by the Named 
Veterinary Surgeon and Home Office Inspector with no cause for concern.  
The rifampicin-containing solution for in situ probe flushing and the rifampicin for oral 
administration were prepared separately for each pair of guinea pigs. The microdialysis 
equipment was set up as described in Chapter 4 and checked to ensure it was working as 
expected i.e. correct volume of sample being collected. The in situ probes were flushed with the 
rifampicin-containing solution every 8 hours at the point of buprenorphine administration to 
ensure probe patency and to minimise adherence of rifampicin to plastic (as described in 
Chapter 3). On Day 3 (Day 2 post- surgery), the syringe pump was switched on in order to flow 
at 2µl/minute for one hour prior to the dialysis period with T1 perfusion fluid to ensure 
equilibration of the perfusion fluid with the surrounding muscle and sufficient sample volume 
for the 30 minute sample.  
Four of the six guinea pigs were successfully dialysed for four hours, with samples collected 
every 30 minutes following oral administration of 50mg/kg rifampicin. Samples were analysed 
via LC-MS/MS as described in Chapter 3. Microdialysis sample volumes were sufficient for 
analysis, and rifampicin was recovered in all of the collected fractions. One of the guinea pigs 
died at the point of drug administration (Guinea Pig C) and was subsequently diagnosed as 
having unexpected heart failure. Upon histological examination, all examined tissues were 
normal including the probe implantation site which had no associated inflammation. The other 
guinea pig (Guinea Pig B) showed no evidence of probe patency on Day 2, however it was 
successfully administered drug and necropsied at two hours post drug administration with a 
view to add additional data to the correlation data set. This was particularly important because 
the outlying datapoint in Figure 4.3 (Chapter 4) was from a guinea pig that was culled at two 
hours post drug administration.  At the point of necropsy it was evident that the probe had 
snapped in situ (Chapter 4).  
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The five guinea pigs (A, B, D, E, F) were bled from the ear at pre-defined time points to time 
match the microdialysis fractions. It was possible to handle these animals, in a controlled 
manner, to enable ear bleeding. Rifampicin was not recovered in all ear bleed samples. Urine 
and faeces were collected during the four-hour dialysis period, and the volume and time of 
excretion were recorded.  Upon necropsy it was evident that all probes had been successfully 
implanted into the sacrospinalis. Guinea pigs were cardiac bled and lungs, livers and two types 
of skeletal muscle (collected from the biceps femoris and sacrospinalis) were removed, 
weighed and processed as described in Chapter 4.  
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5.3. IN VIVO MICRODIALYSIS RESULTS 
5.3.1 RIFAMPICIN RECOVERED IN SACROSPINALIS 
The rifampicin concentrations (µg/ml) recovered from the sacrospinalis from the four dialysed 
guinea pigs are shown in Figure 5.1. 
No samples were collected at 30 and 60 minutes post drug administration for Guinea Pig D. 
The probe showed patency when flushed with the rifampicin-containing solution and during 
the one-hour pre-drug administration flush, however at the point of oral drug administration, 
upon handling the guinea pig, the outlet tubing had to be trimmed because it was causing an 
obstruction. The process of trimming the tubing caused it to be crushed such that no liquid was 
collected. Re-cutting the tubing with a scalpel rectified this and samples were collected from 
90 minutes onwards.  
The data shown in Figure 5.1 indicated that there was a similar profile of change in rifampicin 
concentrations over time in all 4 guinea pigs.  Samples from Guinea Pigs E and F contained the 
approximately the same concentrations at 30 and 60 minute time points (E; 132 and 65µg/ml 
F; 126 and 72µg/ml).  The recovered rifampicin concentrations in Guinea Pigs D and F were 
very similar between 120 and 240 minutes. 
Whilst the kinetics (change over time) of the datasets from each of the four guinea pigs was 
similar, there were variations in the actual values. As mentioned, samples from Guinea Pigs D 
and F contained similar quantities of rifampicin between 120 and 240 minutes (D; 40, 32, 35, 
27, 25µg/ml and F; 38, 28, 32, 21,19µg/ml)  but these concentrations were higher than those 
recovered from Guinea Pigs A (17, 14, 17, 12, 17µg/ml) and E (21, 19, 15, 10, 11µg/ml) with 
the exception of the higher drug concentration at the 30 minute time point associated with 
Guinea Pig A (250µg/ml). 
As previously described, the efficiency of the probe was calculated to be 21±9% by in vitro 
studies (Chapter 3). Hence, the measured unbound concentrations of rifampicin in these 
samples (Figure 5.1) were used to calculate the estimated concentration of unbound drug by 
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correcting  for the efficiency of the probe, which therefore represented an estimate of the actual 
unbound rifampicin concentration expected in vivo in the sacrospinalis. This is shown in Figure 
5.2 where the mean rifampicin concentrations from the sacrospinalis of all 4 guinea pigs was 
plotted either at the measured concentration (21%±9%) or at the estimated concentrations 
with the corrected values to account for probe efficiency. Applying this correction factor 
resulted in an increase in mean rifampicin concentrations from 170µg/ml to 809µg/ml at 30 
minutes and 18µg/ml to 87µg/ml at 240 minutes. Note this is only the concentration of 
unbound rifampicin. 
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FIGURE 5.1: RIFAMPICIN CONCENTRATIONS RECOVERED FROM SACROSPINALIS. Fractions were 
collected over a four-hour (240 minute) period from four guinea pigs (A, D, E, F)  every 30 
minutes. The measured rifampicin concentrations in each fraction are shown.  
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FIGURE 5.2: MEAN RECOVERED UNBOUND RIFAMPICIN CONCENTRATIONS (µG/ML) as collected via microdialysis from all four guinea pigs with a probe 
efficiency of 21±9% (pink line) and the corrected values of estimated unbound rifampicin concentrations to account for the probe efficiency (black 
line). Error bars show the standard deviation. 
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5.3.2 RELATIONSHIP BETWEEN RIFAMPICIN CONCENTRATIONS 
MEASURED BY MICRODIALYSIS AND TOTAL DRUG IN SACROSPINALIS  
At the point of necropsy, the sacrospinalis was collected and processed to measure both bound 
and unbound rifampicin concentrations in order to relate these data to the unbound rifampicin 
concentrations collected via microdialysis. This comparison was conducted between samples 
collected at the four-hour (240 minute) time point.  
Figure 5.3 shows the rifampicin concentrations associated with the sacrospinalis (for each 
guinea pig). The rifampicin concentration in the sacrospinalis was measured following removal 
and homogenisation at 240 minutes. The unbound rifampicin available to collect via 
microdialysis was calculated assuming that 31% of the total measured rifampicin in the 
sacrospinalis was unbound, as rifampicin is 69% plasma protein bound and this was assumed 
to be equivalent to tissue binding.  The mean unbound rifampicin concentrations as collected 
at 240 minutes with the probe operating at 21±9% efficiency and the estimated rifampicin 
concentrations corrected for probe efficiency are also shown.  
The rifampicin concentrations in the sacrospinalis were most similar between Guinea Pigs A & 
F (20 and 22µg/ml respectively) and D & E (10 and 6µg/ml respectively).  The unbound 
rifampicin, measured at 240 minutes with the probe operating at 21% efficiency, was 
approximately 150% higher than the total rifampicin concentrations measured in the 
sacrospinalis for Guinea Pig D and approximately 83% higher for Guinea Pig E. For Guinea Pigs 
A and F, the unbound rifampicin collected with the probe operating at 21% efficiency at 240 
minutes, was 17µg/ml and 19µg/ml respectively which is approximately 3 times higher than 
the rifampicin that was available for collection based upon 69% protein binding.   When 
adjusting the measured unbound concentrations to account for probe efficiency, the unbound 
rifampicin concentrations associated with the sacrospinalis are much higher than expected for 
all guinea pigs based upon total rifampicin concentrations in the sacrospinalis (approximately 
4 times the total concentration for Guinea Pigs A and F, 9 times the total concentration for 
Guinea Pig  E and 12 times the total concentration for Guinea Pig D).   
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FIGURE 5.3: RIFAMPICIN CONCENTRATIONS (µG/ML) IN SACROSPINALIS. Black bars represent rifampicin concentrations measured in the sacrospinalis homogenate 
following necropsy at 240 minutes, pink bars represent unbound rifampicin available to collect based on 69% plasma p rotein binding, blue bars represent 
the unbound rifampicin concentration as collected via microdialysis at 240 minutes whilst the probe was operating at 21% effi ciency (equivalent time point 
to sacrospinalis collection time point), green bars represent est imated unbound rifampicin concentration in sacrospinalis corrected for probe efficiency.
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5.3.3 RELATING SACROSPINALIS CONCENTRATIONS TO LUNG 
CONCENTRATIONS 
5.3.3.1 CORRELATION BETWEEN SKELETAL MUSCLE AND LUNG- ADDITIONAL DATA 
In Chapter 4, a correlation was identified between the concentration of rifampicin in the lung 
and the biceps femoris (skeletal muscle in the hind leg). This relationship formed the basis of 
the rationale to perform microdialysis in the sacrospinalis in order to generate data that could 
be related to the lungs, the target organ for drugs to treat TB. On completion of the 
microdialysis experiments described in this chapter, lung and skeletal muscle samples were 
taken at necropsy, after the final 240 minute microdialysis sample, and processed and analysed 
to measure concentrations of rifampicin, using the methods described in Chapter 4. Thus 
additional data points could be added to the correlation data set and the full data set is shown 
in Figure 5.4A.  
The Pearson correlation R2 value of the data shown in  Figure 5.4A was 0.4696 (P value = 0.02). 
The strength of this correlation was weaker than that obtained with a minimal data set 
(Chapter 4), however the second order polynomial fitted the data well with an R2 value of 
0.8432. There was a notable outlying data point which contrasted with the data set as a whole 
by the fact that the concentration of rifampicin was the same (29.20µg/ml) in both lung and 
skeletal muscle, whereas the lung concentration was generally found to be higher than in the 
skeletal muscle in all other guinea pigs. Additionally, with this data point included, when the 
rifampicin concentration in the skeletal muscle was greater than 20.4µg/ml the concentration 
in the lung decreased, which was an unlikely scenario.  
Removing the outlying data point strengthened the correlation (Pearson R2 = 0.8595 (P value 
= 0.0001)) and a second order polynomial also fitted these data well (Pearson R2 =0.8735 (data 
not shown)). However, the unlikely scenario described above of high skeletal muscle 
concentrations equalling decreasing lung concentrations remained when the data was fitted 
with the second order polynomial. In this case, skeletal muscle rifampicin concentrations over 
35µg/ml calculated negative rifampicin concentrations in the lung. Therefore, linear 
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interpolation was used to fit the data with R2 value of 0.8595 (Sy.x=6.91) as shown in Figure 
5.4B. Although there was one outlier excluded from this data set, data from all other guinea 
pigs was incorporated. 
The equation generated by fitting the data with linear interpolation, as shown Figure 5.4B, was 
used to estimate the rifampicin concentrations in the lung as calculated from the measured 
rifampicin concentrations within the skeletal muscle (sacrospinalis). This equation gave 
realistic lung concentrations at high skeletal muscle concentrations (primarily 30 minute 
skeletal muscle concentrations as shown in Figure 5.1). 
The equation used was:  
𝑌 = 𝐵0 + 𝐵1 ∗ 𝑋 
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FIGURE 5.4: A; CORRELATION BETWEEN RIFAMPICIN CONCENTRATIONS MEASURED IN LUNG AND BICEPS FEMORIS (SKELETAL MUSCLE FROM HIND LEG). All data points 
are shown from experiments described in chapter 4 and the animals used for in vivo microdialysis.  B; CORRELATION BETWEEN RIFAMPICIN CONCENTRATIONS 
MEASURED IN LUNG AND  BICEPS FEMORIS (SKELETAL MUSCLE FROM HIND LEG). Data from pre-existing correlation data set as shown in Chapter 4 and from guinea 
pigs used for in vivo microdialysis. Data point at 29.20µg/ml in both lung and skeletal muscle removed.  Data fitted with linear interpolation and the following 
equation generated; Y=B0+B1*X, where B0= 4.317, B1= 2.695,  X= unbound rifampicin concentration (µg/ml) recovered from sacrospinalis can be used to 
calculate Y, the estimated unbound rifampicin concentration in lung (µg/ml).
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5.3.3.2 ESTIMATED LUNG CONCENTRATIONS OF RIFAMPICIN FROM MICRODIALYSIS 
OF SKELETAL MUSCLE 
Using the equation generated by linear interpolation of the data points (Figure 5.4B) 
(Y=B0+B1*X), Y which is the estimated unbound rifampicin concentration (µg/ml)  in the lungs 
could be calculated using the equation constants generated by GraphPad Prism  (B0= 4.317 
(±3.381), B1= 2.695 (±0.38)) and  the unbound rifampicin concentration (µg/ml) recovered 
from sacrospinalis (X). It is important to note that the data set in Figure 5.4B is comprised of 
total rifampicin concentrations measured in the organs whereas samples collected via 
microdialysis contain only the unbound pharmacologically active rifampicin. An assumption 
has been made that the relationship between the lung and skeletal muscle associated with total 
drug concentrations will remain the same for unbound drug concentrations. Therefore, it was 
valid to extrapolate unbound drug concentrations in the lung from unbound drug 
concentrations measured in the skeletal muscle by microdialysis.  
Rifampicin concentrations measured via microdialysis from the sacrospinalis (21% probe 
efficiency) were thus used to calculate the unbound rifampicin concentrations in the lung (Pink 
line; Figure 5.5). An estimate of actual in vivo rifampicin concentrations in the lung was made 
by correcting for probe efficiency. This is the gold line in Figure 5.5. Rifampicin is 69% protein 
bound in guinea pigs therefore a further adjustment was made to estimate the total (B+UB) 
rifampicin concentrations in the lung (Black line; Figure 5.5).  
Mean rifampicin concentrations in the lung from all four guinea pigs, over the 240 minute 
dialysis period, are shown in Figure 5.5. 
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FIGURE 5.5: MEAN LUNG CONCENTRATIONS (µG/ML) GENERATED USING THE EQUATION Y=B0+B1*X. Pink line shows unbound rifampicin in lung calculated from the 
unbound rifampicin concentrations recovered from the sacrospinalis. Gold line represents estimated unbound rifampicin concentrations in the lung corrected 
for probe efficiency. Black line is an estimate of total (B+UB) rifampicin concentrations in the lung based on  the estimated unbound rifampicin corrected for 
probe efficiency and 69% plasma protein binding. Error bars show standard deviation. 
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5.3.3.3 RELATING ESTIMATED LUNG CONCENTRATIONS TO MEASURED TOTAL 
LUNG CONCENTRATIONS 
Prior to homogenisation, lungs were dialysed ex vivo as shown in Chapter 4. One ex vivo sample 
was collected after 30 minutes. Taking these ex vivo concentrations, the data generated in 
Figure 5.5 whereby rifampicin concentrations in the lung were estimated by correlating the 
measured unbound rifampicin in the sacrospinalis (probe efficiency of 21%) via the equation 
generated in Figure 5.4B, as well as the measured concentration of total drug in lung tissue at 
necropsy, it was possible to test the ability of skeletal muscle microdialysis to estimate 
unbound lung concentrations. These data are shown in Figure 5.6. 
The total rifampicin concentration measured in the lung homogenate was lower in each guinea 
pig (~1.75 times for Guinea Pigs A and D; ~2.5 times for Guinea Pigs E and F) than the 
estimated unbound rifampicin in the lung at 240 minutes (21% probe efficiency). The 
estimated unbound lung concentrations were even higher when extrapolated to correct for 
probe efficiency (~ 8 times for Guinea Pigs A and D; ~12 times for Guinea Pigs E and F) than 
the total rifampicin measured in the lung homogenate. The estimated unbound rifampicin 
concentrations in the lungs were generally higher than the concentrations collected via ex vivo 
microdialysis (at equivalent probe efficiencies), however, the estimated concentration in the 
lung and the measured ex vivo concentrations of unbound rifampicin were similar (44, 31 and 
28µg/ml unbound rifampicin collected ex vivo for Guinea Pigs D, E and F respectively; 72, 35, 
and 56µg/ml unbound rifampicin as estimated in lungs (UB by correlation) for Guinea Pigs D, 
E and F respectively at 21% probe efficiency).  
The unbound concentration of rifampicin in the lung as collected directly from the pre-
homogenised lung ex vivo (21% probe efficiency) was on average 1.5 times higher, than the 
total concentrations for Guinea Pigs D, E and F. The concentration recovered ex vivo was lower 
for Guinea Pig A than for the other three guinea pigs, which may be an exceptional result when 
considering the similarities between all animals with respect to the total rifampicin in the lung 
homogenate and the estimated concentrations in the lung based on microdialysis data. When 
the concentrations were corrected for probe efficiency, the unbound concentrations (as 
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collected via ex vivo microdialysis) were 1.6, 5.3, 10.6 and 6.5 times higher (for Guinea Pigs A, 
D, E and F respectively) than the total  for all animals. This indicated that the total rifampicin 
concentration measured in the lung homogenate was unexpectedly low when compared to the 
estimated unbound rifampicin concentration in the lung as calculated by sacrospinalis 
microdialysis in vivo and also lower than the unbound rifampicin collected by ex vivo 
microdialysis.   
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FIGURE 5.6: RIFAMPICIN CONCENTRATIONS (µG/ML) IN THE LUNG. Dark pink bar represents the total (bound and unbound) rifampicin  in the lung homogenate 
collected at necropsy at 240 minutes and then dialysed for an additional 30 minutes prior to homogenisation. Light pink bar is the unbound concentration of 
rifampicin recovered from the lung via ex vivo microdialysis post necropsy and pre -homogenisation with the probe operating at 21% efficiency and the black 
bar is the estimated ex vivo unbound rifampicin concentration corrected for probe efficiency. One sample was collected at 30 minutes. Gold bar is the lung 
concentration of rifampicin at the 240 minute time point as calculated from the unbound rifampicin concentrations recovered from the sacrospinalis using 
the 21% efficiency value and the aquamarine bar is  the concentration corrected for probe efficiency .  
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Total (B+UB) rifampicin concentrations in the lung from dialysed guinea pigs were compared 
against total rifampicin concentrations in the lungs of guinea pigs that were not dialysed 
(animals used for the study described in Chapter 4) to understand if the removal of drug via 
microdialysis was causing the total rifampicin concentrations in the lung to be lower than 
expected. The concentrations of rifampicin measured in the lungs of the two un-dialysed 
guinea pigs, at 4hours post 50mg/kg rifampicin administration, were 17.7 and 2.7µg/ml. These 
data indicate that the total rifampicin concentrations measured in the lung homogenate of 
Guinea Pigs A, D, E and F are not lower than expected, when related to the estimated unbound 
rifampicin concentrations, because of the microdialysis methodology. These data also 
demonstrate the animal to animal variation associated with measuring drug concentrations in 
homogenate, whereas the concentrations measured via microdialysis are much more 
reproducible. 
 5.3.3.4 COMPARISON OF HOMOGENATE VS ESTIMATED LUNG AND SACROSPINALIS 
CONCENTRATIONS 
In addition to measuring the total rifampicin concentration in the lungs removed at necropsy, 
the total drug in the sacrospinalis was also measured. It was thus possible to compare the  
measured total concentrations of drug in these two organs, and to relate these values to those 
estimated by in vivo microdialysis. The data shown in Figure 5.7 are total (B +UB) rifampicin 
concentrations as measured in the organ homogenate or  an estimated total (B+UB) rifampicin 
concentration based on the unbound rifampicin concentrations collected via microdialysis at 
240 minutes post-drug administration. The measured unbound concentrations have been 
corrected for probe efficiency and 69% protein binding. 
Figure 5.7 shows that the rifampicin concentrations measured in the homogenate were similar 
between the lung and sacrospinalis at the 240 minute time point, although (apart from Guinea 
Pig F) there was a tendency for the lung concentration to be higher (between 1.4 to 4 times) 
than that measured in the muscle. When comparing the homogenate concentrations of 
rifampicin with the estimated concentrations of rifampicin based on microdialysis data, it is 
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evident, in both organs, that the total concentration as measured in the homogenate was lower 
than expected. 
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FIGURE 5.7: TOTAL (BOUND AND UNBOUND) RIFAMPICIN CONCENTRATIONS (µG/ML) IN THE LUNG AND SACROSPINALIS AT 240 MINUTES. Total (B+UB) rifampicin 
concentrations as measured following necropsy and homogenisation are shown against the estimated total rifampicin concentrati ons in the organs based on 
unbound rifampicin concentrations as measured via  microdialysis in the sacrospinalis. UB concentrations have been corrected for probe efficiency and 69% 
protein binding. 
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5.3.5 COMPARISON OF TOTAL SKELETAL MUSCLE CONCENTRATIONS OF 
RIFAMPICIN 
Muscle is often grouped together for PK modelling as it is assumed that skeletal muscle 
throughout the body will contain the same concentration of drug. The sacrospinalis and bicep 
femoris (skeletal muscle from the spine and hind leg respectively) were collected from the 
dialysed guinea pigs at necropsy. The biceps femoris was the skeletal muscle used to generate 
the data set in Figure 5.4B and the sacrospinalis was the anatomical location of the probe 
implantation. Total  (bound and unbound) rifampicin concentrations were compared for each 
guinea pig in Figure 5.8. 
When comparing the concentration of rifampicin in the two skeletal muscle samples from the 
four guinea pigs (Figure 5.8), there were similarities between them, particularly in Guinea pigs 
A, D and E (sacrospinalis concentrations; 20.2, 10.49 and 6.26µg/ml; biceps femoris 
concentrations; 29.2, 12.5 and 7.2µg/ml for Guinea Pigs A, D and E respectively). The 
concentration of rifampicin in the sacrospinalis was slightly lower than in the biceps femoris 
for Guinea Pigs A, D and E, but this might be explained by the fact that the sacrospinalis  muscle 
was dialysed. Guinea Pig F is the only animal in which the concentration of rifampicin in the 
sacrospinalis (22.03µg/ml) was higher than the concentration in the biceps femoris 
(6.96µg/ml). This was likely due to an unexpectedly high concentration of drug in the 
sacrospinalis, which is supported by the data in Figure 5.7 (lung vs sacrospinalis) where the 
sacrospinalis concentration of rifampicin in Guinea Pig F was higher than expected, given an 
overall trend of lower concentrations of drug in the muscle compared to the lung.   
When the mean total organ concentrations of rifampicin were compared, as shown in Figure 
5.9,  the concentration of rifampicin was relatively similar regardless of the anatomical location 
yet the lung concentration was higher (lung (26.4µg/ml) than the biceps femoris (13.9µg/ml) 
or sacrospinalis (14.75µg/ml)). 
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FIGURE 5.8: TOTAL RIFAMPICIN CONCENTRATIONS (µG/ML) IN SKELETAL MUSCLE COLLECTED FROM TWO DIFFERENT ANATOMICAL LOCATIONS. At the point of necropsy 
the biceps femoris and the sacrospinalis were homogenised, processed and analysed to measure total (bound and unbound) rifampicin concentrations.   The 
concentrations for each guinea pig are shown.
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FIGURE 5.9: MEAN RIFAMPICIN CONCENTRATIONS (µG/ML) IN THE TWO DIFFERENT ANATOMICAL 
SITES OF SKELETAL MUSCLE (BICEPS FEMORIS AND SACROSPINALIS) AND THE LUNG FOR GUINEA 
PIGS A, D, E AND F. Lungs and skeletal muscle were taken at the point of necropsy (240 
minutes), homogenised, processed and analysed to measure total rifampicin concentrations.  
Error bars show standard deviation. 
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5.3.7 BLOOD CONCENTRATIONS (EAR BLEED AND CARDIAC BLEED) 
Blood samples were taken from the guinea pigs that were dialysed in order to compare drug 
concentrations in tissues with those in the circulating blood. Ear bleeds were collected as a 
representation of total (B+UB) rifampicin concentrations in peripheral blood, as the marginal 
vein in the ear is relatively easy to collect blood from in the guinea pig. Rifampicin was not 
recovered in all of the ear bleed samples which meant that not all microdialysis fractions could 
be time matched to blood concentrations. The data are shown in Figure 5.10 alongside the 
mean unbound rifampicin as collected from the sacrospinalis via microdialysis, the mean 
rifampicin concentration measured in cardiac blood (at four hours post drug administration) 
and the estimated unbound lung concentration as calculated via the equation generated in 
Figure 5.4B. Also plotted are the estimated total rifampicin (B+UB) concentrations in the 
sacrospinalis and lung corrected for probe efficiency and 69% protein binding.   
The drug concentrations measured in ear bleeds were lower than those recovered via 
microdialysis in the skeletal muscle. The same trend of decreasing concentration over time was 
observed in both skeletal muscle and blood with the exception of the 240 minute time point, 
where the drug concentration in blood was higher than at any other time point.  This was an 
unusual result. These data show that rifampicin concentrations measured in the peripheral 
blood are not indicative of those in the organs, as they are substantially lower, particularly 
when the organ concentrations were corrected for probe efficiency and 69% protein binding. 
This was unexpected as blood contains bound and unbound drug, and only the unbound drug 
was measured in the organs.  
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FIGURE 5.10: A COMPARISON BETWEEN RIFAMPICIN CONCENTRATIONS (µG/ML) MEASURED IN  GUINEA PIGS A, D, E AND F. Black line indicates mean concentrations 
in peripheral blood as collected from ear bleeds, pink line is mean unbound rifampicin concentrations as recovered from the s acrospinalis via microdialysis 
(21% probe efficiency), dark pink line is the mean total rif ampicin concentrations as recovered from the sacrospinalis via microdialysis corrected for 69% 
tissue binding and probe efficiency, mean cardiac bleed concentrations at 240 minutes are indicated as well as mean estimated unbound rifampicin 
concentrations in the lung as calculated from the equation generated in Figure 5.4B(gold line). Dark gold line is the mean total rifampicin concen trations in 
the lung as calculated by the equation corrected for 69% tissue protein binding and probe efficiency.  Error bars represent standard deviation.
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The mean total (B+UB) rifampicin concentration measured in the cardiac blood at 240 minutes 
(36.8µg/ml) was similar to the estimated (by the equation generated in Figure 5.4B) unbound  
concentration of drug in the lung at the same time point (53.5µg/ml) before any corrections 
were applied for probe efficiency and protein binding. It is assumed that 79% more drug is in 
the tissue than measured with the microdialysis probe working at 21±9% efficiency. Therefore 
with corrections applied, the cardiac blood, although containing a higher concentration of 
rifampicin than the ear bleed samples, did not represent the drug concentrations estimated in 
the lung. 
In Chapter 2,  ear bleeds were collected to enable calculation of the AUC0-t to understand if 
human -like exposures were achieved post drug administration. Additional ear bleed data were 
obtained in the study described in Chapter 4. All of these data were collated with the ear bleed 
data generated as part of the microdialysis studies to form a more robust data set to enable a 
comparison between total rifampicin concentrations measured in the peripheral blood (ear 
bleeds) and the cardiac blood with estimated unbound rifampicin concentrations in the organ 
(lung). All guinea pigs received a dose of 50mg/kg rifampicin. These data are shown in Figure 
5.11.
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FIGURE 5.11:  MEAN RIFAMPICIN CONCENTRATIONS (µG/ML) AS RECOVERED FROM EAR BLEEDS AND CARDIAC BLEEDS FROM GUINEA PIGS THAT RECEIVED 50MG/KG 
DOSE OF RIFAMPICIN. Pink line indicates total rifampicin concentrations in the peripheral blood (collected  via ear bleed) and black line indicates total 
rifampicin concentrations cardiac blood. Gold line represents total rifampicin in the lung calculated from unbound rifampicin concentrations in the 
sacrospinalis recovered via microdialysis. These data were then corrected to total  concentrations by correcting for probe efficiency and assuming 69% tissue 
binding.  
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The additional blood sample data points (Figure 5.11) reinforce the interpretation of the data  
shown in Figure 5.10 in relation to cardiac blood, demonstrating over the time course that 
rifampicin concentrations measured in the cardiac blood (60 to 240 minutes), did not match 
(i.e were lower) the corresponding rifampicin concentration in the lung (calculated via 
microdialysis). The rifampicin concentrations in the cardiac blood were closer to the estimated 
concentration of rifampicin in the lung than those measured in ear bleed samples but were still 
much lower. Furthermore, the kinetics of concentration over time for both blood sample type 
did not match that of the organ concentrations.  
5.3.8 LIVER, URINE & FAECES CONCENTRATIONS OF RIFAMPICIN 
Liver, urine and faeces were collected to aid in characterisation of elimination (Chapter 1). 
Rifampicin concentrations in the liver were measured in the six guinea pigs used in Chapter 4 
and the five guinea pigs used in the in vivo microdialysis study in order to obtain data at 1, 2 
and 4 hours post drug administration. These data are shown in Figure 5.12. 
The highest mean rifampicin concentration in the liver was at one-hour post drug 
administration (508µg/ml). The concentrations in the liver then decreased between one and 
two hours (233µg/ml) and then remained relatively static. This trend is similar to that seen 
with recovered rifampicin in the microdialysis fractions.  
Urine and faeces were collected throughout the four-hour dialysis experiment. Not all guinea 
pigs produced urine and faeces and none of the collected urine samples contained rifampicin. 
The recovered concentrations of rifampicin in the faeces were relatively consistent over time, 
especially at three and four-hour time points (three samples; 15.3, 18.4, 18.4µg/ml rifampicin) 
indicating that rifampicin was being eliminated at a similar rate.  
Relating the liver concentrations to those found in faeces, it is evident that approximately 10% 
of the total rifampicin concentration in the liver was eliminated into the faeces (Table 5.1). 
Guinea Pig B which was culled at two hours post drug administration eliminated 2% of total 
rifampicin concentration recovered in the liver.  
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FIGURE 5.12: MEAN RIFAMPCIN CONCENTRATIONS (µG/ML) recovered in the liver of guinea pigs 
culled at 1, 2 or 4 hours post drug administration. Error bars show standard deviation.  
 
  Rifampicin Concentration µg/ml 
  Liver Faeces % Eliminated 
Guinea Pig F 152 15.6 10.3 
Guinea Pig B 416 42.5 10.2 
 
TABLE 5.1: RIFAMPICIN CONCENTRATIONS (µG/ML) MEASURED IN THE LIVER AND FAECES. At the 
point of necropsy (4 hours post drug administration) livers were removed, processed and 
analysed for rifampicin concentrations. All collected faeces from guinea pigs F and B were 
processed, analysed and the concentrations from all faeces samples were  totalled. % 
eliminated is concentration of rifampicin eliminated in faeces related to rifampicin 
concentrations measured in the liver.  
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5.4 PHARMACOKINETIC DATA 
To generate pharmacokinetic parameters, rifampicin concentrations as measured via 
microdialysis in the sacrospinalis at 21±9% probe efficiency were inputted into PK Solver (as 
described in Chapter 2) 217. A one-compartment analysis was conducted using first order 
kinetics for each dialysed guinea pig, the strength of the fit of the data to the model is indicated 
by the R2 value. PK Solver generated a number of PK parameters and the key parameters that 
were deduced from this analysis are the AUC0-t, AUC0-inf, Cmax and Tmax. The PK graphs 
generated in PK Solver are shown in Figure 5.13. PK parameters are shown in Table 5.2. The 
CV% and geometric mean are shown as an indication of the robustness of the data.  
Table 5.2 and Figure 5.13 show that the amount of drug (A; µg/ml) was similar between Guinea 
Pigs D, E and F which was consistent with the fact that all guinea pigs were administered the 
same dose of drug. The data obtained for Guinea Pig A was markedly different as evidenced by 
the profile shown in Figure 5.1 and 5.13. Absorption rates (ka; 1/h) were similar between 
Guinea Pigs A, E and F, Guinea Pig D was lower but this can be explained by the fact the first 
sample collected for Guinea Pig D was at 90  minutes. Elimination rates (k10) were similar 
between Guinea Pigs D and F, and the steep decline in rifampicin concentration between 30 
and 60 minutes seen with Guinea Pig A explains why the highest elimination rate is associated 
with this guinea pig. Guinea Pig E had a faster elimination rate than D and F as evidenced by 
the steeper decline in recovered rifampicin in microdialysis fractions as seen in Figure 5.1 and 
Figure 5.13. Guinea Pig D had the highest total rifampicin concentration in the liver at four 
hours which could be an explanation for the lowest elimination rate of the four guinea pigs, 
and conversely Guinea Pig E has the highest elimination rate (excluding Guinea Pig A) and the 
lowest total rifampicin concentration in the liver at four hours.  
The half-life of absorption (t1/2 ka; h) was similar between all four guinea pigs, but the half-life 
of elimination (t1/2k10; h) was most similar between Guinea Pigs A and E, and Guinea Pigs D 
and F mimicking the profiles observed in Figure 5.1. Guinea Pig A had the lowest elimination 
half-life as expected due to the steep decline in rifampicin concentration between 30 and 60 
minutes.  
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FIGURE 5.13: PK GRAPHS OF RIFAMPICIN CONCENTRATIONS IN THE SACROSPINALIS FOR GUINEA PIGS A, D, E AND F generated in PKSolver using a one-compartment 
analysis with first order kinetics. Red circles indicate observed (recovered from sacrospinalis) rifampicin concentrations. Note different axis scale for GP A.  
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TABLE 5.2: PHARMACOKINETIC PARAMETERS GENERATED IN PKSOLVER BASED UPON RIFAMPICIN CONCENTRATIONS IN THE SACROSPINALIS (21% PROBE EFFICIENCY) 
AGAINST TIME (every 30 minutes for four hour period). Each guinea pig is attributed a colour to indicate which was associated with the maximum and minimum 
values for each PK parameter. a; amount of drug in body at one time, ka; first order absorption rate constant, k10; clearance, t 1/2 ka/ t1/2 k10; half-lives of 
absorption and elimination, AUC0-t; systemic exposure over four hour time period, AUC0-inf; systemic exposure over infinity; AUMC; area under first moment 
of the plasma concentration time curve from 0-infinity, V/F; volume of distribution, CL/F; clearance, Tmax; time at which maximum concentrations occurs; 
Cmax; maximum concentration.  
(first-order kinetics) One-Compartment Analysis Parameters 
  A D E F   
  R2 0.985 0.963 0.985 0.984 
Mean SD Min Median Max CV% 
Geometric 
Mean 
µg/ml A 2960.5 159.6 231.7 163.8 878.9 1388.13 159.60 197.75 2960.50 157.9 365.94 
1/min ka 0.528 0.257 0.69 0.65 0.53 0.20 0.257 0.59 0.69 36.8 0.50 
1/min k10 0.08 0.009 0.0195 0.011 0.03 0.03 0.009 0.02 0.08 112.9 0.02 
min 
 t1/2 ka 1.311 2.695 0.99 1.065 1.515 0.798 0.990 1.188 2.695 52.7 1.4 
t1/2k10 8.42 76.51 35.4 63 45.833 30.245 8.420 49.200 76.510 66.0 34.6 
µg/ml*min 
AUC 0-t 30361.89 15000.28 11412.79 13578.56 17588.4 8642.5 11412.8 14289.4 30361.9 49.1 16299.3 
AUC 0-inf 30361.89 17004.36 11521.51 14641.17 18382.2 8296.1 11521.5 15822.8 30361.9 45.1 17178.8 
µg/ml*min^2 AUMC 426287 1943204.2 605971.7 1353438.1 1082225.2 700455.5 426287.0 979704.9 1943204.2 64.7 907878.7 
(mg/kg)/(µg/ml) V/F 0.02 0.32 0.22 0.31 0.218 0.139 0.020 0.265 0.320 64.0 0.14 
(mg/kg)/(µg/ml)/min Cl/F 0.0016 0.0029 0.0043 0.0034 0.003 0.001 0.0016 0.0032 0.0043 36.9 0.00 
min Tmax 4.16 13.48 5.29 6.37 7.32   4.16   13.48     
mg/L Cmax 1773.4 136.3 203 150.1 565.7 805.6 136.3 176.6 1773.4 142.4 293.0 
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The average Tmax (time that the maximum concentration occurs) was 7 minutes, indicating 
that rifampicin penetration into the tissues occurred rapidly, however this is based on the 
predicted as opposed to observed rifampicin concentrations used to generate the PK curves 
shown in Figure 5.13. The data for Guinea Pig D, due to the lack of collected samples at 30 and 
60 minutes, caused the Tmax average to increase, because excluding the data from Guinea Pig 
D lowers the average Tmax to approximately 5 minutes. Although the microdialysis sampling 
scheme is much richer than that associated with ear bleed and cardiac bleed sampling due to 
samples being collected every 30 minutes, each collected fraction represents all the drug 
collected between 0 and 30 minutes. For the purpose of generating PK parameters, the 
measured rifampicin concentration was inputted at each 30 minute time segment (30, 60, 90, 
120, 150, 180, 210, 240 minutes) however the Tmax and Cmax could be different if these 
parameters occurred at a point in between the  30 minute collection period i.e. at 15 or 20 
minutes. The Cmax is the maximum measured concentration and the mean Cmax for all four 
guinea pigs was 565mg/L. 
Other generated PK parameters were as expected (AUMC and Volume of distribution (V/F)) 
based on the data in Figure 5.1. Guinea Pig E has the highest rate of clearance (Cl/F) as it has 
the steepest decline over time, and Guinea Pig A has the lowest rate as concentrations remain 
relatively static after 60 minutes.  
 
 
 
 
 
 
 
 
 
199 
 
The AUC0-t and AUC0-inf is a measure of total systemic exposure to rifampicin over time and can 
be used to identify if human-like exposures (human AUC) are achieved indicating whether the 
dose of rifampicin administered to the guinea pigs is clinically relevant. AUC0-t and AUC0-inf 
(µg/ml*min) are highest for Guinea Pig A. The mean AUC0-t and AUC0-inf for all four guinea pigs 
was corrected to account for probe efficiency in order to estimate the actual in vivo 
concentration. At 21% probe efficiency the mean unbound rifampicin AUC0-t  was 
17.58mg/ml*min and AUC0-inf was 18.38mg/ml*min and when corrected for probe efficiency 
the AUC0-t was 64.1mg/ml*min and AUC0-t was 64.5mg/ml*min.  
Key PK parameters (AUC0-t, AUC0-inf and Cmax) were also generated in PKSolver for the mean 
estimated unbound rifampicin concentrations in the lung as shown in Figure 5.5 as well as for 
blood concentrations of rifampicin as collected via ear bleeds and cardiac bleeds as used for 
Figure 5.11. Blood data were analysed using a non-compartmental analysis. These parameters 
were compared against those generated for the average rifampicin concentrations as 
recovered by microdialysis for all four guinea pigs. Table 5.3 shows the AUC and Cmax data 
calculated in PKSolver for the different sampling sites. The human AUC values (based on total 
rifampicin concentration in blood) are also shown in Table 5.3. To compare the quoted AUCs 
in Table 5.3, the data needed transforming to mg/L*hour, these data are also shown in the 
table.  
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Sample Site  AUC0-t 
(mg/ml*min) 
mg/L*
h 
AUC0-inf 
(mg/ml*min) 
mg/L
*h 
Cmax 
mg/L 
U
n
b
o
u
n
d
 
Sacrospinalis 
As 
Collected 
(21%) 
17.58 1.05 18.3 1.09 565 
Corrected 
value for 
probe 
efficiency 
64.1 3.84 64.5 3.87 1230 
Lung 
Based on 
sacrospin
alis 
(21%) 
37.20 2.23 37.4 2.24 680 
Corrected 
value for 
probe 
efficiency 
177.16 10.62 178.5 10.68 3270 
T
o
ta
l (
B
+
U
B
) 
Sacrospinalis 
Corrected 
value for 
probe 
efficiency 
+69% 
protein 
binding 
206.7 12.4 208 12.48 3960 
Lung 
Corrected 
value for 
probe 
efficiency 
+69% 
protein 
binding 
571.4 34.2 575.8 34.5 10500 
Blood (Ear 
Bleed) 
As 
measured 
0.813 0.048  5.41* 
Blood (Ear 
Bleed/ 
Chapter 2) 
 5.66  7.07 4.3 
Blood (Cardiac 
Bleed) 
6.30 0.37  44.9 
Human Blood (range)  
26.8-
49.9 
 6.6-12.8 
TABLE 5.3: CALCULATED AUC PARAMETERS FOR DIFFERENT SAMPLING SITES. These parameters 
were generated in PKSolver. Shown is sampling site and whether the AUC is for total or 
unbound drug. Also highlighted is whether the measured value has been corrected for probe 
efficiency and protein binding. A column converting mg/ml*min to mg/l*h is shown. Also 
shown is the human AUC and Cmax in blood as published the literature. * = Cmax was 
calculated excluding outlying data point at 240 minutes.  
  
The calculated AUCs associated with the lung and sacrospinalis were based on unbound 
rifampicin concentrations. These data have been corrected for probe efficiency and further 
corrected with a protein binding factor of 69% to enable a direct comparison between the 
estimated lung AUC0-t and the human blood AUC0-t range. Applying these correction factors to 
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the estimated lung AUC0-t (37.20mg/ml*min) generated an estimated lung AUC0-t of 
34.2mg/L*h. This indicated that with a dose of 50mg/kg rifampicin human-like exposures 
were achieved in the lung. Human-like exposures, in relation to Cmax, were achieved in the 
sacrospinalis and lungs of the dialysed guinea pigs. However in the blood, by removing the 
outlying data point at 240 minutes (19.68mg/L; as shown in Figure 5.10 and Figure 5.11) 
meant that human-like exposures were not matched in the blood. The data shown in Table 5.3 
were variable with few similarities observed between the different sampling sites.  
The AUC:MIC and Cmax: MIC are the PK parameters that best predict the efficacy of rifampicin 
in humans. The Cmax: MIC ratio associated with suppression of rifampicin resistance in 
humans is ≥175181. The rifampicin MIC used for these analyses is 45ng/ml231.The AUC: MIC 
ratio in mice associated with a 1 log reduction in colony forming units (CFU) upon infection 
with M.tb is 271232. The AUC and Cmax data shown in Table 5.3 were analysed against the MIC 
to calculate if either of these ratios were achieved in the lung or blood of guinea pigs. The 
results are shown in Table 5.4. 
 Sampling 
Site 
AUC 
mg/L*h 
MIC 
ng/ml 
AUC: MIC 
Cmax 
mg/L 
MIC 
ng/ml 
Cmax: 
MIC 
B+UB Mouse 271 Human 175 
UB 
Lung 
Corrected 
value for 
probe 
efficiency 
10.62 
45 
237 3270 
45 
7.27E+04 
Lung 
Corrected 
value for 
probe 
efficiency 
+69% 
protein 
binding 
34.2 760 10500 2.33E+05 
B+UB Blood (Ear 
Bleed) 
5.66 125 5.41 120.2 
TABLE 5.4: AUC:MIC AND CMAX:MIC RATIOS ASSOCIATED WITH GUINEA PIG LUNG CORRECTED FOR PROBE 
EFFICIENCY WITH AND WITHOUT PROTEIN BINDING CORRECTIONS AND BLOOD. Also shown are human and 
mouse thresholds for rifampicin efficacy. 
Correcting for probe efficiency in the lung calculates an AUC: MIC of 237 which is close to the 
ratio associated with a 1 log reduction in CFU, however when the lung AUC is corrected for 
protein binding the AUC: MIC ratio is 760. The Cmax: MIC ratio in the blood (Chapter 2; Cmax: 
MIC 95.5) following a 50mg/kg dose of rifampicin in guinea pigs does not reach the threshold 
 
 
202 
 
associated with suppression of resistance. However, within the lung, the Cmax: MIC ratios are 
far above the threshold (≥175).  
A dose of 50mg/kg rifampicin in guinea pigs was curative (i.e. decreased bacterial load over 
time course) as shown in Figure 5.14. Briefly, guinea pigs were aerosol challenged with 50-100 
CFU M.tb (H37Rv) and 4 weeks post challenge guinea pigs were administered 50mg/kg 
rifampicin (in fruit puree as was done for these studies) five days a week. Three guinea pigs 
from each treatment group were necropsied at weeks 5, 6, 7 and 8 post-challenge. Lungs were 
homogenised, serially diluted, plated on agar plates and incubated for 3-4 weeks until colonies 
were enumerated. As shown over the time course, rifampicin treated guinea pigs had a 
reduction in bacterial load when compared to the untreated group. These data indicate that 
guinea pigs do not need to receive a dose higher than 50mg/kg rifampicin in order to benefit 
from the therapeutic effects.  
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FIGURE 5.14: VIABLE M.TUBERCULOSIS AS MEASURED IN THE LUNGS OF GUINEA PIGS TREATED WITH 50MG/KG RIFAMPICIN. Delta Log10 total CFU is shown for rifampicin treated guinea 
pigs related to untreated guinea pigs following aerosol infection with 50-100CFU of H37Rv. Each point represents the mean CFU measured in three guinea pigs. 
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5.5 DISCUSSION 
Microdialysis, the only methodology available to measure unbound drug concentrations in 
organs, was used to measure rifampicin concentrations in the lungs of guinea pigs. These data 
were analysed to derive PK parameters which were compared to the equivalent parameters 
within blood in both guinea pigs and humans. 
In  the skeletal muscle of all four dialysed guinea pigs, the measured unbound rifampicin 
concentrations and the associated kinetic profile, over 240 minutes, were very similar as 
shown in Figure 5.1. This highlights the reproducibility and robustness of the microdialysis 
methodology. When comparing the results generated using microdialysis and those generated 
via blood collection (Figure 5.10), the robustness of the microdialysis methodology is further 
highlighted. Figure 5.10 also indicated the irreproducibility of blood samples as the total 
concentration of rifampicin in the peripheral blood (until 240 minutes post drug 
administration) was lower than the unbound rifampicin collected from the sacrospinalis even 
when 100% recovery was not assumed. This was unexpected as it was assumed that the blood 
would contain more rifampicin (bound and unbound) than a sample collected via microdialysis 
which contained only unbound rifampicin. At 240 minutes, the ear bleed concentration was 
similar to the concentration measured via microdialysis (21% efficiency), however the only 
conclusion that can be attributed to this was that peripheral blood data is unreliable and varied. 
Microdialysis consistently recovered unbound rifampicin which generated a much more 
detailed profile of the kinetics of rifampicin in the guinea pig, using less animals than required 
to generate the less adequate blood kinetic profile (Figure 5.11). This is partly due to the design 
of the studies in Chapter 2 but also because rifampicin concentrations were not always 
recovered in the ear bleed samples. 12 guinea pigs were used to generate the kinetic profiles 
in blood and 4 guinea pigs were used to generate the kinetic profile in organs seen in Figure 
5.11.  
An interesting and unexpected result was that in all animals, the unbound concentration of 
rifampicin when corrected for probe efficiency (representing actual in vivo concentrations) in 
the sacrospinalis and lung was higher than the total rifampicin concentration measured in the 
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equivalent organ homogenates following necropsy. This is highlighted in Figure 5.7. It could 
therefore be concluded that the estimated concentrations based on the unbound rifampicin 
collected from the sacrospinalis are over-representing the drug concentrations in the organs, 
potentially due to incorrect assumptions being applied to correct for protein binding or probe 
efficiency. Rifampicin plasma protein binding figures are varied and range between 43% and 
94% in humans 233. In animal models of TB, guinea pigs have the lowest plasma protein binding 
figure (69%) when compared to C57 mice (97.1% PPB) and macaques (90.3% PPB)117. This 
between- species and within- species variation associated with protein binding does suggest 
that the protein binding figure used to correct these data could be lower or higher. A lower 
tissue protein binding factor, meaning there was more unbound drug available to collect via 
microdialysis, would make sense in relation to these data.  
It was assumed (based on blood concentrations) that the expected in vivo organ concentration 
of rifampicin was going to be less than or close to 50µg/ml, and at these concentrations the 
CMA 20 (10mm, 20kDa) probe efficiency was calculated to be 21%±9%. This assumption was 
correct when total organ concentrations were measured as shown in Figure 5.7, Figure 5.8 and 
Figure 5.9. If it was assumed that the probe was operating at 30% efficiency (higher end of the 
calculated 21±9% efficiency), using the data in Figure 5.3, the unbound concentrations of 
rifampicin in the sacrospinalis when corrected for probe efficiency were 57, 84, 38 and 
64µg/ml as opposed to 81.9, 120, 54.2 and 91.4µg/ml (corrected for probe efficiency based on 
21% probe efficiency) for Guinea Pigs A, D, E and F respectively. Although correcting the 
measured unbound rifampicin concentrations with this higher figure (30%) lowered the 
concentration closer to the  total concentration as measured in the organ (20.2, 10.49, 6.26, 
22.03µg/ml for Guinea Pigs A, D, E and F respectively), the total rifampicin concentration 
measured in the sacrospinalis was still lower than expected based on the unbound 
concentration as measured by microdialysis. There were a number of hypothesised reasons for 
this.  
One reason could be that the unbound rifampicin has been dialysed out of the sacrospinalis 
and as such there was less total rifampicin in the sacrospinalis at the point of necropsy.  In the 
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lung, an additional ex vivo sample was collected (270 minutes) and therefore removed more 
rifampicin from the lungs. As this was completed following necropsy, there was no blood 
supply to the lungs hence the distribution equilibrium could not be re-established and 
therefore the measured total rifampicin concentration could be low. Collection of the 
additional 30 minute sample via ex vivo microdialysis could also have caused degradation of 
the remaining rifampicin in the lung.  
Another highly likely reason for the lower than expected total drug concentrations  in organs 
was that the organs required homogenisation. The homogenisation process destroys tissue 
compartments and can release large blood volumes, especially in the lung. The homogenisation 
and protein precipitation process could be a source of drug loss due to the lipophilic nature of 
rifampicin and the associated non-specific binding to plastics. Plastics are an unavoidable 
component of the homogenisation and protein precipitation processes and therefore use of 
these methods for sample preparation may have underestimated the total rifampicin 
concentration in the organ. The homogenisation process could also be why the measured total 
rifampicin concentrations in the organs were variable (20.2, 10.49, 6.26, 22.03µg/ml in the 
sacrospinalis of Guinea Pigs A, D, E and F respectively). Given the similarity of the microdialysis 
data (Figure 5.1) in animals that were dosed separately, it seemed unlikely that the varying 
concentrations of rifampicin in the sacrospinalis were due to different drug doses. Samples 
collected via microdialysis (due to the exclusion of proteins) require no processing, therefore 
it could be deduced that the concentrations as measured by microdialysis are a more accurate 
estimate of rifampicin concentrations in the organs. 
The main reason to dialyse the sacrospinalis was to use the measured unbound concentrations 
to estimate the unbound rifampicin concentration in the lung (µg/ml) (Figure 5.4B). This was 
possible after fitting the data in Figure 5.4B with a linear interpolation after the removal of an 
outlying data point. However, this data point could be indicative of distribution equilibrium 
being reached in the lung and skeletal muscle at 2 hour post drug administration. This, again, 
highlighted the animal to animal variation associated with measuring organ concentrations of 
drug in guinea pigs post necropsy. This variation has not been associated with the collected 
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microdialysis samples. The kinetic profile associated with the estimated rifampicin 
concentrations in the lung matched that in the sacrospinalis (Figure 5.1), which indicated that 
the linear interpolation used to fit the data was the best model. Further support for the use of 
the linear interpolation to accurately predict unbound concentrations in the lung from those 
in the skeletal muscle was that the unbound rifampicin concentrations collected ex vivo from 
the lung were similar to the estimated unbound concentration of rifampicin in the lung as 
calculated from the equation in Figure 5.4B.  These data strengthened the use of skeletal muscle 
as a surrogate for lung. As evidenced in Figure 5.8, the total rifampicin concentrations 
measured in the sacrospinalis and biceps femoris (two skeletal muscles from different 
anatomical sites) were similar for all guinea pigs. This indicated that the relationship between 
rifampicin concentrations in the lung and skeletal muscle was not dependent upon the site of 
skeletal muscle sampled. This was not unexpected as there is no difference in the structure of 
skeletal muscle at different anatomical sites. The data in Figure 5.8 are concordant with the 
literature, in which muscle is not delineated by anatomical site (as concentrations should be 
the same) for PBPK modelling.  When the measured total concentrations of rifampicin in the 
skeletal muscle were averaged the concentrations were similar to that measured in the lung 
(Figure 5.9). This similarity between lung and skeletal muscle unbound drug concentrations 
was identified by both Liu229 and Tasso228,  when measured via microdialysis in anesthetised 
rats. The similarities in rifampicin concentrations shown in Figure 5.9 was unlike the data 
generated in Chapter 4, whereby the total rifampicin concentrations (as measured) were not 
sufficiently similar and an assumption could not be made that rifampicin concentrations in the 
lung and skeletal muscle were the same. However, even with the differences between the 
relationships (same concentrations in both organs vs correlated relationship between both 
organs), these data further strengthened the use of skeletal muscle as a surrogate for lung.  
The measured and estimated unbound drug concentrations in the lung and sacrospinalis were 
inputted into PKSolver and PK parameters were generated as shown in Table 5.2. This is the 
first time that the pharmacokinetics of unbound rifampicin have been described in the organs 
of guinea pigs. The PK parameters associated with blood were defined in Chapter 2 and enable 
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a comparison to the PK parameters associated with the organs as defined in this chapter. The 
strength of these generated organ PK parameters are reinforced by a number of reasons. One 
reason is that more samples were collected via microdialysis to generate the PK parameters. 
During the four-hour experiment, 8 microdialysis samples were collected and only two ear 
bleed samples, this is due to the fact microdialysis does not interfere with blood homeostasis 
whereas the number of blood samples that can be collected is determined by the project 
licence. As mentioned in Chapter 4, guinea pigs can be cannulated to enable more intensive 
blood sampling, however project licence restrictions still apply and expense as well as 
feasibility need to be considered. The continuous serial sampling of organ drug concentrations 
is a key advantage of the microdialysis methodology. Although the microdialysis methodology 
is able to collect samples more frequently than in the blood, each sample, although analysed as 
a 30 (or 30 minute increment) minute sample, actually represents the concentration of 
rifampicin recovered between 0 and 30 minutes. It is known that the lag time of the system is 
3 minutes 36 seconds and although the pharmacokinetic profiles of rifampicin in the organs 
would remain the same, the timing of sample collection would shift by 3 minutes. Use of a one 
compartment model accounts for this. The microdialysis methodology could be adapted to 
collect samples every 15 minutes, although this would require additional  in vitro optimisation 
due to the smaller sample volume that would be available for LC-MS/MS analysis. However, 
using the microdialysis methodology enabled the Tmax to be reported in minutes (Table 5.2) 
as opposed to hours for the first time following a single dose of rifampicin in the guinea pig. 
Note that these data are based upon the ‘predicted’ values as oppose to the measured 
‘observed’ values used to generate the PK curves in PKSolver.  
The differences in blood PK parameters generated between Chapters 2 and 5 of this thesis 
highlight the variability associated with these samples (Table 5.3). The Cmax for the blood data 
in Chapter 2 was 4.3mg/L. The Cmax data generated from peripheral blood samples collected 
from guinea pigs that were also dialysed was relatively similar (5.41mg/L) when the outlying 
data point at 240 minutes was excluded, although when this point was included (19.68mg/L) 
the Cmax data were vastly different. The Cmax data associated with the cardiac blood 
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(44.9mg/L) were much higher than that associated with the peripheral blood. Cardiac blood 
concentrations of rifampicin (at 240 minutes) seemed more relevant to organ drug 
concentrations than peripheral blood concentrations (Figure 5.10). However, when the data 
were corrected for probe efficiency the cardiac blood  underestimated the concentrations of 
unbound rifampicin in the organs. Collection of cardiac blood at necropsy is usually a single 
sample that cannot be easily collected sequentially from the same animal. The kinetic profile 
of rifampicin in cardiac blood (compiled from all guinea pigs bled in Chapter 4 as well as the 
guinea pigs used for in vivo microdialysis) was similar to that generated via microdialysis 
between 120 and 240 minutes, however it still underestimated the estimated unbound 
rifampicin in the organs when these concentrations were corrected for probe efficiency. The 
measured AUC0-t in blood generated during Chapter 2 was 5.66mg/L*h, and for the dialysed 
guinea pigs was 0.0048mg/L*h and 0.37mg/L*h in peripheral and cardiac blood respectively. 
The AUC0-t, was generated over 24 hours in Chapter 2 and over 4 hours in Chapter 5. 
Unfortunately, the peripheral blood data set generated in Chapter 5 was not robust enough to 
generate AUC0-inf hence blood AUC parameters cannot be directly compared.  
An additional difference between the blood samples in Chapter 2 and Chapter 5 was that they 
were analysed at two different sites (Chapter 2; GSK, Chapter 5; Q3 Analytical). There were two 
main differences between the analytical methodologies at the two sites, one was that at GSK 
UPLC was used as opposed to HPLC (Q3 Analytical) and UPLC analysis is known to be more 
sensitive. The other difference was that at GSK, butylhydroxytoluene was added to the samples 
to prevent rifampicin loss by oxidation. It could therefore be assumed that the data generated 
at Q3 Analytical may underestimate the amount of rifampicin in the samples, however the 
similarities between the Cmax data in blood from the two sites (4.3mg/L GSK and 5.41mg/L at 
Q3 Analytical) and the acceptance criteria for method validation gave confidence that both 
methodologies were measuring similar concentrations of rifampicin. All samples generated via 
in vivo microdialysis were analysed at Q3 Analytical and hence measured rifampicin 
concentrations were directly comparable  in terms of analytical methodology.  
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The Tmax values generated in blood (4 hours for peripheral blood, 2 hours for cardiac blood) 
were vastly different to those associated with microdialysis (generated in minutes). Based 
upon the measured rifampicin concentrations in  blood and the associated blood PK 
parameters it could be concluded that a 50mg/kg dose does not achieve human-like exposures 
in the guinea pig (Table 5.3). This conclusion based on PK in blood is strengthened by an 
unpublished data set shared by Anne Lenaerts (Colorado State University)234. Three guinea 
pigs were administered a 50mg/kg oral dose of rifampicin. The Cmax data ranged from 1.38 to 
4.36mg/L. The individual AUC0-t for each guinea pig ranged between 2.79 and 19.37mg/L*h 
and Tmax values in blood were 4.23, 2.03 and 4.07 hours for the three guinea pigs. In another 
data set where guinea pigs were administered a single dose of 50mg/kg rifampicin, the Cmax 
was 2.9±2.0mg/L, the Tmax was 2.0±0.01h and the AUC0-inf  was 13.4±5.8mg/L*h207 in serum. 
In all datasets whereby the PK of rifampicin was measured in blood, neither the measured 
Cmax or AUC0-t PK parameter indicated human-like exposures had been achieved in guinea pigs 
following a 50mg/kg dose. Interestingly, in BALB/C mice, a dose of 50mg/kg  rifampicin 
generated a Cmax of 52±10mg/L and AUC0-24 of 600±81mg/L*h in blood which are far above 
the human range235. In a data set where guinea pigs were administered a 100mg/kg oral dose 
of rifampicin, the mean Cmax in blood was 14.80mg/L (range 6.27-16.86mg/L)220 which was 
inside the human range (6.6-12.8mg/L) but still lower than the parameters achieved following 
a 50mg/kg dose in mice. The AUC0-t range (32.66-124.24mg/L*h) in guinea pigs that were 
administered 100mg/kg of rifampicin, although wide, were within the human range (26.8-
49.9mg/L*h)220. It is important to mention a recent publication which used meta-analysis to 
estimate PK parameters associated with human blood at standard rifampicin doses, and the 
estimated AUC following a single dose of rifampicin was calculated to be 72.56mg/L*h236.  
Based on these data it would be acceptable to conclude that guinea pigs needed to be 
administered an oral dose of 100mg/kg rifampicin to achieve human-like exposures, although 
doses of 100mg/kg of rifampicin have been associated with directly toxic effects in the guinea 
pig207. 
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The calculated AUCs associated with the organs were more relevant to the human data than 
those associated with the blood. Figure 5.9 indicated that mean total rifampicin concentrations 
were similar between lung and skeletal muscle. However, the PK data associated with unbound 
rifampicin show differences in the AUC0-t between the sacrospinalis and the lung especially 
when the data is corrected for probe efficiency. If the relationship between the rifampicin 
concentrations (Figure 5.4B) in the lung and skeletal muscle had not been identified, an 
assumption would have been made that the AUC0-t in guinea pigs did not achieve human-like 
exposures even when a 69% protein binding factor is applied (12.4mg/L*h).   The estimated 
unbound rifampicin AUC0-t in the lung (10.62mg/L*h) is close to that of the lower end of the 
human range (26.8-49.9mg/L*h)218, especially as the AUC0-t associated with the lung was 
calculated for only the unbound drug and the human range was calculated for total drug 
concentrations. To enable a direct comparison between the estimated lung and human AUC0-t 
range, the estimated lung data were corrected for protein binding which calculated the total 
lung AUC0-t to be 34.2mg/L*h. This therefore indicated that with a dose of 50mg/kg rifampicin 
human-like exposures (26.8-49.9mg/L*h) were achieved in the lungs, which are the target 
organ of rifampicin, negating the need for higher doses to be administered to the guinea pig 
and hence reducing the chances of toxic drug effects occurring.    
The PK parameters that are associated with rifampicin efficacy are the AUC:MIC ratio and 
Cmax: MIC ratio (Table 5.4). The Cmax: MIC ratios associated with blood following a 50mg/kg 
dose of rifampicin in guinea pigs does not reach the threshold associated with suppression of 
resistance (≥175). However, Cmax: MIC ratios associated with the organs are above this 
threshold (271) in the organs again suggesting that a 50mg/kg dose is sufficient in guinea pigs. 
Correcting for probe efficiency in the lung calculated an AUC:MIC of 237. This is the unbound 
rifampicin AUC: MIC ratio and was close to 271 which is the figure associated with total (bound 
and unbound rifampicin) AUC:MIC. These data suggest that a dose of 50mg/kg rifampicin was 
sufficient to achieve a 1 log reduction in CFU in the lung, as although the unbound AUC in the 
lung is not at 271, the AUC: MIC ratio when corrected for protein binding was 760. These data 
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indicated that although therapeutic concentrations of rifampicin are not obtained in the blood, 
therapeutic concentrations are achieved in the lungs. 
Microdialysis was used to describe the pharmacokinetic behaviour of unbound rifampicin in 
the lungs as a continuous sampling technique in awake freely moving guinea pigs for the first 
time.  Microdialysis generated more robust, reproducible and human relevant PK data when 
compared to traditional methods such as blood collection and total organ concentrations 
measured post necropsy. This more robust data set compiled by microdialysis was generated 
using less animals which is in line with the 3Rs principles associated with use of animals in 
scientific research. The development of this methodology has significance for pre-clinical 
development of novel anti-TB drugs because the organ PK data was different to the PK data 
generated in blood, and PK data generated in the blood underestimated the equivalent 
parameters in the organs. Blood data indicated that a dose higher than 50mg/kg would need 
to be administered to guinea pigs to achieve human-like exposures, however, use of the 
microdialysis methodology has shown that human-like concentrations are achieved in the 
lungs of guinea pigs following a 50mg/kg dose. 
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CHAPTER 6 
GENERAL DISCUSSION 
Two main hypotheses were tested in the studies detailed in this thesis. The first hypothesis 
was centred around the establishment of the microdialysis methodology in guinea pigs to 
measure the concentration of drugs in the lung. The second hypothesis was that the 
concentrations and concentration-time curves (PK curves) of anti-TB drugs within the blood 
will be significantly different to the concentrations and PK curves in the lungs. 
In relation to the first hypothesis, the microdialysis methodology was successfully established 
for use in the guinea pig and the microdialysis system was optimised with rifampicin, a key 
component of the front-line anti-TB drug regimen. The use of this methodology has enabled 
the successful completion of reproducible and robust experiments to measure unbound drug 
concentrations and therefore generate PK parameters, within the organs of guinea pigs (Figure 
5.13). A clear advantage to the microdialysis methodology over traditional methods (i.e. blood 
collection) was that four guinea pigs were used to generate a data set (Figure 5.1), which would 
have required approximately 16 guinea pigs in order to generate the equivalent data set using 
blood sampling due to the constraints around frequency of blood collection. Hence, the 
microdialysis methodology adheres to the 3Rs principles associated with use of animals in 
scientific research, because microdialysis enabled more (quality and quantity) information to 
be gathered from each guinea pig therefore reducing the amount of animals required and 
refining the information gained from a single animal.  
Whilst development and optimisation of the microdialysis system was successful, several 
technical challenges needed to be overcome. A significant amount of in vitro optimisation was 
required, not only to optimise the microdialysis-specific parameters to improve probe 
efficiencies, but also in the identification of a site for probe implantation. The latter was largely 
dependent on the requirement for guinea pigs to be awake and unanaesthetised and therefore 
there were minimal sites for implantation especially those which were relevant to the lung. A 
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thorough understanding of the physiochemical properties of the drugs was imperative in the 
optimisation of microdialysis-specific parameters and in the identification of a relationship 
between lung and skeletal muscle drug concentrations to enable probe implantation into the 
sacrospinalis. Having performed in vitro microdialysis with three of the four front-line anti-TB 
drugs, important data were generated enabling assumptions to be made based upon the 
physiochemical properties of other anti-TB drugs. Probe efficiencies could be estimated and 
whether skeletal muscle could be used as a surrogate for lung.  As an example, it would be 
expected that the probe efficiency associated with pyrazinamide would be very similar to that 
of isoniazid (~67%) due to the similarities in  physiochemical properties between the two 
drugs. The probe efficiency associated with the other rifamycins (rifabutin and rifapentine) is 
estimated to be around 21% due to the shared similarities with rifampicin. However, caution 
must be exercised when making assumptions about drugs based solely upon their  
physiochemical properties. This was highlighted in this thesis with isoniazid, because no 
relationship was identified between lung and skeletal muscle isoniazid concentrations. This 
was unexpected as isoniazid has similar physiochemical properties to gatifloxicin228 
(Mw:375.39, LogS:-1.71, LogP:1.31) and cefpodoxime229 (Mw:427.188, LogS:-1.47, LogP:-0.32) 
and both of these drugs showed similar concentrations in the lung and skeletal muscle. A 
relationship between lung and skeletal muscle rifampicin concentrations was shown which 
might not have been predicted based upon the physiochemical properties of rifampicin which 
differ from those of gatifloxicin and cefpodoxime.   
In order to use the microdialysis methodology with other anti-TB drugs, in vitro optimisation 
would need to be conducted to ascertain the probe efficiency associated with the drug. Hence, 
a significant disadvantage to the microdialysis methodology is that it is more time consuming 
to implement than traditional methods and also requires the use of specialist equipment.  
However, the microdialysis-specific parameters optimised in these studies with rifampicin, 
serve as an important starting point. For example, the same parameters were used for isoniazid 
and achieved high relative recoveries, even though rifampicin and isoniazid share few 
physiochemical properties. An interesting drug to trial and optimise in the microdialysis 
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system to measure the unbound concentration of in organs would be bedaquiline. In guinea 
pigs and humans, bedaquiline is ~99% plasma protein bound117, and it would be important to 
understand if this is similar in tissues and measure the actual quantities of unbound 
bedaquiline via microdialysis. The high LogP value associated with bedaquiline (6.24) 
indicates that there would be non-specific binding of the drug to the plastics within the 
microdialysis system. However, it has been shown in these studies that such issues associated 
with rifampicin can be overcome by prior exposure of the probes to drug and use of the 300µl 
microdialysis collection tubes. The PK of bedaquiline has been previously established in the 
plasma and lungs of BALB/C and C3HeB/FeJ mice with similar results between the two 
sampling sites in both species27.  However, the lung PK data in those studies was based upon 
total drug concentrations in homogenate. Use of the microdialysis methodology in guinea pigs 
would enable unbound bedaquiline to be measured in vivo and to identify whether blood 
concentrations truly reflect the amount of unbound drug in the lungs. This has the potential to 
optimise dosing regimens for this important new TB drug.  
Technical refinements can be made to further optimise the microdialysis system with the anti-
TB drugs. A simple and easy to implement refinement would be the use of a slower flow rate 
or to decrease the lag time (3 minutes 36 seconds). This would enable more temporal 
resolution to further define Tmax parameters in the organs. As discussed in Chapter 5 the Tmax 
data were reported in minutes, however this was based on the predicted as opposed to 
observed (measured) drug concentrations (i.e. use of a one compartment model). Adjusting the 
microdialysis system to enable the collection of fractions every 10 or 15 minutes (using 2µl 
minute flow rate) could be completed with minimal optimisation as 5µl is the minimum 
sufficient sample volume for LC-MS/MS.  Incorporation of online analysis into the microdialysis 
methodology, whereby dialysate is directly injected into the HPLC, would reduce sample 
volumes even further as well as providing near real time information165.  This online directly 
coupled analysis is a unique feature of microdialysis, due to the generation of protein free 
samples and hence the lack of requirement to process the samples prior to analysis237. 
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However, incorporation of online analysis could only be conducted in a dedicated microdialysis 
facility.  
Another technical refinement to improve the data generated using microdialysis would be to 
further characterise the PK of drugs by sampling for a longer period of time (~24 hours). This 
longer dialysis period would be especially important for drugs with longer half-lives such as 
bedaquiline27. The microdialysis experiments performed with rifampicin were conducted over 
a period of 4 hours.  In terms of animal welfare, there was no evidence of guinea pig discomfort 
during the dialysis period and no welfare concerns were raised by either the Home Office 
Inspector or Named Veterinary Surgeon upon inspection of the guinea pigs. There has been 
evidence of associated tissue trauma following probe implantation especially if the probe is 
implanted for longer than 12 hours169, however in the guinea pigs used for these studies where 
the probe had been in situ for ~50 hours there was no evidence of tissue inflammation 
identified (as shown via histopathological analysis) at the probe implantation site. This 
suggests that microdialysis is a minimally invasive method. Hence, the microdialysis 
experiments could be easily adjusted to incorporate a longer dialysis period.  
An important conclusion from the data generated in these studies is that blood samples 
(collected via ear bleeds) no longer need to be collected as part of the microdialysis 
experiments because the data generated via blood sampling was less reliable than that 
generated by microdialysis. If blood samples are required, a more robust method for sampling 
(i.e. jugular vein catherization) must be employed, however this would require amendments 
to the Home Office licence as well as ensuring that more frequent collection of blood samples 
would not affect the associated PK parameters. A similar disparity between blood and organ 
drug concentrations has also been shown in the rabbit model where it was found that plasma 
and lung homogenate were not a suitable surrogate for drug concentrations in lesions within 
the lungs of rabbits infected with M.tb192. Verification of the amount of total drug in an organ 
following microdialysis was found to be important and is recommended for future studies. 
However, there was evidence that drug concentrations were underestimated in organ 
homogenates. As highlighted in Figure 5.3, there was a disparity between drug concentrations 
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measured in the homogenate and those measured via microdialysis (especially when the 
microdialysis concentrations were corrected for probe efficiency). It is hypothesised that the 
concentrations measured via microdialysis (due to the lack of requirement for sample 
processing) are more representative of in vivo drug concentrations. To address this hypothesis, 
different methods of tissue homogenisation could be used to more efficiently measure total 
drug concentrations. The Ystral homogeniser used in these studies to homogenise every 0.2g 
tissue in 1ml PBS should have achieved a uniform subcellular particle size of 10µm which can 
be extracted efficiently, however with tougher tissue such as muscle a uniform homogenate 
may not have  been created. Alternative methods such as bead beating could be used to more 
efficiently break down the tissue, although this may increase the available surface area for non-
specific drug binding, however addition of an organic solvent (phosphate buffer) can aid in 
drug recovery by reducing this binding238.  
The studies performed in this thesis showed definitively that a dose of 50mg/kg rifampicin in 
guinea pigs did not achieve human-like exposures in the blood, yet human-like exposures were 
achieved in the lung. A dose of 50mg/kg was shown to be therapeutic (Figure 5.14) which 
suggests that sufficient drug concentrations are achieved in the lung and microdialysis is the 
most efficient way of measuring this.  As TB is a predominantly pulmonary disease, there is 
interest in delivering anti-TB drugs by aerosol in order to deliver them directly to the lung 44, 
111.112. Studies were focussed on the aerosolisation of aminoglycosides as it is known that 
parenteral administration of these drugs is associated with low total drug concentrations in 
the lung239. Aerosolised capreomycin administered to guinea pigs resulted in a high drug 
exposure in the lung as measured via bronchiolar lavage but a significantly reduced systemic 
exposure based upon plasma measurements111. Although the PK parameters have been 
measured in the lungs of guinea pigs following aerosolisation of capreomycin, the data where 
obtained at a single time point. Microdialysis could be used to measure the PK parameters 
(especially the AUC0-t) associated with aerosolised drugs over a time course within the same 
guinea pig.  These data could be compared to the same PK parameters generated for orally 
administered drugs. However, a limitation associated with the microdialysis methodology 
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established in this thesis is that sampling the sacrospinalis via microdialysis may 
underestimate the associated lung concentrations and therefore the unbound drug 
concentrations in the lung following aerosol administration may only be established via ex vivo 
microdialysis (if unanesthetised guinea pigs are to be used).  
The main advantage to using guinea pigs as a model species for drug evaluation against TB, is 
that upon aerosol infection with M.tb, the disease progression recapitulates the main 
pathologies of human TB disease including the presence of primary and secondary lesions206. 
The morphological features of lesions impact the drugs ability to enter the lesion and gain 
access to the bacteria. For example, granulomas in guinea pigs, similarly to humans, have a 
reduced vascular supply impeding drug delivery. Bacterial persistence is also associated with 
these lesions, and hence lesions are an important feature to factor into the associated 
pharmacokinetics of the anti-TB drugs240. It would therefore be very important to understand 
the effects of TB disease on the unbound rifampicin concentrations measured via microdialysis, 
especially to measure if human-equivalent exposures can still be achieved within the lungs of 
TB infected guinea pigs. Given the specific nature of TB disease in the lung, skeletal muscle may 
be a less relevant surrogate to measure drug concentrations in infected lungs. It would 
therefore need to be ascertained prior to performing in vivo microdialysis if the relationship 
between drug concentrations in the lung and skeletal muscle still existed following infection 
with M.tb, which most likely will require the use of further animals to establish this relationship 
between drug concentrations. If this relationship remained, following aerosol infection and a 
period of time for disease establishment, guinea pigs could undergo surgery to insert the 
microdialysis probe into the sacrospinalis. The surgery would need to be conducted at 
Containment Level 3 (CL3) and protocols and associated risk assessments would need to be 
established to reflect this. There is no evidence in the literature of lung microdialysis in awake, 
freely moving small animals.  In vivo microdialysis of the lung has only been performed in 
anesthetised animals following a thoracic rib resection228,229.  
The effects of anaesthesia would need to be investigated to identify any effects on drug 
concentrations although it has been shown by others that there was no effect of anaesthesia on 
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the PK  of bromosulfophthalein, a drug with similar physiochemical and metabolism properties 
as rifampicin, in rats241.   
An alternative to dialysing the lungs in vivo would be to dialyse them ex vivo following 
necropsy.  ex vivo dialysis of the lungs gave meaningful results (Figure 5.6), albeit at only one 
time point and there would be no additional data gained by increasing the length of dialysis 
time as this is a static system. Lesions could be directly dialysed to measure unbound drug 
concentrations as drug concentration of rifampicin measured in lesions of rabbits were found 
to be significantly lower than plasma concentrations and penetration of rifampicin into healthy 
lung tissue was greater than that in lesions192. Ex vivo dialysis of TB cavities has also been 
performed in human TB patients with MDR-TB. Interestingly, there was a good correlation 
between levofloxacin concentrations in the serum and cavities (r=0.71, p=0.01)158.  
Following establishment of the microdialysis methodology to measure unbound rifampicin 
concentrations in the lungs of guinea pigs, an experiment was conducted to test the second 
hypothesis of this thesis that blood and organ drug concentrations would be different. 
Therapeutic thresholds of rifampicin based on the PK/PD indices Cmax :MIC and AUC:MIC, 
were not achieved in blood, however the therapeutic thresholds  associated with the two ratios 
were achieved in the lungs. These data were further strengthened by the fact that a dose of 
50mg/kg rifampicin provided a therapeutic benefit in aerosol infected guinea pigs (Figure 
5.14). The organ-specific PK data associated with the lung indicated that blood concentrations 
of the drug are not a good representative of drug concentrations at the site of infection (the 
lungs). These novel organ PK data generated in vivo indicate that administration of a dose 
higher than 50mg/kg rifampicin in guinea pigs would be in effect ‘over-dosing’ the guinea pigs 
and therefore it is unsurprising that toxic effects can occur207. This conclusion could not be 
drawn from the PK parameters measured in blood and incorrect assumptions on required 
doses would be made.   
Building on the data generated in this thesis, the main application of the microdialysis 
methodology in the guinea pig could be centred around dose optimisation studies during pre-
clinical drug development. This could be conducted in infected or uninfected guinea pigs. 
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Initially the microdialysis methodology could be used in guinea pigs that have been 
administered lower doses of rifampicin (<50mg/kg) to measure if the estimated lung AUC0-t 
and subsequent PK/PD indices were still within the human range (when corrections for 
protein binding and probe efficiency are applied). Conversely, higher doses of rifampicin could 
be administered in guinea pigs in order to match human-like exposures in the blood. Using 
microdialysis to estimate the subsequent concentration of rifampicin in the lung will give an 
indication of how ‘over-exposed’ the lung is to rifampicin. For the studies detailed in this thesis 
in order to orally administer 50mg/kg rifampicin to the guinea pigs, the rifampicin was mixed 
with a fruit puree to aid palatability. In other studies that have measured blood PK of rifampicin 
in guinea pigs, rifampicin was administered in a 40% sucrose solution220,207. However, co-
administration of rifampicin with food is known to decrease oral bioavailability in humans242. 
Rifampicin could be administered in a non-food based vehicle to understand effects of dosing 
mixtures on measured PK, or as a tablet (as is in humans) to ensure the full dose was being 
administered.  
An additional parameter to measure could be the effects of the co-administration of rifampicin 
and probiotic on organ PK parameters. Probiotics often need to be administered to guinea pigs 
receiving drug treatment due to the sensitivity of their gut207, however probiotic is known to 
change PK parameters via  changing gut microbiota composition and enzyme activities209. 
Microdialysis could be used to measure organ PK parameters associated with rifampicin 
following co-administration with a probiotic in guinea pigs. If the measured PK parameters 
remained unchanged, probiotic could be administered with drugs ensuring no effect on organ 
PK parameters but also improving guinea pig comfort and welfare.  Data generated from these 
dosing studies (i.e. higher or lower than 50mg/kg rifampicin) can be applied in PBPK 
predictions or used to generate a ‘numerical factor’ that can be applied, in the future, to 
measured drug concentrations in blood to estimate drug concentrations in the lungs without 
the need for additional microdialysis experiments.  
Additional studies can be performed in the guinea pig using the microdialysis methodology to 
further understand differences between rifampicin PK parameters measured in blood, organ 
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homogenate and those measured via microdialysis. In Chapter 2, when a dose of 75mg/kg 
rifampicin was administered to guinea pigs that had previously received a dose of 50mg/kg 
rifampicin, the associated total systemic exposure (AUC0-t) in blood was lower following the 
75mg/kg dose (when compared to the 50mg/kg dose). This indicated that auto-induction of 
metabolism was occurring in the guinea pig following secondary exposure to rifampicin. Dutta 
et al220 and Kjellsson et al192 have stated that auto-induction does not occur in guinea pigs or 
rabbits. Assuming auto-induction of metabolism was occurring following secondary exposure 
to rifampicin would suggest that total liver concentrations of rifampicin would be highest 
almost immediately following drug administration. Livers were collected at necropsy during 
the studies detailed in this thesis and total rifampicin concentrations measured. The highest 
rifampicin concentration measured in the liver was at one hour post drug administration 
(Figure 5.12) and the rapid decline after one hour could be associated with the rapid 
metabolism of rifampicin in the guinea pig which has also been shown in baboons where 
rifampicin is entirely cleared from the liver by 3 hours post drug administration115. In the 
guinea pig, rifampicin was still detectable in the liver at 4 hours post drug administration in 
similar concentrations to those measured at 1 and 2 hours.  
Microdialysis can be used to understand the effects of repeat administration of rifampicin as 
although the feasibility of probe implantation into the liver was found to be limited (Chapter 
4), there are studies where microdialysis has been conducted in the bile duct of anesthetised 
rats 243,244 . It is known that rifampicin is excreted via the biliary route245 in humans and that 
guinea pigs possess a bile duct and are able to excrete xenobiotics via this mechanism246. 
Consistent with this, rifampicin was measured in the faecal samples of the guinea pigs which 
were administered rifampicin (Table 5.1). The rifampicin measured in the faeces was 
approximately 10% of the liver concentration. Although likely to require anaesthesia, 
measurement of unbound rifampicin in the bile duct following repeated administration of 
rifampicin would add further information on auto-induction of metabolism (as well as 
elimination) in the guinea pig. This would provide important information of dosing frequency.  
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Although able to induce it’s own metabolism, rifampicin is also known to affect the metabolism 
and overarching pharmacokinetics of other drugs, most notably the anti-retrovirals247. This has 
an impact on TB treatment as 25% of all tuberculosis related deaths are due to HIV co-
infection1. However, the measured changes in PK parameters associated with co-
administration of rifampicin with other drugs is based on data generated in the blood. It has 
been shown that blood is not a reliable surrogate for organ concentrations of rifampicin and it 
would therefore be important to measure PK parameters in the organs. Microdialysis could be 
used to understand the effects of co-administration of other drugs with rifampicin on the 
measured organ PK parameters. Administration of a combination of the four front-line anti-TB 
drugs (as given in humans) would be an important application of this methodology since it 
would allow studies to investigate timing of rifampicin administration relative to the other 
drugs to  limit drug-drug interactions, however this would require additional optimisation 
further than that of calculating probe efficiency,  especially in relation to drug interactions at 
the probe membrane and analytical methods 85,207.  
In the future, it would be interesting to use the microdialysis methodology in other animal 
models associated with TB especially in relation to rifampicin concentrations in infected 
animals.  In infected rabbits, a dose of 30mg/kg rifampicin does not achieve human-like 
exposures in the plasma (Cmax: 1.2mg/L, AUC0-t: 14.7mg/L*h)192 whereas in infected mice a 
dose of 10mg/kg does achieve human-like exposures in plasma (Cmax 11mg/L, AUC0-24 
121mg/L*h)235. However, as was shown in the guinea pig, measuring the PK parameters 
associated with the organs may give congruent results to those measured in the blood. There 
would need to be significant additional development to the microdialysis methodology for use 
in other animal models, as although most microdialysis-specific parameters could remain the 
same, in smaller animals some features such as the 10mm probe membrane may prove to be 
problematic. Although microdialysis has been performed in mice, the probe is usually inserted 
into the brain and it appears that any peripheral tissue dialysis of mice (which is limited) has 
occurred under anaesthesia248. There seems to be no evidence in the literature of in vivo 
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microdialysis in the peripheral tissues of mice or rabbits associated with measuring the PK of 
drugs.  
Although guinea pigs are the gold standard of animal models for TB vaccine research205, they 
are not  as frequently used for anti-TB drug development. This is in part due to the high doses 
required to achieve human-like exposures in guinea pigs and doses of this magnitude have 
been associated with toxicity. However, use of the microdialysis methodology in the guinea pig 
has shown that a dose of 50mg/kg rifampicin was sufficient to achieve human-like PK 
parameters in the lung although not in the blood. Although, it is of vital importance that the PK 
data generated in the guinea pig (or other model species) are as relevant to humans as possible, 
it seems these PK parameters should be matched at the clinically relevant site of disease and 
not in the blood.  These results can help refine the use of rifampicin, a very important front-
line anti-TB drug, as well as potentially reducing associated drug toxicities in animal models  
and ultimately may impact  the initial dose selection for human clinical trials.  
Overall the studies described in this thesis address the two hypotheses. The first hypothesis 
was centred around the establishment of the microdialysis methodology in guinea pigs to 
measure the concentration of drugs in the lung. These studies demonstrate that microdialysis 
in guinea pigs is feasible and that the methodology shows great potential to more accurately 
define the PK of drugs in organs. These studies also identified some limitations associated with 
microdialysis and areas for improvement. The second hypothesis was that the concentrations 
and concentration-time curves (PK curves) of anti-TB drugs within the blood will be 
significantly different to the concentrations and PK curves in the lungs. The use of the 
microdialysis methodology in the guinea pig has proven that generation of organ-specific 
pharmacokinetic data is possible as well as highlighting the relevance of these data when 
compared to those data generated in blood. In conclusion, the use of microdialysis in guinea 
pigs can be an integral part of the pre-clinical drug development pipeline especially in relation 
to dose optimisation studies.  
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APPENDIX 
RELATIVE RECOVERIES FOLLOWING ISONIAZID IN VITRO  
MICRODIALYSIS WITH PHYSIOLOGICALLY RELEVANT DOSE SOLUTIONS 
(50 AND 5µG/ML) 
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210 14.5 78.4 
240 16.2 88.5 
1 
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:5
µ
g/
m
l 
A
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al
:5
.2
5
µ
g/
m
l 30 11.6 221.0 
63.0 56.1 89.0 
60 4.15 79.0 
90 3.33 63.4 
120 3.87 73.7 
150 2.80 53.3 
180 2.97 56.6 
210 2.73 52.0 
2 
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.4
9
µ
g/
m
l 30 11.8 214.9 
81.2 56.0 68.9 
60 4.58 83.4 
90 3.57 65.0 
120 3.21 58.5 
150 3.22 58.7 
180 2.40 43.7 
210 2.43 44.3 
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ISONIAZID PROBE EFFICIENCIES 
INH Conc (µg) %RR Probe Efficiency 
5.25 63 
61±2% 
67.5±3.4% 
5.49 59 
20.3 86 
83.5±4% 
28.0 81 
949 41 
58%±4% 992 44 
1.00 (mg) 64 
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ORGAN EFFECTS ON ISONIAZID RECOVERIES 
It was hypothesised that there is 0.12µg (120ng/ 41.5% Fu) of free isoniazid available in the homogenate for collection via microdialysis. Using the 
calculated probe efficiency of 61% and the proposed free (unbound) drug in the homogenate a line (lower line) was drawn on the graph which shows 
61% of 120ng. An additional line has been marked on the graphs at 10 times this proposed efficiency.  
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